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Abstract 
 
Chronic infections with Pseudomonas aeruginosa are primarily responsible for the 
decline in lung function and ultimate mortality in cystic fibrosis patients. The overall 
aim of this project was to elucidate some of the molecular mechanisms governing the 
pathogenesis of P. aeruginosa in the cystic fibrosis lung. This was with particular 
reference to (a) quorum sensing, a cell-to-cell communication system controlling the 
production of virulence determinants in a population density dependent manner using 
diffusible signal molecules and (b) the pseudomonas lectins, LecA and LecB, which are 
known to contribute to biofilm formation. Serial sputum samples were collected from 
adult and paediatric patients with cystic fibrosis and a cohort of clinical P. aeruginosa 
isolates was assembled. Using bioreporters, these isolates were shown to synthesise a 
range of quorum sensing signal molecules. Furthermore, the direct detection of these 
P. aeruginosa products from infected sputum samples in conjunction with patient 
clinical data implied an association between sputum quorum sensing signal molecule 
level and cystic fibrosis disease status, response to intravenous antibiotics and the 
presence of non-culturable P. aeruginosa. 
Quorum sensing also makes an important contribution to P. aeruginosa biofilm 
maturation, antibiotic tolerance and resistance to host defences. There is evidence that 
the quorum sensing regulated lectins LecA and LecB contribute to biofilm development 
and this was investigated using different biofilm assays, including the flowchamber 
biofilm system. This work demonstrated that LecA contributed to biofilm maturation in 
both laboratory and clinical strains and hydrophobic galactosides were shown to be able 
to inhibit biofilm development. The putative biofilm target ligand for LecA was 
tentatively identified as the Psl exopolysaccharide. Mutants deficient in either lecA or 
lecB produced defective biofilms, which could be inhibited and/or dispersed by 
galactosides or furanosides respectively, including novel synthetic furanoside 
dendrimers. The latter proved inhibitory to both laboratory and clinical P. aeruginosa 
isolates and constitute a potential novel therapeutic. 
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DTT  Dithiothreitol 
DTU  Danish Technical University 
EDTA  Ethylenediaminetetraacetic acid 
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ELISA  Enzyme-linked immunoSorbent assay 
EPS  Extracellular polymeric substance 
EtOH  Ethanol 
FEV1  Forced expiratory volume in one second 
FISH  Fluorescence in situ hybridisation 
FITC  Fluorescein isothiocyanate 
g  Gram 
g  Centrifugal force 
GFP  Green fluorescent protein 
GLM  General linear model 
Gm  Gentamicin 
GP  General practitioner 
h  Hour 
Ha  Alternative hypothesis 
H0  Null hypothesis 
H2O  Water 
HHQ  2-heptyl-4-quinolone 
HPLC  High pressure liquid chromatography 
ID  Inner diameter 
i.e.  id est (Latin for Òthat is to sayÕ) 
IPTG  Isopropyl-β-D-thiogalactoside 
IMS  Industrial methylated spirit 
IV  Intravenous 
kDa  Kilodalton 
kb  Kilobase pair 
L  Litre 
LB  Luria Bertani medium  
LC-MS Liquid chromatography Ð Mass spectroscopy  
LP  Long pass (confocal microscope emission filter) 
LPS  Lipopolysaccharide 
MS  Mass spectroscopy  
Mbp  Mega base pairs 
MeOH  Methanol 
min  Minute 
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ml  Millilitre 
mM  Millimolar concentration 
MOA  Marasmium oreades agglutinin 
MOPS  4-morpholinepropanesulfonic acid 
MRMTT  Multiple Reaction Monitoring Triggered Traps  
NB  Nutrient broth 
NCBI  National Center for Biotechnology Information 
nm  Nanometre 
NPF  p-Nitrophenyl-α-L-fucose 
NYB  Nutrient yeast broth 
Ω  Ohm 
OD  Outer diameter 
OD600  Optical density at 600 nanometres 
OP  Oropharyngeal cultures 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDL  Poly-D-lysine  
PI  Propidium iodide 
PIA  Pseudomonas isolation agar 
PON  Paraoxonase  
PQS Pseudomonas quinolone signal (2-heptyl-3-hydroxy-4-quinolone) 
RAPD  Random amplified polymorphic DNA analysis 
R&D  Research and Development 
RLU  Relative light unit 
RP-HPLC  Reverse phase liquid chromatography 
r  PearsonÕs correlation coefficient 
rpm  Revolutions per minute 
RT-PCR Reverse transcription polymerase chain reaction 
s  Second 
SDS  Sodium dodecyl sulphate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
SEM  Standard error of the mean 
SI  Sputum induction 
TAE  Tris-acetate-EDTA buffer 
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Tc  Tetracycline 
TEMED N, N, NÕ, NÕ-tetramethylethylenediamine 
3D  Three-dimensional 
TLC  Thin layer chromotography 
Tm  Melting temperature 
Tris  Tris hydeoxymethyl aminomethane 
µl  Microlitre 
UV  Ultraviolet 
V  Volt 
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1 Chapter 1:  Introduction 
 
1.1 General Introduction 
Microorganisms are often viewed as simple creatures, however the study of microbial 
development has shown that they are capable of complex differentiation and behaviours 
(O'Toole et al., 2000a). This is well illustrated by the tiny fraction which have the 
capacity to cause disease and continue to threaten human health and welfare. A major 
challenge is the emergence of bacterial strains exhibiting resistance to multiple 
traditional antibiotic classes. 
An appreciation of the fact that bacteria need to adopt and regulate particular 
mechanisms in order to grow and survive in vivo is the basis for the study of bacterial 
pathogenicity. The aim of understanding this capacity to cause disease is to identify new 
targets for intervention and provide alternative strategies for disease control. In recent 
times this has been facilitated by advances in molecular techniques, which enable the 
manipulation and investigation of these microorganisms in dynamic and diverse ways.  
One intensely studied example is Pseudomonas aeruginosa. This ubiquitous 
environmental organism demonstrates considerable nutritional and metabolic versatility 
and adaptability. This in part reflects the fact that is has a very large genome (6.3 mega 
base pairs [Mbp]; 1.7 Mbp larger than Escherichia coli) containing a high proportion of 
regulatory genes, giving it a genetic complexity approaching that of a simple eukaryotic 
organism (Stover et al., 2000). 
P. aeruginosa is the most important human pathogen of its genus and draws on an 
impressive array of mechanisms to infect almost any external site or organ (Williams et 
al., 2000). Most community infections are mild and superficial, but in hospital patients, 
infections are more frequent, more severe and more varied. In fact, it is one of the most 
common Gram-negative bacteria found in hospital-acquired infections, representing a 
major cause of pneumonia, urinary tract, surgical wound, burn wound and bloodstream 
infections (Van Delden and Iglewski, 1998). 
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Chronic pulmonary infections with P. aeruginosa are the major cause of morbidity and 
mortality in cystic fibrosis (CF) patients (Lyczak et al., 2002). This disorder is the most 
common autosomal recessive condition amongst Caucasians, with a frequency of about 
1 in 2,500 livebirths (Ratjen and Doring, 2003), affecting approximately 60,000 
individuals worldwide (Gibson et al., 2003). Despite the discovery of the mutated gene 
encoding a defective chloride channel in epithelial cells, no curative treatment is 
currently available. With symptomatic treatment alone, life expectancy has improved 
considerably over the last few decades and the predicted median survival for babies 
born in the 21st century is now more than 50 years (Dodge et al., 2007). 
The lung environment of these patients appears to provide a unique niche that promotes 
chronic microbial colonisation, with P. aeruginosa being the most common isolate 
recovered (Cystic Fibrosis Foundation, 2006). Indeed, once established, its treatment is 
hugely problematic and eradication almost impossible. The reasons for this are 
themselves the subject of intense study and widely overlap with exciting areas of work 
that are unravelling aspects of bacterial communication and community living. 
It is apparent that the remarkable ability of P. aeruginosa to cause disease is not only 
the consequence of individual attributes. Its success can also be explained by its 
behaviour as a population, where individual members can communicate (termed 
quorum sensing [QS]) and hence live in communities (known as biofilms). 
Understanding the mechanisms of biofilm formation provides insight into how 
populations of P. aeruginosa persist in the environment of the CF lung and may identify 
much needed targets for intervention. A promising new focus is the molecular basis for 
the contribution of the sugar-binding lectins LecA and LecB to biofilm development. 
Hence this introduction aims to present what is already known in this field by first 
briefly examining the general pathogenicity of P. aeruginosa and then concentrating on 
the specific pathogenicity of this organism in CF. In doing so, the aim is to establish the 
context within which research into QS and lectin-mediated biofilm maturation is based. 
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1.2 General pathogenicity of P. aeruginosa  
1.2.1 Characteristics of P. aeruginosa 
P. aeruginosa is a Gram-negative rod belonging to the family Pseudomonadaceae. It is 
non-sporing and non-capsulate and usually motile by means of one or two polar 
flagella. It is a strict aerobe except in the presence of nitrate and grows readily on a 
wide variety of culture media over a wide temperature range. Typical colonies and their 
surrounding medium are greenish-blue due to the production of a soluble blue 
phenazine pigment, pyocyanin and the yellow-green fluorescent pigment pyoverdin, 
which acts as a major siderophore. Energy is derived from carbohydrates by oxidative 
rather than fermentative metabolism. In culture it emits a sweet grape-like odour that is 
easily recognised and all strains give a rapid positive oxidase reaction and this is a 
useful preliminary test (Govan et al., 2003). 
1.2.2 Epidemiology of P. aeruginosa 
P. aeruginosa is a cosmopolitan organism, growing and surviving in almost any 
environment, though it does have a preference for moist surroundings. As such, human 
colonisation occurs at sites such as the axilla, ear and perineum and moisture is also a 
key factor in hospital reservoirs of P. aeruginosa which include respiratory equipment, 
sinks, medicines and disinfectants. Whilst carriage of the organism by healthy 
individuals in the community is relatively low, hospitalisation can lead to greatly 
increased colonisation rates and this frequently precedes overt infection (Pollack et al., 
2000). Patient-to-patient transmission may occur directly, via the hands of medical staff 
or from contaminated equipment (Govan et al., 2003). 
1.2.3 Pathogenesis: a successful opportunist 
Unlike the so-called Ôprimary pathogensÕ, P. aeruginosa does not possess the specific 
genetic traits to cause disease in healthy people with intact immune systems. It can only 
cause disease in those individuals whose natural defences against bacterial infection are 
impaired in some way and is thus referred to as an Ôopportunistic pathogenÕ.  
Often such immunocompromised individuals are treated with antibiotics in an attempt 
to create a means of defence against infecting organisms. Such treatment inevitably and 
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inadvertently disrupts the hostÕs indigenous microflora, the very first biological barrier 
against subsequent colonisation. In fact, P. aeruginosa exploits the situation even 
further for as a common environmental organism, it happens to be innately resistant to 
many of the traditional antibiotics developed against frequent human pathogens 
(Martinez and Baquero, 2002). Escalation of treatment with further exposure to 
different classes of antibiotics has led to the development of problematic multidrug-
resistant strains. 
1.2.4 Virulence determinants of P. aeruginosa 
As a pathogenic organism, P. aeruginosa not only invades and grows within a host (i.e. 
causes infection) but it also does harm to the host (i.e. causes disease). To achieve this, 
it must gain entry into the host, multiply in the extra- or intracellular body compartment, 
resist host defences, damage host tissues to cause the symptoms and signs of disease 
and finally disseminate through the host and/or to another host. To perform this 
multistage adaptive process in vivo, P. aeruginosa synthesises a wide range of virulence 
determinants (Williams, 2002), which can be cell-associated or extracellular. 
Cell-associated factors such as type IV pili, nonpilus adhesins, flagella, alginate and 
lipopolysaccharide (LPS) are thought to mediate adherence of the organism to altered 
epithelium of mucosal surfaces and allow initial colonisation of host tissues. 
Subsequently, P. aeruginosa produces several extracellular factors, which can cause 
extensive tissue damage, bloodstream invasion and dissemination. These include 
proteases (LasB elastase, LasA elastase, alkaline protease), haemolysins (phospholipase 
C, rhamnolipid), exotoxin A and exoenzyme S, pyocyanin and lectins (Pollack et al., 
2000) (Van Delden, 2004). The extracellular release of these substances is achieved by 
dedicated molecular machineries termed secretion pathways and P. aeruginosa utilises 
types I, II and III (Filloux et al., 1990) (Guzzo et al., 1991) (Yahr et al., 1997). 
1.2.5 The regulation of virulence 
Gene expression, necessary for the production of virulence determinants, is expensive in 
terms of energy utilisation and therefore it makes sense that this process is subject to 
sophisticated regulatory mechanisms. These enable bacteria to sense and respond 
appropriately (i.e. adapt) to the chemical and physical cues in their surroundings. One 
such system allows bacteria to perceive the density of the surrounding bacterial 
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population and to coordinately respond to this information by regulating various genes. 
This regulatory phenomenon has been termed Ôquorum sensingÕ (QS) because it reflects 
the requirement for a quorate population of bacterial cells prior to the activation of 
target genes (Fuqua et al., 1994).  
1.2.6 Quorum sensing 
In simple terms, QS can be thought of as a regulatory circuit consisting of three 
components: a small signal molecule called an autoinducer, the gene coding for the 
autoinducer synthase protein and the gene for a response regulator protein. At low 
population densities, individual bacterial cells make the autoinducer at a basal rate, 
which then diffuses or is pumped out of the cell. As the population grows, the 
concentration of the autoinducer increases. At a threshold concentration, it binds to and 
activates a response regulator which in turn directly or indirectly activates or represses 
target gene expression (Diggle et al., 2007a). The gene which encodes for the 
autoinducer synthase is itself activated by the autoinducer-activated response regulator 
and hence a positive-feedback loop is established. In this way, the resulting increase in 
gene expression can reach 1,000-fold. 
In 1970 the lux system was the first QS system to be described following investigation 
into cell density-dependent bioluminescence in the Gram-negative marine bacterium 
Vibrio fischeri. It was found that the supernatants of high density cultures of V. fischeri 
contained a substance, which at a critical concentration, would induce light emission in 
cultures at low cell density (Nealson et al., 1970). This was the autoinducer N-(3-
oxohexanoyl)-L-homoserine lactone (3-oxo-C6-HSL) (Eberhard et al., 1981), a member 
of the N-acyl-L-homoserine lactone family (AHL), synthesised by LuxI. At a critical 
concentration, it binds to LuxR and together this complex binds to a regulatory region 
known as the lux box. Hence there is increased transcription of the downstream genes 
luxCDABE, which make the luciferase and fatty acid reductase complex required for 
light production (Engebrecht and Silverman, 1984) (Figure 1-1). In this way, cell-cell 
communication enables individual cells to detect when the circumstances are right to 
partake in the energy-expensive production of light, which is only effective at the 
population level. 
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Figure 1-1 Bioluminescence mechanism in V. fischeri. 
 
In the early 1990s, the discovery that 3-oxo-C6-HSL regulated production of the β-
lactam antibiotic carbapenem by the terrestrial plant pathogenic bacterium Erwinia 
cartovora suggested that QS systems may be more widespread throughout the bacterial 
kingdom. To test this hypothesis, plasmid-based AHL-biosensors were engineered to 
detect the accumulation of these signal molecules in spent culture supernatants (Bainton 
et al., 1992). This approach revealed that QS occurs in a range of Gram-negative 
organisms, which possess LuxRI homologues and that 3-oxo-C6-HSL belongs to a 
family of AHL autoinducer molecules. The application of sophisticated chemical 
purification techniques such as high pressure liquid chromatography (HPLC) revealed 
that AHLs consist of a homoserine lactone moiety derived from amino acids, linked to a 
N-acyl side-chain of between 4 and 14 carbon atoms, with or without either an oxo- or a 
hydroxy- moiety at the C3 position (Chhabra et al., 2004).  
The AHL lactone ring is readily hydrolysed under alkaline conditions to form the 
corresponding N-acylhomoserine compound (Ôring openÕ form), which is inactive as a 
QS signal molecule (Yates et al., 2002). Furthermore, the 3-oxo-AHLs can also undergo 
an alkali-driven rearrangement reaction to form the corresponding tetramic acids, 
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compounds with iron chelating and antibacterial activities (Kaufmann et al., 2005). 
Examples of the these structures produced by P. aeruginosa are presented further on in  
Figure 1-3. 
Gram-positive bacteria are also known to quorum sense although they do not produce 
AHLs as signal molecules. Instead, they utilise post-translationally modified peptides 
which are recognised by receptor kinases and this sets off a signalling cascade that 
activates the target relevant genes (Sturme et al., 2002). 
1.2.7 Quorum sensing in P. aeruginosa 
The first cell-to-cell signalling system described in P. aeruginosa was found to regulate 
expression of the lasB gene (coding for elastase) and was therefore named the las 
system (Passador et al., 1993). This consisted of the AHL autoinducer N-(3- 
oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL), produced by the LasI 
synthase, and the LasR transcriptional activator protein (Gambello and Iglewski, 1991) 
(Pearson et al., 1994).  
A second system is also present, named rhl because of its ability to control the 
production of rhamnolipid. In this case, the signal molecule is N-butanoyl-L-homoserine 
lactone (C4-HSL), made by RhlI, which binds to the transcriptional activator RhlR 
(Latifi et al., 1995).  
These two QS circuits have been found to regulate the genes for a number of virulence 
determinants in P. aeruginosa to varying degrees. These include toxA (exotoxin A), 
lasB (LasB elastase), lecA (LecA lectin), rhlAB (rhamnolipids), aprA (alkaline 
protease), hcnAB (hydrogen cyanide), katA (catalase), sodA and sodB (superoxide 
dismutases) and xcpR and xcpP (type II secretion systems) (Brint and Ohman, 1995) 
(Chapon-Herve et al., 1997) (Gambello et al., 1993) (Glessner et al., 1999) (Hassett et 
al., 1999) (Latifi et al., 1995) (Pessi and Haas, 2001) (Winzer et al., 2000). In addition, 
synthesis of type IV pili and siderophores as well as biofilm maturation have also been 
shown, at least in part, to be regulated by QS (Glessner et al., 1999) (Stintzi et al., 
1998) (Davies et al., 1998). Overall, it has been estimated that between 3 and over 10 % 
of the genome of P. aeruginosa may be controlled to some degree by QS (Whiteley et 
al., 1999) (Schuster et al., 2003) (Wagner et al., 2003). 
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Whilst there is considerable overlap in the genes regulated by these two systems, it is 
also evident that they do not function independently of each other. In fact, the LasR-3-
oxo-C12-HSL complex activates the expression of rhlR and rhlI placing the las system 
above the rhl system in a signalling hierarchy (Latifi et al., 1996). This represents the 
core of the P. aeruginosa QS system and ongoing work has demonstrated the presence 
of many additional layers of complexity. 
For example, in contrast to light-production in V. fischeri and carbapenem production 
by E. carotovora, the addition of exogenous AHLs did not advance the expression of 
several QS-dependent genes such as lecA, lasB or rhlR (Diggle et al., 2002). Therefore 
population size, translated into an increase in AHLs, is not the only determinant 
controlling multiple genes. Rather, it appears that the expression of certain genes is 
coordinated with growth phase and growth environment by additional regulators. These 
include the positive regulators GacA (Reimmann et al., 1997) and Vfr (Albus et al., 
1997) and those that act as repressors, such as RsaL (de Kievit et al., 1999), RsmA 
(Pessi et al., 2001), MvaT (Diggle et al., 2002) and the third homologue of LuxR, QscR 
(Chugani et al., 2001). Recently, a fourth LuxR homologue, VqsR, has been identified 
as a major virulence regulator in the QS hierarchy of P. aeruginosa (Juhas et al., 2004). 
The alternative sigma factor RpoS also plays a role, which may allow the regulation of 
virulence determinants with survival in stationary phase (Winzer et al., 2000) (Schuster 
et al., 2004).  
In 1999, Pesci et al. demonstrated that a non-AHL signal produced by P. aeruginosa 
was able to activate lasB expression and whose own synthesis and bioactivity was 
mediated via the las and rhl systems respectively. The molecule responsible for this 
non-AHL-mediated QS signalling pathway was purified and chemically identified as 2-
heptyl-3-hydroxy-4-quinolone and termed the ÔPseudomonas quinolone signalÕ (PQS). 
In fact, PQS belongs to the family of 2-alkyl-4-quinolones (AQs), which were first 
identified in the 1940s and have been previously studied for their antimicrobial 
properties. Other major molecules belonging to this family produced by P. aeruginosa 
include 2-heptyl-4-quinolone (HHQ), 2-nonyl-4-quinolone (NHQ) and 2-heptyl-4-
quinolone N-oxide (HHQNO). 
A five-gene operon termed pqsABCDE is responsible for the synthesis of AQs in 
P. aeruginosa (Gallagher et al., 2002). PQS binds to and activates the LysR-type 
transcriptional regulator PqsR (also known as MvfR), which in turn induces the 
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expression of the pqsABCDE operon. The pqsA-D genes are involved in the 
biosynthesis of the PQS precursor HHQ from anthranilate. A further gene termed pqsH, 
encoding for a predicted FAD-dependent mono-oxygenase, is required for the 
conversion of HHQ into PQS. The expression of pqsH is, at least in part, controlled by 
LasR, thus linking the AHL and AQ signalling pathways (Deziel et al., 2004). Whilst 
the exact function of PqsE is unknown, it has recently been reported that it acts as a 
regulator that is independent of PqsR and PQS, but dependent on the rhl quorum 
sensing system (Farrow et al., 2008) (Fletcher, Pustelny, Diggle, Cmara & Williams, 
unpublished observations).  
Whilst other bacterial species have been shown to make AQs (Diggle et al., 2006a), to 
date, P. aeruginosa is the only organism known to make PQS. Indeed, the PQS 
signalling system plays an important role in pathogenesis by regulating the production 
of diverse virulence factors, including elastase, pyocyanin and LecA lectin as well as 
affecting biofilm formation (Diggle et al., 2003; Gallagher et al., 2002) (Cao et al., 
2001).  
See Figure 1-2 for an overview of P. aeruginosa QS signalling systems and Figure 1-3 
for the structures of the major QS signal molecules and their derivatives. 
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Figure 1-2 An overview of QS in P. aeruginosa.  
The QS cascade is induced at high population cell densities when within the cell, the LasR 
response protein binds to a critical concentration of 3-oxo-C12-HSL signal that has been 
produced by neighbouring cells and taken up from the surrounding environment. This results in 
activation of the las QS system and the production of a number of QS-regulated phenotypes. 
Activation of the las system is also important in the induction of the rhl QS system that is 
required for the production of rhl- controlled phenotypes. 
AHL and AQ-dependent QS are linked since LasR/3-oxo-C12-HSL is required for full 
expression of pqsH and positively regulates pqsR. Both pqsA and pqsR are repressed by the 
action of the RhlR/C4-HSL system. ↓ represent positive regulation. ⊥ represent negative 
regulation. 
(Dubern and Diggle, 2008) 
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Figure 1-3 Structures of the major QS signal molecules and their derivatives. 
(A) C4-HSL (B) ring open C4-HSL (C) 3-oxo-C12-HSL (D) ring open 3-oxo-C12-HSL  
(E) 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl) pyrrolidine-2,4-dione [tetramic acid]  
(F) PQS (G) HHQ 
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1.2.8 The implications of quorum sensing in P. aeruginosa 
It is interesting that many pathogenic AHL producers tend to be opportunists, which can 
exist in multiple environments. In contrast, pathogens which uniquely colonise and 
cause infections in humans, such as Haemophilus influenzae, do not appear to employ 
QS circuits (Swift et al., 1999). So by regulating diverse physiological processes 
including virulence, QS enables adaptation to a niche and hence a survival advantage 
for these microbial opportunists.  
It is the timing of this regulation that is particularly relevant to the establishment of 
infection. QS ensures that P. aeruginosa virulence determinant production occurs 
maximally when the invading organism has reached a critical population density 
sufficient to instigate a unified attack and therefore overwhelm the host before it has 
time to mount an effective defence.  
In vivo evidence for the role of QS in the regulation of virulence comes from testing 
strains of P. aeruginosa that contain deletions in one or more QS genes in various 
models of infection. These include a neonatal mouse model of acute pneumonia and a 
burned mouse model of infection (Tang et al., 1996) (Pearson et al., 2000) (Rumbaugh 
et al., 1999a). In these studies, the mutant strains were found to induce less tissue 
destruction and reduced cases of pneumonia than wild-type P. aeruginosa. Interestingly, 
the QS mutants were not completely avirulent. This emphasises the multifactorial nature 
of virulence and fact that other factors play a role in regulating pathogenesis. 
Increasingly, it is recognised that the QS signal molecules themselves can interact with 
eukaryotic cells and hence directly affect the host, acting as virulence determinants in 
their own right. For example, there are several reports that 3-oxo-C12-HSL is a potent 
immune modulator which impacts on cytokine production and immune cell activity in 
vitro and in vivo (Pritchard, 2006). In addition, this molecule has been shown to exert a 
pharmacological effect on the cardiovascular system, inhibiting vasoconstrictor tone of 
both pulmonary and coronary blood vessels from the pig (Lawrence et al., 1999) and 
triggering bradycardic effects in rats (Gardiner et al., 2001). Hence, this AHL QS signal 
molecule itself may enhance P. aeruginosa survival in the host by increasing nutrient 
supply via the bloodstream and downregulating host defences. Furthermore, there is 
evidence that PQS is a more potent immune modulator than 3-oxo-C12-HSL and 
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together, they are capable of acting synergistically to inhibit T-cell proliferation (Hooi 
et al., 2004). 
Clearly, as global regulatory systems, the QS circuits represent novel and attractive 
therapeutic targets for the attenuation of virulence. Possible strategies include depletion 
of the signal molecule, either by its destruction or the inhibition of its synthesis, or 
alternatively to block transmission of the signal by antagonising the formation of the 
AHL-LuxR complex (Williams, 2002). Such approaches would overcome conventional 
antibiotic resistance mechanisms and reduce the selective pressure for the emergence of 
resistant strains. However, as there is no bactericidal action, effective host defences 
would be needed for bacterial clearance and this may limit such an approach in the 
immunocompromised, a target patient population for opportunistic pathogens. As such, 
QS inhibitors may have a prophylactic role or be used in synergy with more 
conventional classes of antibiotic (Williams, 2002). 
Overall QS has changed our view of bacteria as simple unicellular organisms existing in 
isolation, when in fact they are capable of complex and sophisticated patterns of 
multicellular behaviour (Williams et al., 2000). With communication comes community 
living and this pattern of existence is crucial to the understanding of the pathogenesis of 
P. aeruginosa in the CF lung.  
1.3 The pathogenicity of P. aeruginosa in CF  
1.3.1 Parasite-host interaction 
In the clinical sense, the virulence of an organism is a manifestation of a complex 
parasite-host relationship in which the capacity of the organism to cause disease is 
considered in relation to the resistance of the host (Ala'Aldeen et al., 2003). Nearly all 
clinical cases of P. aeruginosa infection are associated with compromise of the host. In 
patients with general immunosuppression such as those with AIDs or neutropenia 
following chemotherapy, P. aeruginosa is one of a number of potential bacterial, viral 
and fungal pathogens. Such scenarios, therefore, do not yield information which is 
specific to the pathogenesis of P. aeruginosa (Lyczak et al., 2000). However, in CF, the 
genetic defect leads to a particular phenotype that makes these patients especially 
susceptible to lung infections with P. aeruginosa. In this environment, P. aeruginosa 
selects certain virulence determinants from its repertoire to behave in a specific way. It 
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is interesting to review what is currently known about this host environment and the 
molecular and cellular mechanisms of the parasiteÕs behaviour. 
1.3.2 CF: the host phenotype 
CF is an autosomally recessive inherited disease affecting cells of the exocrine glands. 
It is characterised by mucus hypersecretion, chronic bacterial infection and airway 
inflammation, as well as exocrine pancreatic insufficiency and being underweight. The 
disorder predominantly occurs in Caucasian populations of European ancestry, who 
have a carrier frequency of 1 in 25. Overall, the condition has an incidence of about 1 in 
2500 livebirths (Ratjen and Doring, 2003) 
1.3.3 Pathology: the genetic defect 
The understanding of the genetic basis of CF was initiated and advanced by the work of 
Dorothy Andersen. In 1938 she published a detailed study of 49 patients (Andersen, 
1938) that for the first time allowed CF to be thought of as a single disease with diverse 
effects rather than a loose collection of related disease states of the alimentary and 
respiratory tracts. In 1946 she published a pedigree type analysis of CF in 20 affected 
families (Andersen and Hodges, 1946). The disease was found to occur with a 
frequency approximating 25% in the affected families, the value expected for an 
autosomal recessive disorder inherited in a classical Mendelian fashion. 
An additional clue to aetiology was provided by di SantÕAgnese and colleagues in 1953 
who found that the sweat of CF patients contained abnormally high concentrations of 
sodium, chloride and potassium (Di Sant'Agnese et al., 1953). This ultimately led to the 
work that demonstrated that CF patients have abnormalities in chloride conductance in 
and out of cells (Quinton and Bijman, 1983). 
The cause of this defect in chloride conductance and of its mode of inheritance was 
determined in 1989, a milestone in CF research, when the gene encoding for the defect 
that manifests as CF was identified and cloned (Kerem et al., 1989) (Riordan et al., 
1989). Chromosomal walking experiments confirmed the localisation of the gene to the 
long arm of chromosome 7 (Rommens et al., 1989). The gene itself is large, spans 250 
kilobases (kb) and is composed of 27 exons (Zielenski et al., 1991). It is transcribed into 
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a 6.5-kb messenger RNA that encodes the 1,480 amino acid protein termed the cystic 
fibrosis transmembrane regulator (CFTR). 
The CFTR protein, located in the apical membranes of epithelial cells, is a member of 
the ATP binding cassette (ABC) family of transporters. It contains two nucleotide-
binding domains that bind and hydrolyse ATP, two dual sets of membrane-spanning 
segments that form the channel, and a central regulatory (R) domain. The R domain is 
unique to CFTR and is highly charged with numerous phosphorylation sites for protein 
kinases A or C (Figure 1-4). 
 
Figure 1-4 The cystic fibrosis transmembrane conductance regulator (CFTR) gene and its 
encoded polypeptide 
(Gibson et al., 2003) 
 
The CFTR protein has a dual role as a cAMP-sensitive chloride channel of low 
conductance with no preference for the direction of chloride transport and as a 
conductance regulator due to its ability to regulate other protein channels and 
transporters. In the CF sweat gland, chloride absorption is hindered by defective CFTR 
function. As a result, sweat that reaches the skin surface has higher than normal chloride 
concentration (>60 mEq) and this provides the basis for the diagnostic sweat test. In the 
airway epithelium, the CFTR defect results in loss or reduction of chloride secretion 
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into the airways. The physiological effects of this defect on the salt concentration and 
volume of the airway surface fluid is an area of debate and the competing theories are 
discussed further on in the context of the pathophysiology of the CF lung disease. 
Over 1500 naturally occurring mutations in the CFTR gene have been described so far, 
(Cystic Fibrosis Foundation Mutation database, http://www.genet.sickkids.on.ca/ 
cftr/StatisticsPage.html, accessed 09.06.08). The vast majority involve three or fewer 
nucleotides and result in predominantly amino acid substitutions, frameshifts, splice site 
or nonsense mutations. CFTR mutations can be grouped into six classes that reflect the 
biosynthetic pathway and function of the CFTR (Vankeerberghen et al., 2002): 
 
1 CFTR is not synthesised 
2 defective processing 
3 defective regulation 
4 defective conductance 
5 partly defective production or processing 
6 defective regulation of other channels 
Classes 1-3 are the most common, with the most frequent mutation worldwide 
belonging to class 2, caused by deletion of phenylalanine at position 508 of CFTR 
(phe508del, until recently known as ∆F508) (Ratjen and Doring, 2003). Interestingly, 
the incidence of this mutation varies between ethnic groups, for example 82% of 
patients with CF have phe508del in Denmark in contrast to only 32% in Turkey (Morral 
et al., 1994). This has led to the theory that selective pressure has been operating, 
perhaps due to a heterozygote advantage such as protection against fatal infections. 
Although several theories have been proposed suggesting a selective advantage for 
phe508del heterozygotes such as resistance to secretory diarrhoea from cholera (Gabriel 
et al., 1994) or protection against bronchial asthma (Schroeder et al., 1995) no 
confirmatory data is available. 
Attempts to link mutations in CFTR to severity of lung disease have not been successful 
(The Cystic Fibrosis Genotype-Phenotype, 1993) and it is suggested that environmental 
factors, genes other than CFTR, or both, modify development, progression and disease 
severity (Ratjen and Doring, 2003). 
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1.3.4 Diagnosis 
Although the genetic basis is well understood, the diagnosis of CF is usually made 
clinically and not genetically. The disease leads to pathological changes in organs that 
express CFTR, including secretory cells, sinuses, lungs, pancreas, liver and reproductive 
tract. These result in clinical signs and symptoms which can be used to make a 
preliminary diagnosis. Additionally, a positive family history or a positive finding at 
newborn screening can be informative. The diagnosis can then be confirmed by tests of 
abnormal ion concentration (sweat chloride concentration or nasal epithelium potential 
difference) and genotyping of the most common mutations. Clinical tests which do not 
directly assess the CFTR defect can also aid diagnosis, for example tests of pancreatic 
insufficiency or sinus radiographs looking for the total opacification of the paranasal 
sinuses commonly seen in this disorder (Ratjen and Doring, 2003). See Figure 1-5 for 
the clinical signs of CF. 
 
Chronic airway disease 
Chronic cough 
Airway colonisation with pathogens 
Persistent abnormalities on chest radiograph 
Airway obstruction 
Clubbing 
Pansinusitis 
Nasal polyps 
Gastrointestinal disease 
Meconium ileus, distal obstruction syndrome, rectal prolapse 
Pancreatic insufficiency, pancreatitis 
Biliary cirrhosis 
Failure to thrive, oedema with hypoproteinaemia, 
deficiency of fat-soluble vitamins 
Pseudo-Bartterʼs syndrome (salt wasting with metabolic alkalosis) 
Infertility due to obstructive azoospermia 
 
Figure 1-5 Clinical signs of CF 
(Ratjen and Doring, 2003) 
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1.3.5 Screening 
Neonatal screening programmes have been introduced in many countries with 50 % of 
all patients in the USA diagnosed by the age of 6 months (Cystic Fibrosis, 2006). 
Modern screening programmes are based on a two-step approach: first, test for immune-
reactive trypsin in dried blood spots; and second confirm result by DNA analysis in 
positive cases. Only a few studies have evaluated screening and whether early diagnosis 
will affect long-term outcome continues to cause controversy (Merelle et al., 2001). 
1.3.6 Monitoring 
Routine clinical investigations provide the means for assessing pulmonary status and 
are used to monitor disease progression and response to treatment. These include 
laboratory investigations (white cell count and C reactive protein) and pulmonary 
imaging (chest X-rays and high resolution CT scanning). Lung function testing with 
spirometry or plethysmography is the principal measure of pulmonary status in 
individuals with CF older than 5 years of age. Serial measurements document stability 
or progression of airway obstruction and air trapping. These measures are also useful in 
documenting acute changes associated with pulmonary exacerbations and response to 
therapy. 
1.3.7 The parasites 
While the gene defect results in a myriad of clinical problems for the patient, pulmonary 
disease, in the form of chronic pulmonary infection, accounts for most morbidity and 
mortality (Lyczak et al., 2002). In fact, CF can be described as Òan inherited 
susceptibility to bacterial respiratory infectionsÓ (Tummler and Kiewitz, 1999) caused 
by surprisingly few bacterial pathogens. Overall, P. aeruginosa is the most common 
isolate, followed by Staphylococcus aureus and H. influenzae (Cystic Fibrosis 
Foundation, 2006). See Figure 1-6. 
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Figure 1-6 Age-specific prevalence of airway infections in patients with CF. 
(Cystic Fibrosis Foundation, 2006) 
 
S. aureus was the first pulmonary pathogen recognised in patients with CF and in the 
present day, it is often the first organism cultured from the respiratory tract of young 
children with CF. Historically, the development of antistaphylococcal penicillins has 
been associated with significant improvements in patient longevity. Clearly the presence 
of S. aureus in the lower respiratory tract is representative of a pathological situation 
and there is a consensus amongst clinicians about a beneficial effect from treatment of 
S. aureus associated with clearance of the organism from the sputum. However, the 
degree of pathology associated with its presence in the lungs has never been adequately 
assessed in CF patients and there is no data indicating that its treatment leads to 
improved lung function or other clinical benefit (Lyczak et al., 2002). There are reports 
in the literature which question the benefit of prophylactic antistaphylococcal therapy 
(Ratjen, 2001) (Stutman et al., 2002) and there is evidence that the presence of 
S. aureus and the absence of P. aeruginosa predicts long-term survival in CF patients 
after the age of 18 years (Huang et al., 1987) (Hudson et al., 1993). 
While essentially all patients prior to the 1950s died by the age of 10 years, by the 
1990s approximately one-third were surviving to adulthood (Fitzsimmons, 1993). This 
increased mean survival has had a dramatic impact on the nature of CF as an infectious 
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disease since the longer survival of patients has created opportunities for infection with 
organisms other than S. aureus. 
H. influenzae is the third most commonly recovered bacterium from the respiratory 
tracts of CF patients, typically children. The infecting organism is nontypeable and is 
therefore not prevented by childhood immunisation against H. influenzae type b. Data 
related to the pathogenic potential of nontypeable H. influenzae are virtually nonexistent 
yet many clinicians regard the possibility of this organism colonising the lung as 
significant enough to warrant therapy. 
Today P. aeruginosa is the most prevalent pulmonary pathogen in CF patients, 
irrespective of geographical location. Yet this has not always been the situation. Prior to 
1946 the reported prevalence of CF pseudomonal infections was low (Di Sant'Agnese 
and Andersen, 1946), however a variety of sources indicate that during the 1960s, 
P. aeruginosa became the most prevalent organism in the airways of these patients 
(Pier, 1985) and this coincided temporally with the introduction of regional centres 
which specialised in CF care. Whilst these centres have promoted standardised 
principles of multidisciplinary therapy, which has made an important contribution to 
increasing the mean survival of patients (Ramsey, 1996), there is evidence to support 
the theory that they are potential sites for the increased risk of spread of P. aeruginosa 
(Pedersen et al., 1986). 
CF patients can acquire P. aeruginosa in their respiratory tracts at any time with most 
studies indicating that 70-80 % are infected by their teens (Lyczak et al., 2002). In fact, 
there is evidence that most infection probably occurs within the first 3 years of life, 
which is much earlier than previously believed. The diversity of clones seen suggests 
that most clinical isolates originate from the environment (Burns et al., 2001), however, 
there is mounting evidence that some widespread clonal lineages are apparently 
contracted through cross infection from other CF patients (Jones et al., 2001). Risk 
factors for initial P. aeruginosa airway infection in patients with CF diagnosed by 
newborn screening included female sex, homozygous phe508del genotype and 
S. aureus isolation (Maselli et al., 2003). Individuals fortunate enough to avoid 
colonisation show survival rates twice that of colonised individuals (Hutchison and 
Govan, 1999).  
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Other organisms that are identified later in the course of CF airways disease include 
Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, 
methicillin-resistant S. aureus, fungi including Aspergillus and nontuberculous 
mycobacteria. B. cepacia was first described as a significant pathogen among this 
patient population in 1984 (Isles et al., 1984) and is now known to include at least nine 
genomovars or genomic species, collectively referred to as B. cepacia complex. 
Whether strategies to reduce the prevalence of P. aeruginosa infections could lead to 
the situation where B. cepacia complex or one of the other emerging pathogens 
dominates in the CF airways is unknown, but a worrying possibility. 
1.3.8 Diagnostic microbiology  
It is accepted that the upper respiratory tract is colonised by normal flora while the 
lower respiratory tract is maintained sterile by various defences of the host. Therefore 
any organism recovered from the lower airway is considered a pathogen. A significant 
issue in the diagnostic microbiology of CF is sampling of the airways. Expectorated 
sputum is currently the preferred source of airway secretions in CF subjects and is 
composed of lower respiratory tract secretions along with nasopharyngeal and 
oropharyngeal secretions, cellular debris and microorganisms. It is accepted to be an 
accurate indicator of lower airway microbiology (Thomassen et al., 1984) (Henig et al., 
2001), with insignificant levels of oropharyngeal contamination (Gilljam et al., 1986). 
However subjects with mild disease, young subjects or those not colonised with 
P. aeruginosa may not produce much if any sputum.  
Alternative sources of specimens are oropharyngeal cultures (OP) or throat swabs, 
which are often used in young children, broncheolar lavage fluid (BAL) and sputum 
induction (SI). Studies comparing OP and BAL cultures indicate that OP cultures have 
high specificity (i.e. a negative culture is useful in ruling out lower airway infection) but 
poor sensitivity (i.e. a positive culture is not reliable to make the diagnosis of 
P. aeruginosa in the lower airway) (Rosenfeld et al., 1999). Whilst culture of BAL fluid 
is considered a more sensitive measure of infection in nonexpectorating patients, the 
procedure is more invasive and requires sedation, thus increasing risk and cost. One 
important caveat is that BAL fluid samples are obtained from only a small portion of 
the lung, leaving the possibility that pathogens might be present in parts of the lung not 
sampled by lavage. 
 42 
Hypertonic saline induction of sputum has been reported to be a good surrogate for 
lower airway sampling for both microbiology and inflammatory markers, in both adult 
and older paediatric patients with CF. In a comparison of culture results from 
expectorated sputum, BAL fluid and induced sputum, similar detection rates for bacteria 
and fungi were identified with all three sample sources (Henig et al., 2001). Currently, 
such a method may have an important role as a research tool and is not a routine feature 
of clinical practice. 
1.3.9 The environmental niche 
The causal associations between mutant forms of the CFTR and susceptibility to lung 
infection remain controversial. Several competing theories exist which attempt to define 
the host factors that create the unique environmental niche within which P. aeruginosa 
dominates. 
The cell-receptor hypothesis suggests that CF cell organelles are more acidic (Poschet et 
al., 2001) or alkaline (Imundo et al., 1995) than organelles from normal cells and that 
altered pH leads to reduced sialysation of glycoconjugates on CF epithelial cell 
membranes. Increasing numbers of asialoGM1 molecules (a receptor for many bacterial 
respiratory pathogens) may result in increased binding of P. aeruginosa (Poschet et al., 
2001) and S. aureus (Imundo et al., 1995). CFTR itself has been characterised as a 
receptor for P. aeruginosa with the outer core region of the LPS acting as the ligand. 
When CFTR displays normal function, the cell can internalise and kill the pathogen. By 
contrast, phe508del CFTR cannot bind this pathogen, leaving bacteria free to multiply 
in the airway lumen of the lungs of these patients (Pier et al., 1996). 
Alternative hypotheses debate the contribution of the defective CFTR to the nature of 
the biphasic mucus layer in CF. This consists of a low-viscosity liquid perciliary layer 
within which cilia beat, causing the mucus to flow unidirectionally toward the 
oesophagus. Above this is a more viscous layer consisting of high molecular weight 
mucins. These are glycoproteins whose properties are altered by water content, ion 
concentrations and pH. It is within this upper layer that microorganisms and other 
particles become trapped, often binding to the carbohydrate side chains of mucins. 
Hence the salt-defensin or compositional hypothesis is based on the assumption that in 
the CF airway there is a raised mucus salt concentration (Smith et al., 1996; 
 43 
Widdicombe, 2001). Since the activity of airway antimicrobial peptides or defensins is 
inactivated by a salt concentration greater than 50 mmol/L, bacteria can multiply on the 
respiratory epithelial cell surfaces of these patients, leading to infection. 
The tonicity of airway fluid is still the matter of much debate. Thus the competing 
isotonic fluid depletion hypothesis proposes isotonic salt concentrations as a result of 
abnormal sodium absorption from the airway lumen, coupled with a failure of CFTR to 
secrete chloride (Matsui et al., 1998) leading to a water/volume depleted periciliary 
liquid. Water loss increases overall mucus viscosity and impairs mucociliary clearance 
and cough clearance. Bacteria invading the CF lung are trapped in this viscous mucus 
on top of respiratory epithelial cells. At this stage, the anoxic mucus hypothesis 
proposes that the bacteria encounter microaerophilic or anaerobic growth conditions 
(because of abnormal oxygen consumption of the CF cell). These growth conditions 
trigger a switch of S. aureus and P. aeruginosa from non-mucoid to mucoid cell-types, 
the main phenotype in the CF lung (Worlitzsch et al., 2002). 
No single hypothesis alone adequately explains why only a select group of organisms 
occur, why they show a particular sequence of colonisation and particular phenotypes 
such as mucoidy occur. What is established, however, is that there is no evidence for a 
systemic immunodeficiency in CF to explain this chronic endobronchial infection. 
There is no increased frequency or severity of infections outside the respiratory tract 
and patients with CF have normal responses to standard immunisations (Chmiel et al., 
2002). In this sense, airway infections with P. aeruginosa are unique and further 
clarification of the host factors, which enhance the propensity for this opportunist to 
initially colonise, is awaited. 
1.3.10 Adaptation to a niche  
A defining feature of P. aeruginosa lung infections in CF is chronicity. The use of 
genomic fingerprinting has shown that most individuals become colonised with a single 
clone of P. aeruginosa that persists throughout the patientÕs lifetime (Romling et al., 
1994). Further, when sputum from a single patient is plated out, a broad spectrum of 
clonal morphology is seen, reflecting the remarkable adaptation and diversification of a 
single clone to various niches in the lung (Tummler and Kiewitz, 1999). 
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In addition to spatial adaptation, characteristic temporal changes are seen. Early and 
sometimes intermittent colonisation of the lung occurs with organisms which resemble 
environmental isolates in their phenotype. They are motile, free swimming (planktonic) 
with a nonmucoid phenotype and smooth lipopolysaccharide (LPS). With time, certain 
phenotypic characteristics appear to be selected in the CF airways and chronic 
colonisation by a transformed nonmotile, sessile, mucoid phenotype with a rough LPS 
contained within a complex biofilm is seen (Hutchison and Govan, 1999) (Tummler and 
Kiewitz, 1999). Given that chronic infection with P. aeruginosa is the main proven 
perpetrator of lung function decline and ultimate mortality in CF patients, understanding 
these mechanisms which enable P. aeruginosa to persist and resist treatment are crucial. 
1.3.11 The Biofilm Mode of Growth 
Light and electron microscopy of sputum and post-mortem samples have revealed that 
rather than existing as isolated organisms, P. aeruginosa forms microcolonies or 
biofilms in the CF lung (Lam et al., 1980) (Worlitzsch et al., 2002). Additional 
physiological evidence shows a change in QS signal profiles comparing planktonic and 
biofilm P. aeruginosa organisms (Singh et al., 2000). 
A biofilm is a structured community of bacterial cells (single or mixture of species) 
enclosed in a self-produced polymeric matrix. Biofilms are widely seen in natural 
environments and are said to occur whenever bacteria come into contact with a surface. 
Interestingly, in the CF lung, the pseudomonads have been seen to colonise the 
bronchiolar lumen and it is unclear whether the respiratory epithelium or mucus itself 
represents the anchoring surface (Worlitzsch et al., 2002) (Hasset et al., 2002). 
Biofilms are highly hydrated structures, consisting predominantly of water and only 10-
20 % bacteria. They have a clear structure of polysaccharide penetrated by minute 
anatomising water channels as a primitive circulation (Costerton et al., 1994) and 
gradients of oxygen, nutrients, waste and signalling factors exist. The environmental 
heterogeneity creates a heterogeneous population of bacterial cells (Mah and O'Toole, 
2001), although they typically show reduced growth compared with planktonic bacteria 
(Brown et al., 1988). In fact the complexity of biofilm structure and metabolism has led 
to the analogy of biofilms to tissues of higher organisms (Costerton et al., 1995). 
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Whilst recognised for about 100 years, detailed molecular study of biofilms only began 
three decades ago and P. aeruginosa is among the best studied biofilm formers 
(O'Toole, 2003). This has been achieved in vitro by examining static growth on inert 
surfaces or in specially constructed flow-chambers, which allow a more representative 
simulation of in vivo conditions. Animal models of biofilm bacteria can be established 
in rats and mice by intratracheal inoculation of bacteria in agar beads and alginate beads 
(Hoiby et al., 2001). The recent advances in confocal laser scanning microscopy 
(CLSM) allow examination of living fully hydrated biofilms in three-dimensions. In situ 
gene expression can also be evaluated microscopically by the use of green fluorescent 
protein (GFP) fusion reporter constructs. 
1.3.12  Biofilm formation and regulation 
 It is widely accepted that the planktonic-biofilm transition is a complex and highly 
regulated bacterial developmental process. Current models suggest that biofilm 
formation involves particular stages or bacterial phenotypes that are well conserved 
among a wide range of organisms. These include a reversible then irreversible 
attachment of organisms, maturation of the biofilm and then dispersion.  Bacteria within 
each stage of development are generally believed to be physiologically distinct from 
cells in other stages of development and in mature biofilms all stages of development 
may be present to some degree at the same time (Sauer et al., 2002). 
Microbial factors that enable biofilm formation are beginning to be characterised and 
include those that facilitate motility and adherence as well as those contributing to the 
biofilm architecture. The initiation and regulation of these factors is thought to involve 
environmental conditions and cues such as nutrient and oxygen availability, 
hydrodynamics and the nature of the surface adhered to (Hall-Stoodley and Stoodley, 
2002) (Geesey, 2001). These then trigger multiple complex genetic regulatory 
pathways, which may show redundancy and overlap. Like other developmental 
pathways, a number of different regulators are involved. For example, Crc is a global 
carbon metabolism regulator which has also been shown to regulate the genes involved 
in early biofilm formation (O'Toole et al., 2000b). A crc mutant had attenuated biofilm 
formation suggesting that Crc may be part of a signal transduction pathway that relays 
signals (such as carbon availability) and thereby regulates the transition from planktonic 
to biofilm growth. 
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The possibility of a role for QS in biofilm formation was first hypothesised by Williams 
and Stewart (Williams et al., 1994). Indeed, QS seems ideally suited for bacteria in a 
diffusion-limited environment such as a biofilm. The detection of lasR transcripts 
(Storey et al., 1998) and AHLs in CF sputum (Middleton et al., 2002) and the 
production of PQS by P. aeruginosa isolates from CF airways (Guina et al., 2003) is 
compelling evidence that it does indeed plays a role in vivo in the pathogenesis of this 
organism in the CF lung.  
Much interest and rapid progress in biofilm research followed the publication of a paper 
by Davies and colleagues (Davies et al., 1998) in which evidence for a correlation 
between biofilm formation and QS in P. aeruginosa was presented. They hypothesised 
that because QS requires a sufficient density of bacteria, signals would not be expected 
to participate in the initial stages of biofilm formation, attachment and proliferation. 
However they may be involved in differentiation. In support of this, they demonstrated 
that lasI mutants incapable of synthesising 3-oxo-C12-HSL formed biofilms with 
abnormal structure (thin and undifferentiated) that were more sensitive to the detergent 
biocide sodium dodecyl sulphate (SDS).  
Along side this, OÕToole and Kolter (O'Toole and Kolter, 1998) conducted a simple 
genetic screen in which random transposon mutants were grown in microtitre plates and 
those that did not form biofilms were investigated further. They found that flagellar 
motility was required for primary adhesion and that type IV pili were essential for 
cellular aggregation. In a following paper, Glessner and coworkers (Glessner et al., 
1999) demonstrated that both the las and rhl QS systems are required for type-IV pilus-
dependent twitching motility. C4-HSL in particular appeared to influence both the 
export and surface assembly of surface type IV pili, while 3-oxo-C12-HSL played a role 
in maintaining cell-cell spacing and associations required for effective twitching 
motility. 
Subsequent research, however, has challenged these original findings. In a study 
investigating the influence of alginate production on biofilm structure in the laboratory 
strain PAO1, the wildtype control biofilm was flat and appeared more like the QS lasI 
mutant biofilm reported above. This was attributed to differences in media composition 
(Hentzer et al., 2001). In fact, Beatson et al. (Beatson et al., 2002) have suggested that 
the results obtained by Davies et al. (1998) and Glessner et al. (1999) were most likely 
due to the occurrence of spontaneous secondary mutations in key regulatory genes in 
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the strains shared by these two groups. Additionally, Heydorn and colleagues have 
provided evidence that twitching motility is not required for microcolony formation and 
that cell-cell signalling via lasI-lasR QS is not required for the development of mature 
biofilms (Heydorn et al., 2002). 
This debate serves to illustrate the challenges of studying the role of QS in biofilm 
formation and of biofilm formation itself. Whilst compelling evidence from research in 
other species leaves no doubt that QS is essential for the development of biofilms 
(Lynch et al., 2002), as a global regulator of operons encoding different functionalities, 
mutations in the QS control system will have diverse effects with potentially complex 
consequences for the expression of many genes. Other regulators, experimental 
conditions, such as the nutritional environment (Shrout et al., 2006) and the methods of 
analysis will also have an impact. Ongoing research aims to develop the methodologies 
and technologies, which can accommodate these complexities inherent in the 
investigation of biofilms (Heydorn et al., 2000b) (O'Toole, 2003). 
1.3.13  The extracellular polymeric substance (EPS) matrix 
A key feature of biofilms is that they enable P. aeruginosa to persist in the CF lung and 
this has been attributed to the nature of the biofilms developing in this unique 
environment. The hallmark of a mature biofilm is the production of an extracellular 
matrix or EPS, which determines its architecture and may also contribute to its strength 
and material properties (Hall-Stoodley and Stoodley, 2002). The chemistry of the EPS 
is complex and includes polysaccharides, nucleic acids and proteins, although their 
nature and relative contributions are ill-defined.  
Historically, research has focused on the role of alginate, a polymer of the uronic acids 
mannuronic and guluronic acid and alginate overproduction leads to the mucoid 
phenotype of P. aeruginosa. This appears to be a unique adaptation to the CF lung 
environment as it is not seen in infections elsewhere in the body and mucoid isolates 
typically revert to the nonmucoid phenotype when grown on laboratory medium 
(Nivens et al., 2001). The mechanism for the overproduction of alginate is complex and 
requires several regulatory proteins that act in a hierarchical regulatory cascade 
(Wozniak and Ohman, 1994). Possible triggers for this conversion include hypoxia 
(Worlitzsch et al., 2002), hydrogen peroxide (Mathee et al., 1999) and contact with a 
surface (Davies et al., 1993). Alginate is thought to promote persistence of 
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P. aeruginosa by offering a degree of protection in the harsh lung environment in which 
bacteria are continually subjected to oxidative stress and attack by the immune system 
(Simpson et al., 1988). 
In keeping with its contribution to the chronicity of lung disease, there is evidence that 
alginate production enhances biofilm structure and increases biofilm resistance to the 
antibiotic tobramycin (Nivens et al., 2001) (Hentzer et al., 2001). Yet the relationship 
between biofilm formation and the conversion to mucoidy remains unclear. Notably, 
alginate is not actually required for biofilm formation (Nivens et al., 2001). Both 
mucoid and nonmucoid strains readily form biofilms and this demonstrates that alginate 
cannot be the universal structural matrix. Whilst it is accepted that its expression and 
role may be important under certain environmental conditions, the suggestion that other 
exopolysaccharides might be important must be entertained. 
Another candidate molecule is LPS: a major component of the cell wall of Gram-
negative bacteria that consists of a hydrophobic lipid A region, a central core 
oligosaccharide region and a repeating polysaccharide portion termed the O antigen. 
LPS molecules are important for the structure of individual bacterial cells and also 
mediate interactions with the neighbouring environment. Indeed, changes in the LPS are 
characteristically seen in the CF lung and are thought to contribute to biofilm formation. 
For example, a transition from a ÔsmoothÕ to a ÔroughÕ phenotype by the loss of the O 
antigen is a typical feature of chronic infection and studies have shown that rough 
mutants form a more stable biofilm (Flemming et al., 1998). 
Several groups have undertaken studies to identify alternative polysaccharide candidates 
for the biofilm matrix and two loci have been discovered. The pel genes produce a 
glucose-rich matrix polysaccharide that was found to be essential for biofilm formation 
at the air-liquid interface of standing cultures (pellicles) and for biofilm structure in 
laboratory strains PA14 and PAK (Friedman and Kolter, 2004a) (Vasseur et al., 2005). 
This Pel polysaccharide is biochemically and genetically distinct from the second 
polysaccharide identified: Psl (polysaccharide synthesis locus).  The psl operon was 
found to be essential for biofilm formation in strains PAO1 and ZK2870 (Friedman and 
Kolter, 2004b; Jackson et al., 2004) and has been shown to be mannose and galactose-
rich (Ma et al., 2007). 
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Whilst polysaccharides are the most-studied component of the EPS, there is a paucity of 
data as to their exact nature. Ultimately this comes down to the difficulties in studying 
polysaccharides, which is in part due to the difficulty in the separation and extraction of 
EPS from bacterial cells as well as the complexities of analysing polysaccharides, which 
can be highly branched with a wide variety of linkages and side groups (Hall-Stoodley 
and Stoodley, 2002). Given that it is widely accepted that carbohydrates represent 
important binding ligands in biofilms, an alternative and promising avenue of 
investigation concerns their receptors. 
1.3.14 Lectins 
 ÒLectins are ubiquitous proteins that bind carbohydrates specifically and reversibly and 
may therefore aggregate cells and glycosylated macromoleculesÓ (Garber et al., 1992) 
such as the EPS of bacterial biofilms. 
P. aeruginosa synthesises two lectins termed LecA and LecB (formerly PA-IL and PA-
IIL respectively).  LecA was discovered because of the ability of P. aeruginosa cell-free 
extracts to haemagglutinate papain-treated human erythrocytes (Gilboa-Garber, 1972) 
and it was the first bacterial lectin to be purified by the use of affinity chromatography 
(Gilboa-Garber et al., 1972). Subsequently, LecB was discovered in extracts of the 
same bacterium isolate when cultured in a different medium (Gilboa-Garber, 1982). The 
combined sugar-binding spectra of these two lectins cover a wide range of human 
antigens (ABH, P and I systems) that are common to all human cells and tissues and 
this may well be related to the reported ability of P. aeruginosa to infect most of them 
(Imberty et al., 2004). 
The lecA gene consists of 366 bp and codes for a 51 kDa tetrameric protein composed 
of four 12.75 kDa subunits, each made up of 121 amino acids (Gilboa-Garber et al., 
1972). Calcium together with a unique network of hydrogen bonds generates a binding 
site endowed with a selective specificity for D-galactose and its derivatives. 
Equilibrium dialysis and haemagglutination inhibition tests by Garber and colleagues 
(Garber et al., 1992) have shown that LecA binds hydrophobic derivatives of 
thiogalactose and galactose better than D-galactose itself. 
The 47 kDa lectin LecB is also a tetramer, with each subunit consisting of 114 amino 
acids. Its gene, lecB (345 bp) is located about 867.5 kb away from lecA on the 
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P. aeruginosa chromosome. There are two calcium ions at the binding site, which 
shows affinity for L-fucose and other monosaccharides such as mannose (Gilboa-
Garber et al., 2000). See Figure 1-7 for the crystal structures of the lectin/cognate-
carbohydrate complexes and Table 1-1 for a comparison of the properties of the two 
lectins. 
 
Figure 1-7 Crystal structure of the LecA/galactose and LecB/fucose complexes.  
(A) Tetramer with stick representation of monosaccharide and space-filling representation of 
calcium ions. (B) Monomer with the β-sheets represented by two colours. 
(Imberty et al., 2004) 
 
A B 
LecA (PA-IL) 
LecB (PA-IIL) 
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Table 1-1 Comparison of LecA (PA-IL) and LecB (PA-IIL) properties 
(Imberty et al., 2004) 
 
Sudakevitz and Gilboa-Garber (Sudakevitz and Gilboa-Garber, 1987) have 
demonstrated that LecA and LecB are present in the extracts of most P. aeruginosa 
strains, including hospital isolates. Whilst most of their activity is stored intracellularly, 
small but significant fractions of these lectins are present on the cytoplasmic membrane, 
on the outer membrane and in the periplasmic space (Glick and Garber, 1983). It is said 
that the lectins are released from bacteria following their lysis and this may occur 
secondary to the disruption of cells by host defences (Imberty et al., 2004). An 
alternative theory is that the lectins are secreted by the bacterial cell, possibly via the 
type II pathway (Stacey, 2003), however the lecA gene does not appear to carry a signal 
sequence. 
For many Gram-negative bacteria, lectin-carbohydrate interactions are involved in 
microbial pathogenicity, especially by enhancing bacterial adherence to epithelial cells 
(Beuth et al., 1990). For example, Laughlin et al. (Laughlin et al., 2000) demonstrated 
that LecA not only aids adhesion of P. aeruginosa to intestinal epithelial cells in lethal 
gut-derived sepsis in the mouse, but also induces a permeability defect, allowing 
cytotoxic exoproducts, including exotoxin A, to cross the epithelial barrier. There is 
evidence that LecA promotes adherence to the respiratory epithelium (Plotkowski et al., 
1989) and significantly, Bajolet-Laudinat et al. (Bajolet-Laudinat et al., 1994) have 
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demonstrated a dose-dependent cytotoxic effect of LecA on respiratory epithelial cells 
in vitro. In addition, a search of sequence databases for proteins displaying similarities 
to these lectins yielded no positive hit for LecA (Imberty et al., 2004), suggesting that 
any pathogenic role it may play in the lung is unique to P. aeruginosa. 
In fact, recent microarray work by Whiteley and colleagues has shown that lecA is over 
1000-fold induced during anaerobic growth and as such, is the most highly regulated 
anaerobic gene that their group has seen (Whiteley 2004, personal correspondence). 
This has great significance given that there is evidence that CF mucus is essentially 
anaerobic and that P. aeruginosa seems to thrive as biofilms under these conditions 
(Borriello et al., 2004) (Hasset et al., 2002). 
The regulation of lectins in P. aeruginosa is complex and involves the las and rhl QS 
systems. Most work has been undertaken on lecA expression, which has been shown to 
be dependent on RhlR/C4-HSL. Furthermore, LecA production is growth-phase 
dependent and requires RpoS (Diggle et al., 2002) (Winzer et al., 2000). Additional 
regulatory elements exist such as the post-transcriptional regulator RsmA (Pessi et al., 
2001). PQS is also needed and its presence can overcome the cell-density but not 
growth-phase dependency of lecA regulation (Diggle et al., 2003). 
The role of MvaT, a novel global regulator of virulence gene expression in 
P. aeruginosa is also being unravelled. A mutation in mvaT results in enhanced lecA 
expression and the addition of exogenous AHLs to this mutant advances lecA 
expression, suggesting that MvaT is involved in growth phase-dependent regulation 
(Diggle et al., 2002). Interestingly, the phenotype of this MvaT mutant demonstrates an 
increased ability to form biofilms and the question of whether this is the result of altered 
lectin production was raised (Stacey, 2003). 
To investigate this hypothesis, Diggle et al. (Diggle et al., 2006b) demonstrated that 
lecA is expressed in P. aeruginosa PAO1 wildtype biofilms and provided evidence that 
in contrast to this parent strain, a lecA mutant was unable to form mature biofilms. A 
mutant defective in MvaT, which overproduces LecA, was observed to form 
significantly thicker biofilms, which covered a correspondingly greater surface area. 
The addition of exogenous galactosides with a strong affinity for LecA abolished 
biofilm formation on stainless steel and dispersed pre-formed biofilms.  
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Further clues detailing this proposed role for LecA in biofilm formation arise from the 
realisation that lecA is not the only gene upregulated in the enhanced biofilm-forming 
mvaT mutant. A recently identified gene cluster, termed cupA, is also negatively 
controlled by MvaT (Vallet et al., 2004). This is believed to be important in the 
assembly of putative fimbrial structures and may therefore play an important role in the 
initial colonisation of surfaces (Vallet et al., 2001). There is data to suggest that whilst 
cupA genes play an important role in the early stages of biofilm formation, the lecA-
encoded LecA contributes to cell-cell interaction and hence biofilm maturation at a later 
stage (Vallet et al., 2004) (Diggle et al., 2006b). The hypothesis that it contributes to the 
structure of biofilms by means of its ability to bind carbohydrates is lent support by the 
observation that purified LecA preparations always contain traces of bound LPS 
(Gilboa-Garber, 1997). 
Work has also been undertaken to investigate whether LecB contributes to 
P. aeruginosa biofilms. Diggle et al. found that the addition of a furanoside with a 
strong affinity for LecB, at a concentration likely to be effective, did not have an effect 
on biofilm formation (Diggle et al., 2006b). However data published by Tielker and 
colleagues has provided evidence that LecB is located in the outer membrane and that a 
LecB-deficient mutant was impaired in biofilm formation (Tielker et al., 2005). The 
report that this defect in biofilm formation is due to lack of pilus biosythesis in the lecB 
mutant strain raises the important point that some of the ascribed functions of LecA and 
LecB may be secondary effects on other systems rather than direct effects of the lectins 
themselves (Sonawane et al., 2006).  
1.3.15  The significance of the biofilm mode of growth 
Whilst the details of biofilm formation have yet to be clarified, the huge significance of 
biofilms cannot be disputed and is the fuel which powers research in this field. Biofilms 
are ubiquitous in the environment and in man. Whilst precise figures are lacking, it has 
been estimated that biofilms are associated with 65 % of nosocomial infections 
(Licking, 1999) and account for over 80 % of microbial infections in the body 
(http://grants.nih.gov/grants/guide/pa-files/PA-03-047.html). In response, there is 
growing concern that the adoption of biofilm concepts in medical microbiology lags far 
behind the acceptance of these notions of bacterial growth in adjacent areas of research, 
such as microbial ecology and industrial microbiology (Costerton, 2001).  
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Whilst much research has focused on single species P. aeruginosa biofilms, mixed 
biofilms are more representative of those which occur in nature. In the CF lung, 
P. aeruginosa and the emerging human pathogen B. cepacia may coexist in biofilms 
and this environment may provide the means for interaction between these two 
organisms. Both species are know to employ QS and investigations by Riedel et al. 
(Riedel et al., 2001) provide evidence for unidirectional cross-talk, with B. cepacia 
capable of perceiving AHL QS signals of P. aeruginosa but the latter not responding to 
the AHL signals of the former. Interestingly, although S. aureus uses a different 
peptide-based QS system, the exogenous addition of AHLs produced by P. aeruginosa 
to cultures of S. aureus affected virulence-determinant production by this organism, 
suggesting that QS may allow P. aeruginosa to displace S. aureus in the CF lung (Qazi 
et al., 2006). In contrast, it has been reported that HQNO from P. aeruginosa can lead 
to the development of antibiotic resistant and difficult to detect small colony variants of 
S. aureus (Hoffman et al., 2006). This could allow P. aeruginosa to benefit from useful 
S. aureus metabolites, such as iron (Mashburn et al., 2005). 
A major role of biofilms is their contribution to the persistence of P. aeruginosa in the 
CF lung. This strategy has been characterised as tenacious survival rather than 
aggressive virulence and seems to be the result of biofilm resistance to treatment and 
protection from the host immune response.  
The intrinsic ability of P. aeruginosa to develop resistance to many commonly used 
antibiotics is not well understood but has been speculated to be due to the structure of 
the cell wall, the extensive linkage of outer membrane proteins to the LPS or the 
extremely hydrophilic nature of the outer membrane, which may exclude many 
hydrophobic antibiotics (Lyczak et al., 2002). However, these individual mechanisms of 
antibiotic resistance do not seem to be responsible for the protection of bacteria in a 
biofilm and other multicellular strategies have been proposed. These include failure of 
the antibiotic to penetrate the full depth of the biofilm, an altered chemical 
microenvironment within the biofilm affecting antibiotic action and speculation that 
some biofilm bacteria may adopt a protective, spore-like state (Stewart and Costerton, 
2001). 
Hence, antibiotic therapy (developed against planktonic cells and selected because of 
results of planktonic assays) typically reverses the symptoms caused by planktonic 
bacteria released from the biofilm but fails to kill the biofilm itself. For this reason 
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biofilm infections, such as P. aeruginosa infections in the CF lung, typically show 
recurring symptoms or exacerbations necessitating repeated cycles of symptomatic but 
not curative antibiotic therapy (Costerton et al., 1999). 
The immune response is an important player in the host-parasite interaction, yet its 
ineffectiveness against biofilms is another major reason why P. aeruginosa persists in 
the CF lung. Sessile P. aeruginosa communities release antigens whilst growing as 
biofilms and very high concentrations of antibodies to P. aeruginosa are seen in the 
circulating blood and in the lungs. These react with their specific antigens in the outer 
reaches of the matrices but neither their bactericidal nor opsonising capabilities are 
realised and in fact may lead to a worse clinical outcome because they may cause 
immune complex damage to surrounding tissues (Costerton et al., 1999). Overall, this 
overstimulated yet frustrated immune response fails to clear the biofilms and together, 
infection and inflammation lead to tissue destruction, loss of function and ultimately, 
the demise of the patient. 
1.4  Perspectives 
Overall, P. aeruginosa infection in CF is a complex series of events involving host 
abnormalities secondary to CFTR dysfunction, exacerbated by consequent cycles of 
bacterial adaptations and host responses. Ultimately, the point of trying to unravel this 
interaction is in order to identify novel targets for intervention. 
Current cornerstones of treatment are nutritional regimes, physical airway clearance 
exercises and antibiotic chemotherapy. These are delivered by multidisciplinary clinical 
teams who adhere to strict infection control measures. Given the intensity of research in 
the field, treatment strategies are flexible in order to incorporate new advances such as 
the use of recombinant human DNase I as a mucolytic and the use of macrolides as 
antiinflammatory agents. There are great expectations for the development of CF gene 
transfer therapy, antiinflammatory therapy and effective immunotherapy as presently, 
lung transplantation is the final therapeutic option for patients with end-stage lung 
disease. 
There is no doubt that chronic infection with P. aeruginosa is the major cause of ill-
health and death in this patient population. Whilst the use of antibiotics leads to 
improvement in lung function (the best predictor of survival in these patients), timing 
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and regime are largely empirical and the rise of resistant strains poses new challenges. 
However, thinking about bacterial populations as connected organisms
 
capable of 
concerted multicellular activities may provide researchers
 
with the opportunity to target 
multicellular behaviour and the formation of multicellular structures such as biofilms.  
In fact, methods for disrupting QS, including destruction of AHLs or interference with 
their binding, are being developed. For example, Hentzer et al. (Hentzer et al., 2002) 
have demonstrated that suppression of thicker more complex biofilm structures was 
possible using a synthetic furanone to inhibit QS. Alongside this, new diagnostic 
systems, which have the capacity to interpret and indicate the presence of QS will be 
needed (Williams, 2002). Indeed if a rise in AHLs and PQS in CF sputum correlates 
with clinical deterioration, they may represent useful diagnostic biomarkers which 
provide additional information about pathogenic behaviour. The ability to detect the 
lectin LecA may indicate that biofilm development is occurring and given its 
cytotoxicity, may also provide a non-invasive marker of airway inflammation and 
damage. 
It is hoped that the recent characterisation of the crystal structures of the two lectins 
may open up a route for the design of carbohydrate-based compounds that would act as 
efficient inhibitors of bacterial adhesion and biofilm formation (Cioci et al., 2003) 
(Loris et al., 2003). A preliminary report, based on a one patient case, has described an 
anti-adhesion based therapy of respiratory P. aeruginosa infection using a fucose and 
galactose containing solution (von Bismarck et al., 2001). Yet to make this work 
applicable to the disruption of P. aeruginosa infections in the CF lung, investigation of 
LecA production by isolates from CF sputum and further details of the specific 
contribution of these lectins to biofilms are needed.  
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1.5 Project aims 
Despite major advances in CF research, premature mortality occurs in this important 
and vulnerable patient group in the prime of their lives. Given that P. aeruginosa is the 
major challenge, unravelling the mechanisms of its unique adaptation and pathogenicity 
is urgently needed in order to develop new treatment strategies to improve health and 
survival. This project was set in the context of exploring the QS related mechanisms 
governing the pathogenesis of P. aeruginosa in the CF lung, including the role of the 
pseudomonas lectins in biofilm formation. The specific aims of the project were: 
1) To isolate and characterise a cohort of clinical P. aeruginosa strains with respect to 
their QS phenotype and establish the conservation and expression of lecA amongst these 
isolates. 
2) To assess the ability to detect QS signal molecules in sputum from CF patients and 
determine whether there was any association between the level of these molecules and 
the clinical status of the patients. 
3) To establish a flowchamber biofilm system and the associated COMSTAT and 
IMARIS technology required to undertake detailed in vitro biofilm study. 
3) To investigate the contribution of LecA to biofilm maturation in both laboratory and 
clinical strains and identify its biofilm target ligand. Thereafter to explore the ability of 
anti-lectin galactosides and furanosides, including novel synthetic furanoside 
dendrimers, to disrupt biofilms with a view to identifying novel therapeutics to tackle 
P. aeruginosa biofilms. 
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2 Chapter 2:  Materials and Methods 
 
2.1 Patient Recruitment 
Applications were submitted to Nottingham Research Ethics Committee 1 and 
Nottingham City Hospital Research and Development (R&D) department for the 
clinical research project entitled ÒLectin-mediated biofilm maturation, quorum sensing 
and Pseudomonas aeruginosa infections in cystic fibrosisÓ. Full approval for the study 
protocol and associated documentation was granted by Ethics and R&D in April 2004, 
with no amendments required. Two subsequent research monitoring visits were 
performed by the Nottingham City Hospital Research Governance Manager and her 
recommendations were implemented. See Appendix 1 for the approved study protocol. 
The study was a prospective, longitudinal cohort study among a population of CF 
patients in Nottinghamshire. Patients were recruited from the Adult and Paediatric CF 
outpatientsÕ clinics at Nottingham City Hospital, UK from May 2004 until August 2005. 
The diagnosis of CF had been established previously in all of these subjects by genetic 
testing and/or sweat test. To be included in the study, subjects had to be sputum 
producers. The presence of B. cepacia was an exclusion criterion. There was no cut off 
level for the forced expiratory volume in 1 second (FEV1). 
Suitable patients were identified by the CF nurse specialists and given patient 
information leaflets to read. Informed voluntary consent was obtained by myself or one 
of the CF doctors. One signed copy of the consent form was given to the patient, one 
was filed in the notes and one kept with the study documentation. If the patient agreed, 
their general practitioner (GP) was informed of their involvement in the study. See 
Appendix 2 for examples of patient information leaflets, consent forms and GP letter.  
2.2 Sputum collection 
Voluntarily expectorated sputum samples were collected by the lung function 
technicians or the CF nurse specialists following spirometry. Samples were obtained at 
each routine clinic visit at approximately two monthly intervals throughout the study 
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period. Specimen pots were labelled with the patientÕs Nottingham City hospital 
number to maintain confidentiality. These were transported routinely on hospital 
transport to the Microbiology specimen reception at the QueenÕs Medical Centre the 
same afternoon. Specimens were stored at 4 ¼C overnight and then collected and 
transported in an airtight plastic box to the Centre for Biomolecular Sciences for further 
analysis.  
Each sample was allocated a unique study code consisting of the letter A (for adult 
patients) or P (for paediatric patients), an individual patient number and the date it was 
produced. For example, sample A001-291204 was provided by adult patient number 1 
on 29 December 2004. 
Analysis of sputum samples was undertaken in a Class 1 microbiological safety cabinet 
within a Category 3 safety facility in order to prevent exposure to airborne droplets or 
particles generated in handling infected sputum samples.  
2.3 Clinical data collection 
Clinical data collection proformas were prepared (Appendix 3) and used to analyse 
patient clinical records. On the date a particular sputum sample was collected for 
analysis, the corresponding clinical data was recovered by Dr Paramita Cifelli, 
Specialist Registrar in Paediatrics, Nottingham City Hospital. This included predicted 
and actual spirometry values, pulse oximetry, white cell count, C reactive protein, 
sputum microbiology, the presence of clinical symptoms of a pulmonary exacerbation 
(Rosenfeld et al., 2001) and antibiotic use. 
2.4 Bacterial strains 
2.4.1 Laboratory bacterial strains 
All laboratory bacterial strains used in this study are listed in Table 2-1.  
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Table 2-1 Laboratory bacterial strain characteristics 
 
Strain Characteristics Reference/Source 
Escherichia coli:   
DH5α F
-
, ϕ80dlacZΔM15, 
Δ(lacZYA-argF)
U169
, deoR, 
recA1, endA1, phoA, 
hsdR17(r
K
-, m
K
+), supE44, 
thi-1, gyrA96, relA1 
GibcoBRL, Life 
Technologies 
JM109 recA1, supE44, endA1, 
hsdR17, gyrA96, relA1, thi 
Δ(lac-proAB), FÕ [traD36, 
proAB
+
, lacIq, lacZΔM15] 
 
(Yanisch-Perron et 
al., 1985)  
 
S17-1 λpir thi, pro, hsdR, hsdM
+
, 
recA, RP4-2-Tc::Mu-
Km::Tn7, λpir 
(Simon et al., 1983) 
Pseudomonas aeruginosa:   
PAO1 Wild-type, Nottingham 
strain 
Holloway collection 
PAO1 lecA::lux lecA::luxCDABE genomic 
reporter fusion in PA01
  
(Winzer et al., 2000) 
PAO1ΔlecA lecA chromosomal deletion 
mutant derived from PAO1 
(Stacey, 2003) 
PAO1ΔlecB lecB chromosomal deletion 
mutant derived from PAO1 
This study 
PAO1 pUCP18::gfpmut3.1 PAO1 containing 
pUCP18::gfpmut3.1 
(Stacey, 2003) 
PAO1ΔlecA 
pUCP18::gfpmut3.1 
lecA chromosomal deletion 
mutant derived from PAO1 
containing 
pUCP18::gfpmut3.1 
This study 
PAO1 lecAÕ::luxΔpqsA 
 
pqsA chromosomal 
deletion mutant derived 
from PA01 lecA::lux 
(Diggle et al., 2006a) 
 
2.4.2 Clinical bacterial isolates 
P. aeruginosa clinical isolates were recovered by streaking a 1 µl loopful of neat 
sputum on Pseudomonas Isolation Agar (PIA). Plates were incubated at 37 ¼C for 24 to 
48 h. Each resulting colony type was Gram-stained and tested for oxidase activity. 
 61 
Those that consisted of rapidly oxidase positive Gram-negative rods were restreaked 
onto fresh PIA and incubated for a further 24 to 48 h. 
The resulting colonies were photographed using a Nikon Coolpx995 digital camera 
under light and dark-phase conditions. A record of colony morphology, pigment 
production and mucoidy was made. 
2.5 Plasmids 
All plasmids used in this study are listed in Table 2-2. 
 
Table 2-2 Plasmids used 
 
Name Description Reference 
pUCP18::gfpmut3.1 pUCP18 containing the gfpmut3.1 
gene, ligated in to MCS with HindIII 
and BamHI 
(Stacey, 2003) 
pSB1142 AHL reporter plasmid containing the 
P. aeruginosa lasR gene and lasI 
promoter fused to luxCDABE operon 
from Photorhabdus luminescens, 
pACYC184 derived (Tc
R
) 
This laboratory 
Unpublished 
pSB536 AHL reporter plasmid containing the 
Aeromonas hydrophila ahyR gene and 
ahyI promoter fused to luxCDABE 
operon from Photorhabdus 
luminescens, pAHP13 derived (Amp
R
) 
(Winson et al., 1998) 
pBLS 
 
pBluescript KS cloning vector; ColE1 
replicon (Amp
 R
) 
Stratagene 
pBLS::lecB 
 
A 4.4 kb SacI, KpnI PAO1 
chromosomal DNA fragment 
containing lecB in pBLS (Amp
 R
) 
This study 
pBLSΔlecB 
 
pBLS containing lecB flanking regions 
and deleted lecB gene (Amp
 R
) 
This study 
pEX18Gm  
 
oriT
+
 sacB
+
, gene replacement  
vector with MCS from pUC18 (Gm
R
) 
(Hoang et al., 1998) 
pEX18GmΔlecB  
 
pEX18Gm containing lecB flanking 
regions and deleted lecB gene (Gm
 R
) 
This study 
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2.6 Oligonucleotide primers 
Oligonucleotide primers were synthesised by Sigma (UK). Where necessary, restriction 
sites were incorporated into the 5Õ end of the primer to aid cloning of the PCR product. 
Primer sequences are listed in Table 2-3. 
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Table 2-3 Oligonucleotide primer sequences 
 
Primer Sequence (5Õ to 3Õ) Function 
lasI3UF CGGGTTCACCGAA
ATCTATC 
Primer used to amplify lasI upstream 
region 
lasI3DR ACTCGCTTTACAGC
GGATTC 
Primer used to amplify lasI downstream 
region 
lasR3UF CCGAATCCATATTT
GGCTGA 
Primer used to amplify lasR upstream 
region 
lasR3DR GAGAACCTGCCCTT
CCCTAT 
Primer used to amplify lasR downstream 
region 
lecAUF TTGGAAAGGTGAG
GTTCTGGCTAAT 
Primer used to amplify lecA internal 
upstream region 
lecADR GACTGATCCTTTCC
AATATTGACAC 
Primer used to amplify lecA internal 
downstream region 
lecBHpa1UR AGGGTGTTAACTCC
TTGTGTTGC 
Primer used to sequence out from the 5Õ 
end of lecB to amplify the upstream 
flanking region and pBluescript plasmid 
DNA incorporating the Hpa1 restriction 
site 
lecBHpa1DF TGGTGGTTAACTGG
CCGCTCGGC 
Primer used to sequence out from the 3Õ 
end of lecB to amplify the downstream 
flanking region and pBluescript plasmid 
DNA incorporating the Hpa1 restriction 
site 
lecBUF TGGCAACACAAGG
AGTGTTC 
Primer used to amplify lecB internal 
upstream region 
lecBDR GCCAGTTGATCACC
ACGAC 
Primer used to amplify lecB internal 
downstream region 
Sac1lecBUF TATGAGCTCAACCC
AACGGGCAAATCG
TTG 
Primer used to amplify lecB and 500 bp 
upstream incorporating the Sac1 
restriction site 
Kpn1lecBDR 
 
ATAGGTACCAGGT
GGCGGTGATCAAC
TTC 
Primer used to amplify lecB and 500 bp 
downstream incorporating the Kpn1 
restriction site 
pqsHintUF CTGGCGCGCGAATT
CACCAAGGCA 
Primer used to amplify pqsH internal 
downstream  region 
pqsHintDR AAGACGCTGGTGG
AGGCGCCTGCG 
Primer used to amplify pqsH internal 
upstream region 
rhlIUF ACGACACGGGGAC
TTGGT 
Primer used to amplify rhlI upstream 
region 
rhlIDR GCAGGAGAAGCGA
AAAA 
Primer used to amplify rhlI downstream 
region 
rhlRUF TGCCATGATTTTGC
CGTAT 
Primer used to amplify rhlR upstream 
region 
rhlRDR CACACATGAGGGG
GAAGACT 
Primer used to amplify rhlR downstream 
region 
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2.7 Chemical reagents 
2.7.1 General chemicals 
Unless otherwise stated, all chemicals were obtained from Sigma (UK). 
2.7.2 Antibiotics 
Stock solutions of antibiotics were prepared according to Sambrook et al. (2003) and 
stored at -20 ¡C. Ampicillin (Amp) was used from a 50 mg/ml in 50 % (v/v) ethanol 
(EtOH) stock, carbenicillin (Cb) from a 50 mg/ml stock in deionised water (dH2O) and 
gentamicin from a 50 mg/ml stock in dH2O (Gibco, Invitrogen). The final concentration 
of antibiotics added to media for the selection and maintenance of plasmids was: Amp 
100 µg/ml (E. coli); Cb 300 µg/ml (P. aeruginosa) and gentamicin 15 µg/ml (E. coli) 
and 100 µg/ml (P. aeruginosa). All reagents were filter sterilised before use (0.22 µm 
pore Minisart venting filter, Sartorius, Germany). 
2.7.3 Synthetic AHLs 
Synthetic 3-oxo-C12-HSL and C4-HSL were made by S. R. Chhabra at the Centre for 
Biomolecular Sciences, University of Nottingham (Chhabra et al., 1993). Stocks of 1 
µg/ml 3-oxo-C12-HSL and 10 µg/ml C4-HSL in acetonitrile were used. Compounds 
were stored at -20 ¼C. 
2.7.4 Synthetic AQs 
Synthetic PQS and its HHQ were synthesised by S. R. Chhabra and stored at -20 ¼C. 
Both were dissolved in methanol and PQS kept as 10 mM stock, HHQ as 5 mM stock. 
2.7.5 Trace metals solution  
Trace metals solution was prepared according to the formulation provided by the Center 
of Biomedical Microbiology (CBM), DTU. It consisted of iron (II) sulphate 2000 mg, 
manganese sulphate monohydrate 200 mg, copper sulphate 200 mg, zinc sulphate 
heptahydrate 200 mg, cobalt sulphate heptahydrate 100 mg, sodium molybdate 
dihydrate 120 mg and boric acid 50 mg in 1 L dH2O, pH 4.5. The solution was 
autoclaved at 121 ¼C for 20 min at 15 p.s.i. (which caused the iron to precipitate).  
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2.8 Growth media 
Media was prepared using dH2O and autoclaved at 121 ¼C for 20 min at 15 p.s.i. The 
sterility of large volumes of media was ensured by running the autoclave cycle with 
Ôload sensingÕ activated and placing the temperature probe in an equivalent volume of 
liquid. This often required a prolonged heating phase in excess of 90 min. 
2.8.1 Luria Bertani medium 
All bacterial strains were routinely grown in Luria Bertani (LB) broth unless otherwise 
stated. LB broth was prepared as described by Sambrook et al., (2003) and consisted of 
tryptone 10 g, yeast extract 5 g and sodium chloride 10 g in 1 L dH2O. 
LB agar was prepared by addition of 0.8 % (w/v) Technical Agar No. 3 (Oxoid) to LB 
broth.  
2.8.2 Soft-top agar 
LB soft-top agar consisted of tryptone 10 g, sodium chloride 5 g and Technical Agar 
No. 3 (Oxoid) 6.5 g in 1 L dH2O. 
2.8.3 Nutrient broth  
Nutrient broth No. 2 (NB) (Oxoid) was prepared according to the manufacturerÕs 
instructions and consisted of ÔLab-lemcoÕ powder 10 g, peptone 10 g and sodium 
chloride 5 g in 1 L dH2O. 
2.8.4 Nutrient yeast broth  
 Nutrient yeast broth (NYB) (Oxoid) was prepared according to the manufacturerÕs 
instructions and consisted of nutrient broth No. 1 25 g and yeast extract 5 g in 1 L 
dH2O. 
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2.8.5 Sucrose/agar broth 
Sucrose agar and broth were used in recombinant-selective experiments. A stock 
concentration of 50 % (w/v) sucrose was made by adding 100 g sucrose to 200 ml 
sterile dH2O and filter sterilised. Sucrose broth consisted of tryptone peptone 10 g and 
yeast extract 5 g in 900 ml sterile dH2O, pH 7. To this, 100 ml sucrose stock solution 
was added aspetically, giving a final sucrose concentration of 5 % (w/v). 
2.8.6 PIA 
PIA (Difco) was prepared according to the manufacturerÕs instructions and consisted of 
peptone 20 g, magnesium chloride 1.4 g, potassium sulphate 10 g, irgasan 0.025 g and 
agar 13.6 g in 1 L dH2O containing 20 ml glycerol. 
2.8.7 JensenÕs minimal media 
JensenÕs minimal media was prepared according to a recipe provided by Luyan Ma, 
Wake Forest University School of Medicine, Winston-Salem (personal 
communication). Stock solutions of 10 x glucose (12.61 g in 100 ml dH2O), 100 x 
magnesium sulphate heptahydrate (33 g in 100 ml dH2O), calcium chloride dehydrate 
(210 mg in 100 ml dH2O), Iron (II) sulphate heptahydrate (11 mg in 100 ml dH2O) and 
zinc sulphate heptahydrate (24 mg in 100 ml dH2O) were made and autoclaved to 
sterilise separately.  
To the 100 ml 10 x glucose stock solution, valine 2.81 g and phenylalanine 1.32 g were 
added and the resulting solution filter sterilised. 
For 1 L final volume 1 x solution, sodium chloride 5 g, dipotassium (hydrogen) 
phosphate 2.51 g and glutamic acid 15.56 g was added to 860 ml dH2O and mixed 
thoroughly. The pH was raised to approximately 7 to enable the glutamic acid to 
dissolve and the solution autoclaved. To this, the 100 ml 10 x glucose stock solution 
containing valine and pheylalanine and 10 mls of each of the 100 x metal stock 
solutions were added aspectically. 
When required, L-arabinose was added sterile to a final concentration of 2 % (w/v). 
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2.8.8 A-10 media 
A-10 media was prepared according to Haagensen et al. (2006). It consisted of 
ammonium sulphate 20 g, disodium (hydrogen) phosphate dehydrate 60 g, potassium 
phosphate 30 g, sodium chloride 30 g in 1 L deionised water, pH 6.4 ± 0.1. 
2.8.9 FB media 
FB media (Haagensen et al., 2006) consisted of 10 ml 1 M magnesium chloride, 1 ml 1 
M calcium chloride, 1 ml trace metals solution (see 2.7.5) in 9 L Milli-Q water.  
2.8.10 ABtrace minimal media  
ABtrace minimal media was prepared by aseptically mixing 1 L A-10 media with 9 L 
FB media and adding glucose as the carbon source to a final concentration of 0.3 mM 
(Haagensen et al., 2006).  
2.9 Growth and storage of bacteria 
2.9.1 Bacterial growth conditions 
Liquid cultures were grown in LB broth with agitation at 200 revolutions per minute 
(rpm) on a Heidolph unimax 2010 shaker (SLS) in a 37 ¼C warm room unless otherwise 
stated.  
2.9.2 Monitoring of bacterial growth 
Growth of bacterial cultures was monitored by absorbance at a wavelength of 600 nm 
(optical density, OD600) using a Novaspec II visible spectrophotometer (Pharmacia LKB 
Ltd., Cambridge, UK).  
For serial growth measures, OD600 was monitored in a 96 well microtitre plate 
(Black/Clear Isoplates, Perkin Elmer Life Sciences) using the GENios Pro 
spectrophotometer (Tecan, UK). Overnight cultures grown in LB were standardised to 
an OD600 of 1, diluted 1:100 in LB and 300 µl aliquots were inoculated into test wells. 
Assays were performed at 37 ¼C and measurements were made from all wells every 30 
min for 24 h. Readings were then analysed using Microsoft Excel 2002. 
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2.9.3 Long term storage of bacterial strains 
For long-term storage of bacterial strains, 0.75 ml of an overnight bacterial culture was 
added to 0.75 ml 50 % (v/v) glycerol and mixed thoroughly in a 2 ml Micro tube 
(Sarstedt, Germany) before being flash frozen in liquid nitrogen. The tubes were then 
stored at -80 ¼C. 
2.9.4 Preparation of cultures for biofilm flowchamber system 
To minimise variation between successive biofilm flowchamber experiments, bacterial 
cultures with the same history were used. A batch of cultures was prepared by 
inoculating 10 ml LB with a loopful of a single colony grown overnight on a LB agar 
plate streaked from a frozen stock. Following overnight incubation at 37 ¡C 200 rpm 
shaking, the OD600 of the culture was standardised to 0.1 in sterile 0.9 % (w/v) sodium 
chloride solution with 10 % (v/v) glycerol. Aliquots of 1.5 ml were flash frozen in 
liquid nitrogen and stored at -80 ¡C. 
2.10 DNA manipulation  
2.10.1 Isolation of chromosomal DNA 
Chromosomal DNA was extracted from P. aeruginosa PAO1 using a method based on 
(Gamper et al., 1992). Briefly, 1.5 ml of an overnight bacterial culture was centrifuged 
at 13,000 rpm for 3 min in a microfuge (Biofuge pico, Kendro, Germany). The 
supernatant was discarded and the pellet resuspended in 1.5 ml TE buffer (10 mM Tris 
HCl, 1 mM EDTA, pH 8). Following a second centrifugation at 13,000 rpm for 2 min, 
the bacterial pellet was resuspended in 300 µl TE buffer. The suspension was treated 
with 100 µl 5 % (w/v) sodium dodecyl sulphate (SDS) and 100 µl Proteinase K (2.5 
mg/ml in dH2O) and incubated for 1 h at 37 ¡C. The liquid was then repeatedly drawn 
up and expelled using a syringe needle to physically disrupt the cells. The DNA was 
extracted with an equal volume of 1:1 phenol:chloroform by vortexing to mix and then 
centrifuging at 14,000 rpm for 5 min. The upper aqueous phase was transferred to a 
fresh tube and the vortexing and centrifugation steps were repeated a further two times. 
To precipitate the DNA, a 1/10
th
 volume of sodium acetate (3 M, pH 5.2) and two 
volumes of ice cold 100 % (v/v) ethanol were added and the solution was centrifuged at 
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13,000 rpm for 10 min. The supernatant was discarded and the pellet washed with 500 
µl 70 % (v/v) ethanol. This was then centrifuged at 13,000 rpm for 10 min, the 
supernatant removed and the DNA pellet was dried in a centrifugal evaporator (Jouan). 
Finally, the pellet was resuspended in 500 µl HPLC grade H2O (Fisher Scientific, UK), 
incubated at 50 ¡C for 1 h to enable gentle dissolution of the DNA and then stored at 
-20 ¡C. 
2.10.2 Isolation of plasmid DNA 
Plasmid DNA isolation was performed using the Qiagen Miniprep kit (Qiagen, UK) 
according to the manufacturerÕs protocol. Briefly, cells pelleted from 1-10 ml of an 
overnight bacterial culture were subjected to alkaline lysis, then neutralised and 
centrifuged in a microfuge (Biofuge pico, Kendro, Germany) at 13,000 rpm for 10 min 
to remove denatured and precipitated cellular debris. Lysates were then loaded onto a 
silica-gel filter, washed and plasmid DNA was eluted into 30-50 µl HPLC grade H2O. 
2.10.3 DNA agarose gel electrophoresis 
DNA loading buffer (5 x stock: 1 ml glycerol; 2 ml 50 x TAE; bromophenol blue 
0.002g; sterile dH2O to 10 ml) was added to DNA samples which were analysed 
routinely on 0.8 % (w/v) agarose gels using a horizontal gel apparatus (Flowgen 
Instruments Ltd., UK). The gels were prepared using the method described by 
Sambrook et al., (2003) using analytical grade agarose (Promega, UK) in 1 x TAE 
buffer (40 mM Tris base, 1 mM EDTA pH 8.0, 0.1142 % [v/v] glacial acetic acid) with 
the addition of ethidium bromide to a final concentration of 10 µg/ml. The gels were run 
in 1 x TAE buffer and electrophoresis was performed at 80-120 V. DNA fragments 
were visualised on a UV transilluminator (UVP, USA). 
2.10.4 DNA molecular weight markers 
To establish the size of DNA fragments, 1 µg Ready-Load 1 kb DNA ladder 
(Invitrogen) was loaded onto agarose gels alongside the sample. 
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2.10.5 DNA restriction enzymes 
Restriction enzymes were purchased from Promega and used according to the 
manufacturerÕs instructions. Restriction digests generally contained 0.5-1 µg plasmid 
DNA, 0.5-1 µl restriction endonuclease(s) and 1 x appropriate restriction buffer made to 
a final volume of 20 µl with sterile dH2O. The reaction mixture was incubated at 37 ¡C 
for a minimum of 1 h or until the digestion was complete. Reactions were analysed on 
agarose gels and the appropriate sized bands cut out prior to DNA extraction using the 
Qiagen Gel Extraction Kit (Qiagen, UK). 
2.10.6 Extraction and purification of DNA from agarose gels 
DNA fragments were purified from agarose gel slices using a Qiagen Gel Extraction Kit 
(Qiagen, UK) according to the manufacturerÕs instructions. DNA was routinely eluted 
in 50 µl sterile dH2O. 
2.10.7 Ligation of DNA fragments 
DNA ligations were routinely performed using 1:1 or 2:1 ratios of vector to insert. 
Reactions were carried out at 4 ¡C overnight using 0.5-1 µl T4 DNA ligase (Promega, 
USA) and 2 µl T4 ligation buffer in a final volume of 20 µl.  
2.10.8 DNA sequence analysis 
DNA sequencing was performed by the commercial company Geneservice (Cambridge, 
UK). Analysis of DNA sequences was performed using the FinchTV computer package 
(http://www.geospiza.com/index.shtml) in combination with the Basic Local Alignment 
Search Tool (BLAST) programme available from the National Center for 
Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov/). 
Comparisons were made to the P. aeruginosa PAO1 reference genome sequence 
(http://www.pseudomonas.com). Any errors detected in the sequences of DNA 
templates were confirmed by repeat sequencing. 
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2.11 Polymerase chain reaction (PCR) 
2.11.1 PCR amplification 
PCR amplifications were performed according to the protocol of Saiki et al., (1988) 
(Saiki et al., 1988) in a final volume of 50 µl. For general PCR reactions, 0.5 µl Taq 
DNA polymerase in 5 x buffer (GoTaq
TM
 Promega, UK) or 0.5 µl Phusion high-fidelity 
DNA polymerase in 5 x Phusion HF buffer (New England Biolabs, Inc.) were used. 
Approximately 1 µg of each primer was included in the reaction mix containing 1.5 mM 
MgCl2 and 2mM dNTPs. When amplifying P. aeruginosa DNA, 8 % (v/v) Dimethyl 
sulphoxide (DMSO) was added to the reaction mixture to aid DNA melting. The DNA 
template used was either from whole cells transferred from a fresh colony or 1 µg 
purified DNA from a chromosomal or plasmid preparation. Reactions were carried out 
in a Progene PCR Thermocycler (Techne) for a total of 30 cycles. Briefly, the DNA 
template was initially denatured at 94 ¡C for 5 min (hot start), followed by 30 cycles of 
denaturation at 94 ¡C for 30 s, annealing at 55-58 ¡C for 30 s and then extension at 
72 ¡C for 1-3 min depending on the length of the DNA to be amplified (1 min per kb). 
The last cycle finished with a final extension stage at 72 ¡C for 8 min to ensure 
completion of all strands. The annealing temperature was varied depending on the 
nature of the primers used and the stringency levels required.  Reaction mixes were then 
incubated at 4 ¡C indefinitely to allow PCR reactions to be carried out overnight. 
2.11.2 Inverse PCR 
To introduce a deletion on a recombinant fragment of DNA from a plasmid, inverse 
PCR was performed using 0.5 µl Taq DNA polymerase in 5 x buffer (GoTaq
TM
 
Promega, UK). Primers were designed to sequence out from both the 5Õ and 3Õ ends of 
the gene of interest to amplify both upstream and downstream flanking regions and 
plasmid DNA, leaving a deleted gene. These primers incorporated a Hpa1 restriction 
site that, after subsequent digestion of the PCR products (section 2.10.5), produced 
blunt ended DNA strands which were subsequently self-ligated (section 2.10.7). The 
restriction site for this Hpa1 digest was manipulated to be in-frame from the start codon 
of the gene of interest, thereby producing in-frame gene deletions when self-ligated. 
The Inverse PCR reaction mix was set up as described in section 2.11.1. 
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2.11.3 Cloning of PCR products 
PCR products were analysed on agarose gels and purified using a Qiagen Gel Extraction 
Kit (Qiagen, UK) according to the manufacturerÕs instructions. The product was then 
digested overnight at 37 ¡C with the relevant restriction enzyme(s) in the appropriate 
buffer. Digested PCR fragments were ligated into an appropriate vector and 
electroporated into E. coli DH5α or S-17 λpir. Transformants containing recombinant 
clones were selected by growth on LB agar plates containing the appropriate antibiotics.  
2.12 Introduction of DNA into bacterial strains 
2.12.1 Preparation of electrocompetent E. coli cells 
To prepare competent E. coli cells a 1 % (v/v) inoculum from an overnight E. coli 
culture was added to 100 ml of sterile NYB in a 1 L conical flask and grown at 37 ¡C, 
200 rpm to an OD
600 
of 0.4-0.8 (approximately 6 h). Cells were harvested by 
centrifugation at 5,500 rpm (JA-14, Beckman) for 10 min at 4 ¡C and washed twice in 
sterile ice cold 10 % (v/v) glycerol containing 1 mM MOPS 
(4-morpholinepropanesulfonic acid) before being resuspended in 1 ml of the same 
buffer. Cells were aliquoted into 50 µl samples, flash frozen in liquid nitrogen and 
stored at -80 ¡C in microcentrifuge tubes. 
2.12.2 Electroporation of electrocompetent E. coli cells 
Electroporation was performed in 0.2 cm electrode gap Gene Pulser cuvettes (BioRad, 
UK) containing 50 µl of competent cells and 2 µl DNA. An electroporation pulse of 
2.5 kV (200 Ω) was delivered using the BioRad Gene Pulsar connected to a BioRad 
pulse controller (BioRad, UK). A 1 ml aliquot of pre-warmed (37 ¡C) LB broth was 
added to the cells which were then incubated at 37 ¡C for 1 h in the absence of 
antibiotics. Aliquots of cells were subsequently plated onto LB agar plates containing 
appropriate antibiotics to select for transformants and grown overnight at 37 ¡C. 
Controls of electroporated cells with no plasmid were also similarly prepared. 
 73 
2.12.3 Preparation of electrocompetent P. aeruginosa cells 
Competent P. aeruginosa cells, for transformation with uncut vector, were prepared by 
centrifugation of 1.5 ml of overnight culture at 13,000 rpm for 5 min in a microfuge 
(Biofuge pico, Kendro, Germany). The cells were washed three times in 1 ml ice cold 
10 % (v/v) glycerol with 1 mM MOPS. The pellet was then resuspended in 50 µl ice 
cold 10 % (v/v) glycerol with 1 mM MOPS. If necessary, the cells were flash frozen in 
liquid nitrogen and stored at -80 ¡C. 
2.12.4 Electroporation of P. aeruginosa  
Transformation of plasmids into electrocompetent P. aeruginosa cells was performed as 
for E. coli (section 2.12.2). 
2.12.5 Conjugation of plasmid DNA into P. aeruginosa  
Plasmid transfer from E. coli donor to P. aeruginosa recipient cells was carried out by 
bacterial conjugation. Donor and recipient cells were each grown in 5 ml of LB by 
overnight incubation. P. aeruginosa recipient strains were grown at 42 ¡C to inactivate 
a restriction enzyme system which degrades incoming foreign DNA, whilst E. coli 
donor strains were grown at 37 ¡C. Cells were harvested from 1.5 ml of each culture by 
centrifugation at 13,000 rpm for 1 min, washed with 1 ml NYB and then repelleted 
under the same conditions. The Pseudomonas pellet was resuspended in 1 ml NYB 
broth and this suspension was added to the E. coli pellet. The pellets were resuspended 
well and spun at 13,000 rpm for 1 min. The majority of the supernatant was removed, 
leaving approximately 100 µl, in which the mixed bacterial pellet was thoroughly 
resuspended. This was spotted as a drop onto a LB agar plate and allowed to air dry. It 
was then incubated at 37 ¡C for at least 3 h to allow bacterial mating to occur. For each 
conjugation, a P. aeruginosa and E. coli control were performed and treated in exactly 
the same way as the actual samples. 
Cells were scraped from the plate using a sterile 10 µl inoculation loop and then 
resuspended in 0.5 ml NYB broth (controls were resuspended in 0.25 ml NYB broth). 
Aliquots of 100 µl were spread on to PIA plates containing the appropriate antibiotics to 
select for P. aeruginosa transconjugants and incubated overnight at 37 ¡C. No growth 
was expected on the control plates. 
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2.13 Construction of PAO1ΔlecB mutant 
A lecB chromosomal deletion mutant in PAO1 was constructed as follows. Using PAO1 
template DNA, a fragment containing the intact lecB gene (348 bp) plus 500 bp 
upstream and 500 bp downstream was amplified using the primer pair Sac1lecBUF and 
Kpn1lecBDR (Table 2-3). The resulting PCR product was cloned into pBLS resulting in 
the plasmid pBLS::lecB. To introduce a deletion of the recombinant lecB gene, the 
primer pair lecBHpa1UR and lecBHpa1DF (Table 2-3), possessing Hpa1 restriction 
sites, was used in conjunction with inverse PCR using pBLS::lecB DNA as the 
template. The resulting blunt-ended PCR product containing a deletion in lecB was self-
ligated, resulting in the plasmid pBLSΔlecB. The PCR product was excised from the 
vector using Sac1 and Kpn1 and cloned into the similarly digested suicide vector 
pEX18Gm (Hoang et al., 1998), resulting in the plasmid pEX18GmΔlecB. Allelic 
exchange using pEX18GmΔlecB contained in E. coli S17-1 λ-pir with PAO1 resulted in 
a P. aeruginosa strain (PAO1ΔlecB) containing an in-frame deletion of the lecB gene. 
This deletion was confirmed by PCR and sequence analysis. 
2.14 RNA analysis 
2.14.1 Stabilisation of RNA and preparation of bacterial lysate  
Total RNA was stabilised and a bacterial lysate prepared as per manufacturerÕs 
instructions using the RNeasy Mini Kit (Qiagen, UK). Briefly, 0.5 ml of an overnight 
culture of P. aeruginosa cells grown in LB (~ 1 x 10
9 
cells) was mixed by vortexing 
with 1 ml RNAprotect Bacterial Reagent (Qiagen, UK) and then incubated at room 
temperature for 5 min. Cells were harvested by centrifugation at 5,000 x g for 10 min in 
a benchtop microfuge and the supernatant decanted. The bacteria were then lysed by 
resuspending in 200 µl TE buffer containing 1 mg/ml lysozyme, vortexing and 
incubating for 5 min at room temperature with agitation. 700 µl Buffer RLT (containing 
10 µl β-mercaptoethanol per 1 ml buffer RLT) was added, the mixture vortexed and 
then centrifuged for 2 min at 13,000 rpm to pellet any particulate material. The 
supernatant was transferred to a fresh microtube and mixed with 500 µl 100 % (v/v) 
EtOH by pipetting. 
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2.14.2 Purification of total RNA from bacterial lystate 
Up to 700 µl bacterial lysate at a time was transferred to an RNEasy Mini spin column 
(Qiagen, UK) which was placed in a collection tube and centrifuged for 15 s at ≥ 10,000 
rpm. The flowthrough was discarded and 700 µl Buffer RW1 was added to the column 
which was centrifuged for 15 s at ≥ 10,000 rpm to wash the membrane. The column was 
placed in a fresh collection tube to which 500 µl Buffer RPE was added. The column 
was centrifuged for 15 s at ≥ 10,000 rpm and the flow-through was discarded. A further 
500 µl Buffer RPE was added followed by a 2 min centrifugation step at ≥ 10,000. The 
spin column was placed in a new collection tube and spun at full speed for 1 min to 
remove all residual EtOH. The column was then placed in a new 1.5 ml collection tube 
and the RNA eluted with 50 µl RNAse-free water and stored immediately at Ð 80 ¡C 
until used. 
2.14.3 Removal of contaminating genomic DNA from total RNA 
20 µl of purified RNA (containing ~ 1 µg/µl RNA) was mixed with 50 µl TURBO 
DNase and 10 µl 10 x TURBO DNase buffer (Ambion) and the reaction volume made 
up to 100 µl with RNAse-free water. This was incubated at 37 ¡C for 1 h to enable 
digestion of contaminating genomic DNA. 
2.14.4 DNase treated RNA sample clean up 
The DNase treated RNA sample was cleaned up using the RNeasy MiniElute kit 
(Qiagen, UK) as per the manufacturerÕs instructions. Briefly, 100 µl sample was mixed 
with 350 µl RLT buffer (without additional β-mercaptoethanol) and mixed thoroughly. 
250 µl 100 % (v/v) EtOH was added to the diluted RNA and mixed by pipetting. The 
whole volume was then applied to a spin column, which was placed in a collection tube 
and centrifuged for 15 s at ≥ 10,000 rpm. The column was transferred to a new 
collection tube and 500 µl Bufffer RPE was added. Following repeat centrifugation, the 
flow-through was discarded and 500 µl 80 % (v/v) EtOH was added. The column was 
centrifuged for 2 min at ≥ 10,000 rpm and then transferred to a new collection tube and 
spun at full speed for 5 min with the cap open to dry the silica-gel membrane. Elution 
was performed with 14 µl RNAase-free water and the resulting 12 µl eluate was stored 
at Ð 80 ¡C until use. 
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2.14.5 One-step reverse transcription PCR 
Reverse transcription PCR (RT-PCR) was performed using the OneStep RT-PCR Kit 
(Qiagen, UK) according to the manufacturerÕs instructions. Briefly, template RNA (2 µl 
cleaned up RNA), primer solutions, dNTP Mix, 5 x QIAGEN OneStep RT-PCR Buffer 
and RNase-free water were thawed and placed on ice. A master-mix was prepared based 
on the volumes of components required for a single reaction listed in Table 2-4. 
 
Table 2-4 Reaction components for one-step RT-PCR 
 
Component Volume/reaction Final concentration 
Master mix   
RNase-free water 20 µl - 
5 x QIAGEN OneStep RT-PCR Buffer 10 µl 1 x 
dNTP Mix (containing 10 mM of each 
dNTP) 
2 µl 400 µM of each 
dNTP 
Primer A (10 mM) 3 µl 0.6 µM 
Primer b (10 mM) 3 µl 0.6 µM 
QIAGEN OneStep RT-PCR Enzyme 
Mix 
2 µl - 
Template RNA   
Template RNA, added separately 2 µl 1 pg Ð 2 µg/reaction 
Total volume 50 µl - 
 
Working on ice, 48 µl aliquots of mastermix were dispensed in to individual PCR tubes 
and 2 µl of the template RNA was added to each tube. Control reactions were 
performed where the RNA template was exchanged for dH2O (negative control) or 
DNA template (positive control). Samples were maintained on ice whilst the T3000 
Thermocycler (Biometra) was started. See Table 2-5. When the thermal cycler had 
reached 50 ¡C the programme was paused and the samples loaded. Following 
amplification, the samples were stored at Ð 20 ¡C until analysed by agarose gel 
electrophoresis. 
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Table 2-5 Thermal cycler conditions 
 
Reverse transcription: 30 min 50 ¡C 
Initial PCR activation step 15 min 95 ¡C 
3-step cycling   
Denaturation 0.5 min 94 ¡C 
Annealing 0.5 min 55-68 ¡C (approx 5 ¡C below Tm of primers) 
Extension 1 min 72 ¡C 
Number of cycles 30  
Final extension 10 min 72 ¡C 
 
2.15 Protein analysis 
2.15.1 Preparation of whole cell protein extracts 
Whole cell protein extracts were prepared by subculturing 250 µl of an overnight 
bacterial culture in 25 ml LB broth and incubating for a further 12 to 16 h. The OD600 of 
the culture was measured and then a 100 µl sample was centrifuged at 13,000 rpm in a 
microfuge (Biofuge pico, Kendro, Germany) for 2 min and the supernatant removed. In 
order to standardise the OD600 to 1, the cells were resuspended in an appropriate volume 
of dithiothreitol (DTT) sample loading buffer (50 mM Trizma base pH 6.8, 2 % (w/v) 
SDS, 10 % (v/v) glycerol, 0.1 % (w/v) bromophenol blue and 100 mM DTT) and boiled 
for 10 min to denature the proteins. 
2.15.2 Preparation of sputum protein extracts 
An equivalent volume of phosphate buffered saline (PBS) or sputolysin (DTT, 
Calbiochem) was added to neat sputum and vortexed vigorously to liquify the sputum. 
100 µl of the resulting suspension was centrifuged at 13,000 rpm for 15 min in a 
microfuge (Biofuge pico, Kendro, Germany). The supernatant was mixed with an 
appropriate volume of 5 x DTT sample loading buffer and boiled. Additionally, the 
sputum pellet was resuspended in 100 µl 1 x DTT sample loading buffer and then 
boiled for 10 min. 
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2.15.3 SDS-polyacrylamide gel electrophoresis 
For the analysis of proteins, SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis) was carried out using the method of Laemmli (1970). 18 % acrylamide 
resolving gels were cast in a Bio-Rad Mini-Protean II casting tray and overlaid with 100 
µl of water saturated with butanol. When set, a 4 % acrylamide stacking gel was 
prepared and added to the separating gel. See Table 2-6. 
 
Table 2-6 Composition of resolving and stacking gels 
 
Component 18 % resolving gel 4 % stacking gel 
Gel buffer (3 M Trizma 
base, 0.5 % (w/v) SDS, pH 
8.45) 
3.3 ml 1.25 ml 
30 % 
acrylamide:bisacrylamide 
6 ml 670 µl 
dH2O 0.7 ml 3.03 ml 
10 % (w/v) ammonium 
persulphate (APS) 
50 µl 50 µl 
N, N, NÕ, NÕ-
tetramethylethylenediamine 
(TEMED) 
10 µl 5 µl 
 
Sample aliquots of 5 µl were loaded onto the gel. Electrophoresis was performed in an 
outer anode buffer (0.1 M Trizma base, pH 8.9) and inner cathode buffer (0.1 M Trizma 
base, 0.1 M Tricine and 0.1 % SDS) at a constant voltage of 150 V until the sample 
buffer had migrated to the bottom of the gel. Precision plus protein standard (BioRad) 
was used as a molecular weight marker in the gels. 
2.15.4 Western blotting 
Proteins to be analysed by Western blotting were first separated by SDS-PAGE as 
described in section 2.15.3. Proteins were then transferred to a nitro-cellulose 
membrane (Hybond ECL, Amersham Biosciences) using a Biorad Mini Trans Blot 
apparatus. Transfer was carried out in Western blot buffer (0.24 % [w/v] Trizma base, 
1.14 % [w/v] glycine, 20 % [v/v] methanol, in dH2O) at 100 V for 2 h. 
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The blot was removed from the apparatus and blocked in PBS containing 0.5 % (v/v) 
Tween 20 (PBST) and 5 % (w/v) dried skimmed milk powder for 1 h at room 
temperature with rocking. The blot was then incubated with the primary anti-lectin 
antibody (1:500 dilution) in PBST containing 5 % skimmed milk for 1 h. The blot was 
washed for 3 x 20 min in PBST and incubated with the secondary antibody (1:3000 
anti-rabbit IgG-horseradish peroxidase conjugate, Amersham Biosciences) in PBST 
containing 5 % (w/v) skimmed milk for 1 h. After washing (3 x 20 min in PBST) the 
blot was developed using the ECL plus Western blotting detection system (Amersham 
Biosciences) according to the manufacturerÕs instructions. Following this, the blot was 
exposed to Hyperfilm ECL (Amersham Biosciences), a high performance 
chemiluminescence film for 5 to 20 min. The film was developed in Ilford PQ universal 
developer for 1-2 min and washed in water. The film was fixed in Ilford Hypam rapid 
fixer, rinsed in water and air-dried. 
2.15.5 Raising of antibodies used in Western blotting 
A polyclonal antibody was raised against the lectin LecA (PA-IL, Sigma) by K. Bishop 
(Institute of Infection, Immunity and Inflammation, University of Nottingham) in a 
New Zealand White rabbit. The rabbit was immunised with 50 µg LecA in 250 µl PBS, 
administered subcutaneously, four times at two weekly intervals. Primary immunisation 
used Freunds Complete adjuvant and the three subsequent immunisations used Freunds 
Incomplete adjuvant. Serum was obtained from the rabbit at week 5 (test bleed) and the 
final bleed was taken two weeks after the fourth immunisation.  
2.16 AHL extraction and detection from broth cultures 
2.16.1 Extraction of AHLs 
Overnight bacterial cultures were standardised to OD600 1.0 before being diluted 1 in 
100 in 25 ml LB and grown in 250 ml flasks at 37 ¡C with shaking at 200 rpm 
overnight. A 900 µl aliquot of this was spun at 13,000 rpm for 5 min in a microfuge 
(Biofuge pico, Kendro, Germany). The supernatant was mixed thoroughly with 100 µl 1 
M hydrochloric acid and incubated at 37 ¼C overnight. Samples were stored at -20 ¼C. 
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2.16.2 Detection of AHLs using thin layer chromatography and a biological reporter 
Extracted AHLs were analysed by thin layer chromatography (TLC) based on the 
methods of Shaw et al. (1997) and McClean et al. (1997). For the detection of the long 
chain 3-oxo-C12-HSL, 1 µl of each sample was spotted onto a 20 x 20 cm Alugram 
reverse phase RP-2/UV254 plate (Macherey-Nagel) along with 1 µl of the synthetic 
standard. The plate was run in 45 % (v/v) MeOH overnight. It was then overlaid with 
soft top agar (100 ml) containing 1 ml of an overnight culture of E. coli S17 λpir 
[pSB1142]. Following incubation at 37 ¼C for 3 h the plate was analysed for light 
production using a Berthold Luminograph LB980. 
For the detection of the short-chain C4-HSL, 5 µl of each sample and 1 µl of the 
standard were loaded onto a 20 x 20 cm aluminium reverse phase RP-18 F2545 plate 
(Merck). The plate was run in 60 % (v/v) MeOH for 1.5 to 2.5 h and then overlaid with 
100 ml soft top agar containing 1 ml of an overnight culture of E. coli JM109 [pSB536]. 
The plate was incubated and viewed as above.  
2.17 PQS extraction and detection from broth cultures 
2.17.1 Extraction of PQS 
PQS was extracted from culture supernatants based on the method of Pesci et al. (1999). 
Overnight bacterial cultures were standardised to OD600 1.0 before being diluted 1 in 
100 in 100 ml LB and grown overnight. 10 ml of the resulting culture was mixed 
thoroughly with 10 ml acidified ethyl acetate (0.01 % [v/v] glacial acetic acid in 1 L 
ethyl acetate) and allowed to separate. The uppermost organic ethyl acetate layer was 
dried to completion using a rotary evaporator (Buchi, Rotovapor R-114) at 45 ¼C. This 
was then re-suspended in 1.2 ml acidified ethyl acetate before being evaporated to 
dryness under a stream of nitrogen gas. Samples were then re-suspended in 50 µl 
MeOH and stored at -20 ¼C. 
2.17.2 Detection of PQS using TLC 
A 20 x 20 cm aluminium plate (silica gel 60 F254, Merck) was prepared by soaking in 5 
% KH2PO4 for 30 min before being air-dried and activated in a hybridisation oven 
(Stuart Scientific) at 100 ¼C for 1 h. 2 µl of the PQS and 1 µl of the HHQ synthetic 
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standards were spotted onto a plate along with 5 µl of each sample. The plate was run in 
a solvent system of dichloromethane (DCM) to MeOH 95:5 for 1.5 to 2 h. The plate 
was viewed immediately using a UV transilluminator (UVP, USA) and photographed 
using a Nikon Coolpix995 digital camera. 
2.17.3 Detection of PQS using a biological reporter 
5 ml of an overnight culture of PAO1 lecA::luxΔpqsA was added to 100 ml soft top agar 
and this was overlaid onto the plate run in 2.17.2. Following incubation at 37 ¼C for a 
minimum of 6 h, lectin production was measured as light production using the Berthold 
luminograph. 
2.18 Detection of QS signal molecules from CF sputum  
2.18.1 Extraction of signal molecules from sputum 
An equivalent volume of 0.9 % (w/v) sodium chloride was added to each sputum 
sample and the mixture vortexed vigorously for 3 min to produce a 50 % (v/v) sputum 
suspension. From this, a 3 ml aliquot was mixed with 3 ml acidified ethyl acetate (see 
2.17.1) and vortexed for 1 min, then centrifuged for 2 min at 3,000 rpm in a microfuge 
(Biofuge pico, Kendro, Germany). The upper organic phase was transferred to a fresh 
glass tube and the remaining aqueous phase was re-extracted a further two times with 3 
ml of solvent on each occasion. The organic phases were combined and dried to 
completion in a rotorvap (Jouan). The solute was dissolved in 50 µl MeOH by vortexing 
for 30 s and then transferred to a fresh 0.1 ml eppendorf. The solution was spun at 
13,000 rpm for 5 min and the supernatant was removed and stored at -20 ¡C. As a 
negative control, six 3 ml volumes of 0.9 % (w/v) sodium chloride were each extracted 
with acidified ethyl acetate. 
2.18.2 Preparation of standards 
Six 3 ml volumes of 0.9 % (w/v) sodium chloride were each spiked with the appropriate 
volumes of synthetic standards in order to achieve a final concentration of 0.1 µM for 
the AHLs and 0.5 µM for the AQs in 50 µl MeOH following extraction with acidified 
ethyl acetate as described in section 2.18.1. In addition, unextracted volumes of MeOH 
containing the standards at the same concentration were analysed. 
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2.18.3 Liquid chromatography Ð Mass spectroscopy (LC-MS) analysis of extracted 
sputum samples 
LC-MS analysis was performed on 5 µl aliquots of extracted sputum. Reverse phase 
liquid chromatography (RP-HPLC) using a Phenomenex Gemini (C18, 5 µM, 250 x 
2.00 mm) column was coupled with mass spectroscopy (MS) (Applied Biosystems 4000 
Q-TRAP) and eluted with a gradient based on 0.1 % (v/v) formic acid. The 
fragmentation ions of each of the anticipated AHLs and AQs were recorded using 
Multiple Reaction Monitoring Triggered Traps (MRMTT). The majority of compounds 
were detected by positive electrospray. The detection of PQS was performed as a 
separate run with the addition of a chelating agent, which served to ÒblockÓ metals 
present in the column and prevent PQS binding to these. The system was additionally 
run in negative for the identification of the acidic ring open forms of 3-oxo-C12-HSL 
and C4-HSL. The threshold for detection for each compound was set by the instrument 
at five times the value of baseline noise unless otherwise stated. 
2.19 Biofilm assays 
2.19.1 Flowchamber biofilm system 
For detailed methodology describing the local establishment of a flowchamber biofilm 
system and the associated COMSTAT and IMARIS image analysis tools, please refer to 
Appendix 4. 
2.19.2 Biofilm microtitre assays 
A modified version of the method described by Stepanovic et al. (2000) was employed. 
Sterilised, clear, ninety-six well, U-bottomed polystyrene microtitre plates (Costar) 
were prepared by adding 300 µl sterile dH2O to the peripheral wells to decrease 
evaporation from test wells. Aliquots of 270 µl culture medium (0.05 % [v/v] nutrient 
broth) were added to internal wells. 30 µl samples of overnight cultures, pre-washed in 
0.05% (v/v) nutrient broth and normalised to an OD600 1.0, were inoculated into the test 
wells. Plates were incubated in a humid environment for 24 h at 37 ¡C. The contents of 
the wells were aspirated and the wells were washed three times with dH2O. They were 
then fixed with 300 µl MeOH for 5 min, before staining with 150 µl 0.1 % (w/v) crystal 
violet for 5 min. After rinsing the wells with dH2O, the contents were resolubilised in 
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33 % (v/v) glacial acetic acid and transferred to a polystyrene flat bottomed 96 well 
plate (Costar). Optical densities of the microtitre wells were determined using a plate 
reader (MRX, Dynex Technologies) at 540 nm. 
2.19.3 Stainless steel coupon biofilm assay  
Biofilms were grown on stainless steel coupons (surgical grade 316L) under conditions 
similar to those described by Dhir and Dodd (1995). Sterile steel coupons were placed 
at the edges of Petri dishes with 10 ml 0.05 % (v/v) nutrient broth containing the 
appropriate concentration of the test compound. Inocula of P. aeruginosa test strains 
were prepared from 5 ml of overnight cultures grown in LB broth. The OD600 of these 
cultures was adjusted to 1.0 with sterile LB broth and aliquots of 100 µl were used to 
inoculate the medium contained within the Petri dishes. The Petri dishes were incubated 
at 37 ¡C on a rotary shaker (60 rpm) for 24 h. An additional 100 µl LB broth was added 
and the Petri dishes were incubated for a further 24 h. The test was performed in 
triplicate for each strain.  
2.19.4 Acridine orange staining of stainless steel coupon biofilms 
The inoculated medium was removed from the Petri dish with a transfer pipette without 
disturbing the steel coupons. 20 ml sterile PBS was then added and the dish agitated at 
60 rpm for 5 minutes to rinse the coupons. The PBS was removed and this rinse step 
was repeated. Following this, the coupons were air-dried and then heat-fixed by passing 
them through a Bunsen flame three times. The surface attached biofilms were then 
stained by applying 200 µl 0.1 % (w/v) acridine orange to the upper surface of each 
coupon and leaving for 2.5 min. To remove unbound acridine orange, 20 ml of sterile 
PBS was then added to the Petri dish and the dish gently agitated as before for 5 
minutes. The PBS was removed and this wash step was repeated two further times. The 
coupons were then air-dried and fixed with tape along their edges to a glass microscope 
slide. 
2.19.5 Visualisation of acridine orange stained steel coupon biofilms 
The coupons were examined for bacterial attachment with an inverted fluorescent 
microscope (Nikon Eclipse TE200) using the x 10 objective lens and green filter. Ten 
images were collected per coupon using a JVC KY-F58 video camera. Sampling was 
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conducted at random from each coupon, avoiding areas at the edges. With the ÔredÕ and 
ÔlowÕ options set to the maximum level of 255, the area fraction for each image was 
calculated using the Lucia G/Comet software (Nikon UK) with a threshold set at 
between 175 and 185. 
2.19.6 Capturing of confocal images 
Coupons were placed in the universal slide holder of an inverted Zeiss Axiovert100M 
microscope and confocal images and Z-stacks were captured with a Zeiss LSM510uv 
META Kombi confocal system. The objective used was a Zeiss Plan-NeoFluar 40x/1.3 
oil immersion lens and the acridine orange was excited with an Argon laser at 488 nm 
and emission collected with a LP560 filter. 
2.19.7 Stainless steel coupon dispersion assay 
Biofilms were grown on stainless steel coupons as described in 1.19.2. Following 
incubation, the inoculated medium was removed from the Petri dish with a transfer 
pipette without disturbing the steel coupons and the coupons were rinsed with 10 ml 
0.05 % nutrient broth. Then, 10 ml fresh 0.05 % (v/v) nutrient broth containing the 
appropriate concentration of the test compound was added to each Petri dish. To the 
control dish, 0.05 % nutrient broth alone was added. The dishes were incubated at 37 ¡C 
on a rotary shaker (60 rpm) for 2 h. The media was collected, vortexed and serially 
diluted to a final dilution of 1:10000. Aliquots of 100 µl were spread onto LB agar 
plates in triplicate and incubated at 37 ¡C overnight. The resulting colonies were 
counted and a calculation of the viable bacterial count made. 
2.20 Conjugation of LecA with Cy5 cyanine fluorescent dye 
1 mg purified LecA protein (PA-IL, Sigma) was dissolved in 1 ml PBS to give a 
concentration of 1 mg/ml protein. Cy5 mono-reactive NHS ester (Amersham) was 
dissolved in DMSO to a final concentration of 5 µg/µl. 500 µl protein (500 µg) was 
mixed with 40 µl carbonate buffer (NaHCO3 142 mM, Na2CO3 8 mM, pH 9.4) and 10 
µl Cy5 solution and the mixture was incubated for 2 h at RT. 
Fluorescent dye removal columns (ThermoScientific) were used to remove free dye 
after the labelling reaction according to the manufacturerÕs instructions. Briefly, 250 µl 
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Dye Removal Resin was added to each of 2 spin columns each placed within a 
collection tube. These were centrifuged for 30 s at 1,000 x g in a microfuge (Biofuge 
pico, Kendro, Germany) to remove the storage solution. The used collection tubes were 
discarded and the columns placed in new tubes. The labelling reaction was divided in to 
two 250 µl aliquots and each was added to a prepared Spin column and mixed briefly by 
vortexing. The column was centrifuged for 30 s at 1,000 x g to collect the purified 
protein. The labelled protein was quantified using the Nanodrop ND-1000 
Spectrophotometer (Labtech) with the protein A-280 option. 
2.21 Labelling of bacterial cells with lectin-fluorophore conjugates 
Lectin staining was undertaken based on the method described by Ma et al. (2007). The 
binding of fluorescently labelled lectins was evaluated by staining planktonically grown 
bacterial strains. Following overnight growth in JensenÕs media, the OD600 of cultures 
was corrected to 1 and the cells were rinsed with PBS before staining with 100 µg/ml 
fluorescein isothiocyanate (FITC) labelled Marasmium oreades agglutinin (MOA) 
mushroom lectin (EY laboratories, Inc.) or Cy5 labelled P. aeruginosa lectin LecA. 
Staining was allowed to progress for 4 h at room temperature with agitation and then 
samples were washed twice with PBS and finally resuspended in 400 µl PBS. This 
entire volume was applied to a poly-D-lysine (PDL) coated round microscope dish 
(Mattek) and then imaged with a Zeiss LSM 510 Axiovert 100M ConfoCor 2 
microscope (Carl Zeiss, Switzerland). The 63 x 1.3 water objective in conjunction with 
the 633 nm Argon laser was used for all image acquisition. 
2.22 Enzyme-linked immunoSorbent assay (ELISA) investigation of bacterial-
protein interactions 
2.22.1 Preparation of wells  
Purified LecA (PA-IL, Sigma) was prepared at a concentration of 10 µg/ml in PBS. 100 
µl aliquots of protein were introduced to each test well of a 96 well Immoblizer Amino 
plate (Nunc) and allowed to covalently couple to the polymer surface by incubation for 
2 h at room temperature with agitation. The control wells were treated with 100 µl 1 % 
(w/v) bovine serum albumin (BSA) in PBS. The wells were then emptied and the 
remaining active sites blocked with 100 µg/ml BSA in PBS for 1 h at room temperature 
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with agitation. This solution was then discarded and the wells washed x 3 with PBST 
detergent solution to remove excess non covalently-bound lectin. 
IPTG was made up at the test concentrations in 1 % (w/v) BSA in PBS (0.2 mM and 2 
mM) and the wells were inoculated and allowed to incubate overnight at 4 ¡C with 
agitation. Untreated wells were simply incubated with 1 % (w/v) BSA in PBS. 
2.22.2 Digoxigenin (DIG-NHS) labelling of bacterial cells 
Overnight cultures of the test strains were grown in JensenÕs minimal media. 1 ml 
volumes of cultures were spun to pellet at 4,000 rpm for 5 min in a microfuge (Biofuge 
pico, Kendro, Germany). The supernatant was removed and the cells were resuspended 
in PBS to wash. Following a second centrifugation, the cells were resuspended in 
carbonate buffer (section 2.20) and the OD600 adjusted to 0.2. Two microlitres of 
digoxigenin-3-0-succinyl-ε-aminocaproic acid-N-hydroxy-succinimide ester (DIG-
NHS, Roche) at a concentration of 10 µg/µl in DMSO was added to each 1 ml volume 
of cells and this was allowed to incubate for 1 h at room temperature with agitation. 
Following this, the cells were spun and rinsed once with PBS. They were finally 
resuspended in PBS containing 1 % (w/v) BSA and diluted to OD600 of 0.02. For the test 
wells blocked with IPTG, the bacterial cells were resuspended in 1 % (w/v) BSA in 
PBS containing the test concentrations of IPTG. 
2.22.3 Inoculation of wells with labelled bacterial cells 
The contents of the wells were discarded and the wells washed x 3 with PBST. Then, 
100 µl aliquots of DIG-NHS-labelled bacterial cells were added. Each strain was tested 
in triplicate. To the control wells, 100 µl 1 % (w/v) BSA in PBS alone was added. The 
wells were incubated at 4 ¡C overnight with agitation at 125 rpm. 
2.22.4 Washing of wells; substrate labelling of bound cells and measurement of 
absorption 
The incubating bacterial culture was removed from the wells and the wells were rinsed 
3 x with PBST. The wells were then incubated for 1 h at room temperature with 100 µl 
enzyme conjugated anti-DIG-NHS monoclonal antibody (Roche) at a dilution of 1:5000 
in 1 % (w/v) BSA in PBS which reacted with the DIG-labelled bacterial cells. 
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Following this, wells were rinsed 4 x with PBST. Then, the complexed enzyme was 
visualised with 100 µl of the soluble substrate ABTS (2,2h-Azino-di-[3-
ethylbenzthiazoline-sulfonate (6)], Roche) added to each well. After 2-4 h incubation at 
room temperature, absorbance was read with an ELISA plate reader (EMS Reader MF, 
Labsystems) at a wavelength of 405 nm. 
2.23 LDH cytotoxicity assay 
All work was performed aseptically in a class 2 microbiological safety cabinet. 
2.23.1 Preparation of multiwell plate 
Human 293T kidney-embryonic cells were prepared by overnight incubation in DMEM 
media (Gibco). The incubating media was removed and the adherent cells harvested by 
the addition of the protease trypsin (Sigma). The cell count was determined using a 
counting chamber and then 200 µl aliquots of cell suspension at 1 x 10
5
 cells/ml were 
added to individual wells of a microtitre plate (Nunc). The plate was incubated 
overnight at 37 ûC, 5 % CO2, 90 % humidity to allow the cells to adhere tightly. 
2.23.2 Addition of test compounds 
The test compound (denrimer D20) was titrated to the appropriate test concentrations 
(0.1 mM, 0.05 mM, 0.025 mM and 0.0125 mM) in the assay medium in a separate 
multiwell plate by serial dilutions. 
The assay medium was removed from the adherent cells (to remove LDH activity 
released from the cells during the overnight incubation) and 100 µl fresh assay medium 
was added to each well. To these, 100 µl of the test substance dilutions were added, 
with each concentration tested in triplicate and the plate was incubated overnight. 
Control wells consisted of assay medium alone (ÔbackgroundÕ); cells incubated in assay 
medium (ÔlowÕ); dendrimer 20 at each test concentration in assay medium (Ôsubstance 
control IÕ) and cells incubated in 2 % Triton X-100 in assay medium (ÔhighÕ). 
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2.23.3 Determination of LDH activity 
The microplate was centrifuged at 250 x g for 10 min and then 100 µl/well cell-free 
supernatant was collected and transferred into the corresponding wells of an optically 
clear 96-well flat bottom microplate. 100 µl freshly prepared LDH detection Reaction 
mixture (Roche) was added to each well and incubated for 30 min at room temperature 
protected from light. The absorbance of the samples was measured at 492 nm using an 
ELISA plate reader (Labsytems Multiskan Ex). 
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3 Chapter 3:  Isolation and characterisation of clinical 
strains from CF sputum 
 
3.1 Introduction 
Research over the past decades has revealed that bacteria preferentially live in 
communities in which the behaviour of individual cells is coordinated by cell-cell 
communication, termed quorum sensing (QS). This is of great importance in enabling 
the interaction of bacterial cells with each other, their environment and higher 
organisms. 
P. aeruginosa is probably the most thoroughly studied bacterium in terms of QS and 
laboratory strains are known to contain two interacting QS systems termed las and rhl. 
These are responsible for the production of the major AHL signals 3-oxo-C12-HSL and 
C4-HSL respectively. In addition, an AQ-based QS system uses PQS (whose immediate 
precursor is HHQ) as its major cognate signal molecule. The las and the rhl systems are 
organised in a hierarchical manner (Latifi et al., 1996) and PQS is interspaced between 
the two (Pesci et al., 1999). These systems are integrated within a complex regulatory 
network in the cell and are under the transcriptional and post-transcriptional control of a 
large number of other regulators (Venturi, 2006). Refer back to Figure 1.2 for an 
overview of P. aeruginosa QS systems. 
These signal molecules bind to transcriptional regulator proteins that specifically induce 
numerous virulence genes. For example, 3-oxo-C12-HSL, together with the 
transcriptional regulator LasR, regulates the production of elastase, alkaline protease 
and exotoxin A (Cmara et al., 2002). Similarly, C4-HSL activates RhlR such that 
RhlR/C4-HSL induces the production of rhamnolipid, elastase, LasA protease, cyanide, 
pyocyanin and siderophores as well as the lectins LecA and LecB (Winzer et al., 2000) 
(Winson et al., 1995). In addition, PQS is known to be essential for both LecA and 
pyocyanin production (Diggle et al., 2003). To date, more than thirty QS-regulated 
virulence factors have been described (Bjarnsholt and Givskov, 2007). 
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The in vivo significance of this regulation is also being elucidated. Studies in a number 
of animal models including mice, nematodes and insects have demonstrated the 
importance of a fully functional QS-circuit for the full virulence of P. aeruginosa 
(Rumbaugh et al., 1999c) (Mahajan-Miklos et al., 2000). In terms of specific 
pathogenic mechanisms, QS has been implicated in the development of bacterial 
biofilms, a key virulence strategy for the establishment of chronic infections (Davies et 
al., 1998). In addition, there are reports of QS-deficient P. aeruginosa biofilms showing 
reduced tolerance to antimicrobial agents (Bjarnsholt et al., 2005) (Hentzer et al., 2003).  
The recognition that different bacterial species make similar signal molecules has led 
the study of their role in interactions between bacterial species (interspecies) as well as 
between bacteria and eukaryotic (interkingdom) organisms sharing a common 
environment. This has been referred to as Ôcross-talkÕ (Riedel et al., 2001) and is also 
understood to mediate pathogenesis, for example by host immunomodulation 
(Pritchard, 2006), with the QS molecules acting as virulence determinants in their own 
right. 
Given the in vitro and animal model evidence for the multiple roles of QS signal 
molecules and signalling in pathogenesis, attention has turned from the well-studied 
behaviour of laboratory strains to understanding the QS-status of isolates of 
P. aeruginosa derived from clinical sources. Indeed, the occurrence of clinical isolates 
deficient in the production of extracellular virulence factors regulated by QS, such as 
elastase and exotoxin A, has been shown (Hamood et al., 1996) (Rumbaugh et al., 
1999b). There are also increasing reports describing both the proficiency and deficiency 
of AHL production by clinical isolates recovered from a number of different sites 
(Hamood et al., 1996) (Geisenberger et al., 2000) (Sokurenko et al., 2001) (Cabrol et 
al., 2003) (Denervaud et al., 2004). Furthermore, measurement of PQS production by 
P. aeruginosa isolates from asymptomatic children with CF indicated that strains with 
increased synthesis of PQS were present during early colonisation of CF patient airways 
(Guina et al., 2003). 
The further characterisation of these isolates has demonstrated that the relative in vitro 
production of 3-oxo-C12-HSL and C4-HSL as well as the associated QS-dependent 
phenotypes (such as elastase production) varied according to their site of isolation, 
suggesting that the host microenvironment selects for different phenotypic behaviours 
(Favre-Bonte et al., 2007). Indeed, growth in low magnesium, which can destabilise the 
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Gram-negative outer cell membrane, was associated with increased induction of 
proteins essential for the production of PQS (Guina et al., 2003). Mutations affecting 
the AHL cell-signalling circuit were found to be located preferentially in the response 
regulator genes (Denervaud et al., 2004) and despite deficiency in AHL production, 
such isolates were still capable of causing clinically significant infections (Bosgelmez-
Tinaz and Ulusoy, 2008) (Schaber et al., 2004). 
The aim of this first chapter was to establish the QS signal molecule profile of a cohort 
of clinical isolates of P. aeruginosa obtained from CF sputum. Given the contribution 
of P. aeruginosa biofilm formation to pathogenesis in CF, the conservation of the QS-
regulated lectin LecA was investigated amongst these isolates with a view to exploring 
further its contribution to biofilm development in subsequent chapters.  
3.2 Results 
3.2.1 Patient recruitment and sample collection 
To enable the characterisation of QS signal molecule production by clinical isolates and 
the detection of QS molecules in sputum from CF patients, a clinical study was 
undertaken. Between May 2004 and July 2005, 37 adult and 25 paediatric patients were 
recruited from the CF outpatientsÕ clinics at Nottingham City Hospital, UK. A further 3 
patients were approached but declined participation in the study. An additional 6 
patients were excluded from the study; 4 of these were not sputum producers, one had 
grown B. cepacia and one 39 year old female adult patient was found to be colonised 
with Burkholderia pseudomallei following travel to South East Asia a number of years 
previously. This organism was suspected when an aminoglycoside and colistin resistant 
Gram-negative oxidase positive rod was detected following routine clinical sputum 
culture. 
Of the 62 patients recruited, at least one sputum sample was provided by 39 (64 %). The 
genotype of both alleles at the CFTR locus was known for 33 patients and the average 
age of diagnosis was 3 years 10 months. The ratio of males to females was 35:27 and 
the median age at entry to the study was 20 years (range 6-52). See Table 3-1 for details 
of the recruited patients. 
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Table 3-1 Recruited patient details. 
 
Study 
number 
Sex Age at 
diagnosis 
(y) year 
(m) 
month 
Age at 
entry 
to study 
(y) year 
(m) 
month 
Allele 1 at 
CFTR 
locus 
Allele 2 at 
CFTR locus 
P. aeruginosa 
established 
 
A001 M 43y 2m 46y 6m Not done Not done Yes 
A002 F 3m 27y 5m phe508del phe508del Yes 
A003 F 0 17y 11m Not done Not done Yes 
A004 F 0 18y 8m phe508del Q493X Yes 
A005 F 50y 4m 52y 7m phe508del Not identified Yes 
A006 M 1m 22y 3m phe508del phe508del Yes 
A007 M 2y 19y 5m Not done Not done Yes 
A008 M 9m 26y phe508del Not identified Yes 
A009 M 5m 22y 3m phe508del Not identified Yes 
A010 M 2y 6m 24y 4m phe508del Not identified Yes 
A011 F 31y 40y 11m phe508del 2789+5G→A Yes 
A012 M 5y 2m 19y 4m phe508del phe508del Yes 
A013 F 16y 25y 11m phe508del phe508del Yes 
A014 F 6y 23y 3m Not done Not done Yes 
A016 M 2y 31y 7m phe508del phe508del Yes 
A017 M 5m 24y Not done Not done Yes 
A018 M 0 27y 4m Not done Not done Yes 
A019 M 0 20y 11m phe508del Not identified Yes 
A021 M 0 28y 6m phe508del Not identified Yes 
A022 F 14y 21y 7m phe508del Not identified No 
A023  F 21y 1m phe508del phe508del Yes 
A024 F Not 
known 
32y 1m phe508del phe508del Yes 
A025 M 6y 46y 8m phe508del phe508del Yes 
A026 F 1m 32y 8m phe508del phe508del Yes 
A027 M 21y 41y 5m phe508del Not identified No 
A028 F 5m 25y 2m phe508del Q493X Yes 
A029 M 0 25y 8m Not done Not done No 
A030 F 8y 20y 9m Not done Not done No 
A031 F 2m 20y 10m phe508del phe508del Yes 
A032 M 2m 22y 3m Not done Not done Yes 
A033 M 7m 22y 4m Not done Not done Yes 
A034 M 0 25y 8m Not done Not done Yes 
A035 M 6m 21y phe508del phe508del Yes 
A036 F 6m 21y 5m Not done Not done Yes 
A037 M 2y 24y 4m phe508del phe508del Yes 
A038 F Not 
known 
30y 10m Not done Not done Yes 
A039 F Not 
known 
28y 2m phe508del phe508del Yes 
P001 M 1m 9y 5m phe508del phe508del Yes 
P002 M 0 14y 2m phe508del R347P Yes 
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Study 
number 
Sex Age at 
diagnosis 
(y) year 
(m) 
month 
Age at 
entry 
to study 
(y) year 
(m) 
month 
Allele 1 at 
CFTR 
locus 
Allele 2 at 
CFTR locus 
P. aeruginosa 
established 
 
P003 F 11m 15y 9m phe508del phe508del Yes 
P004 F 1m 13y 6m phe508del phe508del Yes 
P005 M 9y 5m 14y 11m phe508del Y563D Yes 
P006 F 2m 10y 1m phe508del Not identified Yes 
P007 F 1m 14y 2m phe508del phe508del Yes 
P008 M 3y 9m 10y 3m phe508del phe508del Yes 
P009 M 1m 15y phe508del G542X Yes 
P010 M Not 
known 
16y 5m Not done Not done Yes 
P011 M 1m 13y 8m Not done Not done Yes 
P012 F 0 17y 6m 621+1G>T Not identified Yes 
P013 F 6m 17y 10m phe508del Not identified Yes 
P014 M 0 6y 11m phe508del phe508del Yes 
P015 F 2y 16y 2m phe508del phe508del Yes 
P01 M 1m 8y 8m phe508del Not identified Yes 
P017 M 0 7y 11m phe508del G542X Yes 
P018 F 6m 16y 11m 3850-
1(G>A 
3659delC Yes 
P019 F 1m 15y 4m phe508del phe508del Yes 
P020 M 2y 9m 15y 7m Not 
known 
Not known Yes 
P021 M 0 8y 4m phe508del phe508del Yes 
P022 F 1m 10y 10m phe508del Not identified Yes 
P023 M 1y 3m 16y 5m V520F 3659delC Yes 
P024 M 4m 16y 9m phe508del phe508del Yes 
P025 M 5m 15y 7m phe508del phe508del Yes 
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3.2.2 Recovery of P. aeruginosa clinical isolates 
In order to study the QS signal molecule production of clinical P. aeruginosa isolates, 
43 isolates were recovered from a cohort of 36 individual patient sputum samples. Of 
these isolates, 16 came from samples provided by paediatric patients. Each sputum 
sample was plated onto selective agar as described in 2.4.2. The resulting isolates were 
identified by the same code as the sputum sample, with the addition of the letter A or B 
if more than one colony type was present. This was the case for six sputum samples, in 
each of which a pair of phenotypically different isolates was recovered. 
All isolates were confirmed to be rapidly oxidase positive Gram-negative rods. Twelve 
(28 %) grew as mucoid colonies on PIA after incubation at 37 ¡C for 24 to 48 h. The 
remaining 31 (72 %) were non-mucoid. The proportion of mucoid isolates was similar 
for the subset of isolates obtained from adult patients and for those obtained from 
paediatric patients at 26 % and 31 % respectively. Of the 6 cases in which a pair of 
isolates was recovered from a single sputum sample, 5 of these consisted of a non-
mucoid isolate co-existing with a mucoid isolate. The majority of isolates (31; 72 %) 
produced the green pigment pyocyanin. Of those remaining, 5 (12 %) produced a pink 
pigment, likely to be pyorubin and 7 (16 %) were colourless, suggesting no pigment 
production. See Table 3-2 for phenotypic characteristics of the isolates and Figure 3-1 
for light-phase photographs of a selection of isolates plated on PIA. 
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Table 3-2 Phenotypic characteristics of clinical isolates. 
Strain codes start with A or B depending on whether they were from sputum samples obtained 
from adult or paediatric patients respectively. The code ends in a letter A or B if more than one 
colony type was isolated. 
 
Strain Mucoid (m) 
Non-mucoid 
(nm) 
Pigment  Strain Mucoid (m) 
Non-mucoid 
(nm) 
Pigment 
A001-200804 nm none  A033-200804 nm green 
A002-051104 m none  A035-051104A m pink 
A003-280504 nm green  A035-051104B nm green 
A004-130804 m pink  A037-230205A m pink 
A005-100904 nm green  A037-230205B nm green 
A007-110604 nm green  P003-170804 nm green 
A009-110604 nm green  P004-010205 nm green 
A012-180604A nm green  P006-170804 nm green 
A012-180604B m none  P007-280904 nm green 
A014-291004 nm pink  P009-280904 nm green 
A017-081004 m green  P010-191004 nm green 
A018-151004 nm green  P010-211204 m green 
A019-040205 nm green  P013-101204A m none 
A021-101204A nm green  P013-101204B nm green 
A021-101204B nm green  P015-170804A m none 
A023-200804 nm green  P015-170804B nm green 
A024-270804 nm green  P016-280904 nm none 
A025-221004 m pink  P018-161104 nm green 
A026-130804 nm green  P020-191004 m none 
A029-110305 nm green  P021-211204 nm green 
A031-030904 nm green  P024-070904 m green 
A032-200804 nm green  
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Figure 3-1 Light-phase photographs of a selection of clinical strains plated on PIA. 
 
 
3.2.3 QS signal molecule production by clinical isolates 
The cohort of 43 clinical isolates was investigated for their ability to produce the QS 
signal molecules 3-oxo-C12-HSL, C4-HSL, HHQ and PQS when grown as broth 
cultures. TLC analysis was undertaken in conjunction with specific signal molecule lux-
based bioreporter bacteria. TLC plates were selected to allow the optimal separation of 
each signal molecule in an appropriate solvent system and then overlaid with a lawn of 
bioreporter bacteria. The E. coli reporter strains S17-1 λpir [pSB1142] and JM109 
[pSB536] were used to detect the presence of 3-oxo-C12-HSL and C4-HSL 
respectively. For the detection of PQS and HHQ, PAO1 lecAÕ::lux∆pqsA was used.  
A001-200804 A007-11004 
A014-291004 
A035-051104A 
A023-200804 
A035-051104B 
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Activation of the E. coli JM109 [pSB536] bioreporter by extracted broth cultures 
indicated the presence of C4-HSL for all isolates bar one obtained from an adult patient, 
which was mucoid and coexisted with a non-mucoid C4-HSL producing isolate. Using 
the E. coli S17-1 λpir [pSB1142] bioreporter, 3-oxo-C12-HSL was not detected for 
either of these isolates, nor so from paired isolates from two paediatric patients. In total, 
22 (51 %) isolates were deficient in 3-oxo-C12-HSL. Of these, 17 (77 %) were non-
mucoid. Examining the distribution of these signal molecule-deficient isolates, it was 
apparent that 37 % (10/27) of adult isolates lacked 3-oxo-C12-HSL compared to 75 % 
(12/16) of isolates obtained from paediatric patients.  
The PAO1 lecAÕ::lux∆pqsA bioreporter indicated the presence of HHQ for all isolates 
and in 95 % (41) of isolates, PQS was also detected. The 2 isolates in which PQS was 
not detected were obtained from non-mucoid, pyocyanin-producing paediatric isolates 
which both made low levels of C4-HSL and lacked 3-oxo-C12-HSL. In this instance, 
the production of pyocyanin may have been achieved by the substitution of PQS by 
HHQ. See Figure 3-2 to Figure 3-4 for representative images of QS signal molecule 
detection by TLC and signal molecule bioreporter bacteria and Table 3-3 for a summary 
of clinical isolate QS signal molecule production. 
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Figure 3-2 Detection of 3-oxo-C12-HSL in 
a selection of clinical isolates using TLC 
and the E. coli S17-1 λpir [pSB1142] 
bioreporter strain. 
3-oxo-C12-HSL detection on reverse phase 
RP-2 TLC plates after 3 h incubation at 
37 ¼C. 1 µl 1 µg/ml 3-oxo-C12-HSL was run 
as a standard and PAO1 extract as a control.  
 
 
Figure 3-3 Detection of C4-HSL in a 
selection of clinical isolates using TLC 
and the E. coli JM109 [pSB536] 
bioreporter strain. 
C4-HSL detection on reverse phase RP-18 
TLC plates after 3 h incubation at 37 ¼C. 1 
µl 10 µg/ml C4-HSL was run as a standard 
and PAO1 extract as a control. 
1 3-oxo-C12-HSL standard (1 µg/ml) 
2 PAO1 
3 PAO1∆lecA 
4 A001-200804 
5 A007-110604 
6 A014-291004 
7 A023-200804 
8 A035-051104B 
1 C4-HSL standard (10 µg/ml) 
2 PAO1 
3 PAO1∆lecA 
4 A001-200804 
5 A007-110604 
6 A014-291004 
7 A023-200804 
8 A035-051104B 
 99 
(A) 
 
 
(B)  
 
Figure 3-4 Detection of PQS and HHQ in a 
selection of clinical isolates. 
 (A) Normal phase TLC plates of extracts of the 
clinical isolates viewed under a UV 
transilluminator. 1 µl 5 mM HHQ and 2 µl 10 
mM PQS were run as standards and PAO1 
extract was used as a control. (B) lecA::lux 
expression by PAO1 lecAÕ::luxΔpqsA overlaid 
on TLC plates after 5.5 h incubation at 37 ¼C, 
indicating presence of both PQS and HHQ in a 
selection of clinical isolates.  
 
 
1 PQS standard (10 mM) 
2 HHQ standard (5 mM) 
3 PAO1 
4 PAO1ΔlecA 
5 A001-200804 
6 A007-110604 
7 A014-291004 
8 A023-200804 
9 A035-051104B 
       1       2        3       4        5       6       7        8        9 
PQS 
HHQ 
HHQ 
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Table 3-3 Clinical isolate QS signal molecule production. 
 
Strain C4 C12 HHQ PQS  Strain C4 C12 HHQ PQS 
A001-200804 y y y y  A033-200804 y y y y 
A002-051104 y y y y  A035-051104A y y y y 
A003-280504 y y low y y  A035-051104B y y y y 
A004-130804 y y y y  A037-230205A y y y y 
A005-100904 y y low y y  A037-230205B y y y y 
A007-110604 y y y y  P003-170804 y low n y n 
A009-110604 y y low y y  P004-010205 y y low y y 
A012-180604A y n y y  P006-170804 y low n y n 
A012-180604B n n y y  P007-280904 y n y y 
A014-291004 y y y y  P009-280904 y n y y 
A017-081004 y n y y  P010-191004 y y y y 
A018-151004 y y y y  P010-211204 y n y y 
A019-040205 y n y y  P013-101204A y n y y 
A021-101204A y y y y  P013-101204B y n y y 
A021-101204B y n y y  P015-170804A y n y y 
A023-200804 y y y y  P015-170804B y n y y 
A024-270804 y n y y  P016-280904 y n y y 
A025-221004 y y y y  P018-161104 y n y y 
A026-130804 y n y y  P020-191004 y y y y 
A029-110305 y n y y  P021-211204 y n y y 
A031-030904 y n y y  P024-070904 y y y y 
A032-200804 y n y y  
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3.2.4 Investigation of signal molecule deficient isolates 
Previously it has been shown that QS signal molecule deficient P. aeruginosa strains 
have been recovered from clinical sources and mutations were found to be preferentially 
located in the lasR and rhlR response regulator genes (Dnervaud et al., 2004). In 
addition, Fox et al (2008) have recently reported the spontaneous occurrence of mutants 
in the vfr gene which is known to positively control the expression of lasR. Hence, 
further investigations were conducted on the 22 3-oxo-C12-HSL deficient isolates, the 1 
C4-HSL deficient isolate and the 2 PQS deficient isolates recovered in this study in 
order to characterise whether their deficiency in signal production was due to a defect in 
the synthase or transcriptional regulator genes themselves or in their expression.  
3.2.4.1 Investigation of 22 isolates deficient in 3-oxo-C12-HSL 
As an initial screen for their presence, primers were designed to amplify lasR and lasI 
and when applied to the 3-oxo-C12-HSL signal-deficient isolate templates, a product of 
the appropriate size was obtained for both genes in all cases (data not shown). 
Following this, RT-PCR was undertaken to investigate the expression of lasR and lasI, 
which was found to occur for all isolates. See Figure 3.5. 
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(A) 
 
 
(B) 
 
 
 
 
 
 
 
Figure 3-5 Detection of (A) lasR and (B) 
lasI gene transcripts by RT-PCR in a 
selection of clinical isolates. 
One-step RT-PCR was undertaken using the 
primers pairs (A) lasR2UF/lasR2DR and (B) 
lasI2UF/lasI2DR yielding products of the 
expected sizes when examined on agarose 
gel electrophoresis. 
  
 
 
 
 
1 1 Kb DNA ladder 
2 PAO1 chromosomal DNA 
template 
3 Blank well 
4 PAO1 RNA 
5 A017-081004 
6 A019-040205 
7 A021-101204B 
8 A024-270804 
9 A026-130804 
10 A029-110305 
11 A031-030904 
12 A032-200804 
13 P003-170804 
           1    2    3   4    5   6   7   8    9  10 11 12 13 
      1   2    3   4   5   6   7    8   9   10 11 12 13 
1 Kb 
1 Kb 
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Given this, it was hypothesised that the deficiency in 3-oxo-C12-HSL production may 
be due to a defect in the sequence of the synthase or transcriptional regulator genes 
themselves, affecting their translation into a functional protein product. Hence, the 
initial PCR products of the synthase and transcriptional activator genes were sequenced 
as described in section 2.10.8. BLAST comparisons against the published sequence for 
PAO1 identified 8 isolates with a defect in the lasR gene alone and one isolate with a 
defect in both lasR and lasI. See Table 3-4 and Table 3-5 for a summary of the position, 
nature and consequent amino acid changes of the gene defects detected.  
 
Table 3-4 Summary of mutation detected in lasI of clinical isolate deficient in 3-oxo-C12-
HSL. 
 
Isolate Codon 
number 
Nature of error Original codon 
(amino acid) 
Mutated codon 
(amino acid) 
A017-081004 144 substitution ACC (threonine) ACT (threonine) 
 
Table 3-5 Summary of mutations detected in lasR of clinical isolates deficient in 3-oxo-
C12-HSL. 
 
Isolate Codon 
number 
Nature of error Original codon 
(amino acid) 
Mutated codon 
(amino acid) 
A012-180604A 222 substitution ACC (threonine) ATC (isoleucine) 
A012-180604B 222 substitution ACC (threonine) ATC (isoleucine) 
A017-081004 45 substitution CAG (glutamine) TAG (stop) 
A024-270804 126 substitution GGC (glycine) AGC (serine) 
A026-130804 77 Deletion and 
frameshift 
AGT (serine) AGC (serine) 
89 substitution GAA (glutamate) GAG (glutamate) 
120 substitution GGT (glycine) GGC (glycine) 
121 substitution GCT (alanine) GCC (alanine) 
162 substitution GGT (glycine) GGC (glycine) 
192 substitution AGA (arginine) AAA (lysine) 
224 substitution CGC (arginine) CAC (histidine) 
A031-030904 
225 substitution CGC (arginine) CGT (arginine) 
P006-170804 235 substitution GGT (glycine) GTT (valine) 
P013-101204B 209 substitution AAC (asparagine) AAG (lysine) 
P015-170804B 222 substitution ACC (threonine) ATC (isoleucine) 
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In almost all cases, a single point substitution occurred, leading to the incorporation of a 
different amino acid and hence an alteration to the LasR protein sequence. In 3 of the 3-
oxo-C12-HSL deficient isolates, there was conservation of the error, with a replacement 
of the base cytosine by thymine in codon 222, leading to the incorporation of isoleucine 
rather than threonine. In one isolate (A026-130804), there was a base deletion (thymine) 
and subsequent shift of the reading frame. Isolate A031-030904 was found to have a 
number of defects, however only 3 of these actually coded for a different amino acid.  
Only one isolate (A017-081004) was found to have an error in the sequence of lasI. 
Indeed, this single base substitution did not lead to a consequent change in amino acid 
and its lack of 3-oxo-C12-HSL was most likely due to the substitution of cysteine by 
thymine in codon 45 of its lasR gene, creating a stop codon and hence truncating the 
amino acid chain of the regulator protein.  
3.2.4.2 Investigation of 1 isolate deficient in C4-HSL 
The same set of experiments was conducted to investigate the C4-HSL deficient isolate, 
A012-180604B. Primers were designed to amplify the entire region of the genes rhlR 
and rhlI, yielding PCR products of the appropriate size and RT PCR confirmed the 
expression of both gene transcripts (data not shown). Subsequent sequence analysis and 
BLAST comparison with the genome of PAO1 revealed that both genes were mutated 
as detailed in Table 3-6 and Table 3-7. 
 
Table 3-6 Summary of mutations detected in rhlI of clinical isolate deficient in C4-HSL. 
 
Isolate Codon 
number 
Nature of 
error 
Original codon 
(amino acid) 
Mutated codon 
(amino acid) 
31 substitution GAA (glutamate) GAG (glutamate) 
47 substitution AGC (serine) GGC (glycine) 
50 substitution GGC (glycine) GGT (glycine) 
54 substitution TGC (cysteine) TGT (cysteine) 
58 substitution CTG (leucine) TTG (leucine) 
68 substitution GAC (aspartate) GAA (glutamate) 
79 substitution CGA (arginine) CCA (proline) 
84 substitution TCT (serine) TAT (tyrosine) 
A012-180604B 
99 substitution AGC (serine) AAC (asparagine) 
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Table 3-7 Summary of mutations detected in rhlR of clinical isolate deficient in C4-HSL. 
 
Isolate Codon 
number 
Nature of 
error 
Original codon 
(amino acid) 
Mutated codon 
(amino acid) 
49 substitution CAC (histidine) CAT (histidine) A012-180604B 
197 substitution AGT (serine) AGC (serine) 
 
The two base substitutions in rhlR did not lead to subsequent amino acid changes, hence 
it can be assumed that this protein was functional. However, of the 9 substitution errors 
detected in rhlI, 5 lead to the incorporation of a different amino acid and hence it could 
be deduced that the failure to make C4-HSL was due to a problem with the structure 
and hence function of the RhlI synthase protein. 
3.2.4.3 Investigation of the 2 PQS deficient isolates 
It is known that conversion of HHQ into PQS requires the product of the pqsH gene 
(Gallagher et al., 2002). Therefore to further investigate the two PQS deficient isolates, 
primers were designed to amplify pqsH. These yielded PCR products of the appropriate 
size, confirmed to be the intact internal portions of the pqsH gene by sequence analysis. 
However, the ensuing RT-PCR failed to detect the gene transcripts, indicating that the 
deficiency in PQS production was due to failure of pqsH expression. 
3.2.5 The conservation of lecA and production of LecA by clinical isolates 
The lecA gene (and its corresponding protein product, LecA) is an example of a highly 
QS regulated gene because it is both AHL (Winzer et al., 2000) and PQS (Diggle et al., 
2003) dependent. In addition, this 47 kDa carbohydrate-binding protein is known to be 
an important virulence determinant of P. aeruginosa (Bajolet-Laudinat et al., 1994) and 
a contributor to biofilm formation by this organism (Diggle et al., 2006b). 
 To determine whether lecA (369 bp) was conserved in the cohort of non-mucoid and 
mucoid P. aeruginosa isolates recovered from CF sputum, the strains were subjected to 
PCR analysis for the lecA gene. As it was not known whether there was variation in the 
flanking regions of this gene in strains other than the sequenced strain PAO1, primers 
were designed to amplify an internal fragment of lecA. PAO1 and PAO1ΔlecA 
(containing a chromosomal deletion of lecA) were the positive and negative controls 
respectively.  
 106 
Figure 3-6 depicts an agarose gel of the appropriate size PCR products obtained for the 
wildtype control and a selection of clinical isolates. The wildtype PAO1 PCR product 
was subsequently purified and sequenced. A BLAST analysis against the published 
sequence for lecA demonstrated an intact alignment of nucleotides, implying that this 
primer set was indeed detecting the lecA gene.  
 
Figure 3-6 Example of the detection of 
lecA by PCR in a selection of clinical 
isolates. 
Amplification of an internal fragment of 
lecA using the primers lecAUF and lecADR. 
A product of between 344 and 396 bp was 
detected in all isolates except PAO1ΔlecA 
(negative control). 
 
To determine whether the LecA protein was produced in vitro by the clinical isolates of 
P. aeruginosa, Western blot analysis of SDS-PAGE gels was performed using a 
polyclonal antibody raised against LecA. This was used to detect the presence or 
absence of the lectin in the controls: purified LecA protein (PA-IL, Sigma) and PAO1 
(positive), PAO1ΔlecA and PAO1 lecA::lux (negative).  
Figure 3-7 shows the presence of a band running between the 10 and 15 kDa standards, 
which was present in the positive controls and absent in the negative controls, and likely 
represented the 12.5 kDa monomers of LecA. Further bands were seen around 25 and 
50 kDa which could represent binding to the dimer and tetramer state of the protein 
respectively. Other identical bands were seen in all the P. aeruginosa isolates as a result 
of polyclonal antibody binding to other bacterial proteins (data not shown). See Figure 
3.8 for LecA detection by Western blotting in a selection of clinical isolates. 
1 1 Kb DNA ladder 
2 Empty lane 
3 PAO1 
4 PAO1∆lecA 
5 A002-051104 
6 A004-130804 
7 A035-051104A 
8 P024-070904 
9 A033-200804 
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Figure 3-7 Western blot analysis of LecA 
production by laboratory strains. 
P. aeruginosa whole cell protein extracts 
were prepared and analysed by SDS-PAGE 
and Western blotting as described in 
sections 2.15.3 and 2.15.4 respectively. 
Anti-LecA was added at a dilution of 
1:1000. 
 
 
 
    
              
 
 
Figure 3-8 Western blot analysis of LecA 
production in a selection of clinical 
isolates. 
P. aeruginosa whole cell protein extracts 
were prepared and analysed by SDS-PAGE 
and Western blotting as described in 
sections 2.15.3 and 2.15.4 respectively. 
Anti-LecA was added at a dilution of 1:500. 
 
 
 
1   Purified LecA (10
-4 
mg/ml) 
2   Empty lane 
3   PAO1 
4   PAO1ΔlecA 
5   PAO1 lecA::lux 
1   Purified LecA (10
-4
 mg/ml) 
2   PA01 
3   PAO1ΔlecA 
4   A002-051104 
5   A004-130804 
6   A035-051104A 
7   P024-070904 
8   A033-200804 
 
 1           2             3           4             5            
15 kDa 
10 kDa 
  1      2       3      4       5       6      7      8 
LecA 
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In 6 of the cohort of 43 clinical isolates (14 %), there was failure to detect the lecA gene 
and as expected, no LecA protein was made. A full QS signal molecule profile was 
observed for all of these isolates, except A031-030904, which lacked 3-oxo-C12-HSL. 
See Table 3-8. 
 
Table 3-8 The QS signal molecule profile and lecA status of clinical isolates deficient in 
LecA production. 
 
Strain 
Mucoid/ 
nonmucoid Pigment lecA LecA C4 C12 HHQ PQS 
A014-291004 nm pink n n y y y y 
A018-151004 nm green n n y y y y 
A025-221004 m pink n n y y y y 
A031-030904 nm green n n y n y y 
P010-191004 nm green n n y y y y 
P020-191004 m none n n y y y y 
P021-211204 nm green y n y n y y 
 
The non-mucoid, pyocyanin-producing isolate P021-211204 appeared to possess and 
express lecA (as determined by PCR and RT-PCR respectively), however did not make 
the protein (see Figure 3-9). Sequence analysis of the gene indicated two redundant 
substitution errors, which did not result in changes to the amino acid chain. This isolate 
was noted to be deficient in 3-oxo-C12-HSL production and there was failure to restore 
protein production when a culture was grown in the presence of biologically active 
levels (20 µM) of this signal (data not shown) suggesting that the failure of protein 
production was not due to a disrupted QS circuitry. Other possible reasons for the lack 
of LecA production by this isolate could be problems with the translation or stability of 
the protein. 
 
 
 
 
 
 
Figure 3-9 Isolate P021-211204 does not produce LecA. 
P. aeruginosa whole cell protein extracts were prepared for a selection of clinical isolates and 
analysed by SDS-PAGE and Western blotting. Anti-LecA was added at a dilution of 1:500. 
1         2           3          4          5           6          7 
1 Purified LecA 
(10
-4
 mg/ml) 
2 PAO1 
3 PAO1∆lecA 
4 P004-010205 
5 P018-161104 
6 P020-191004 
7 P021-211204 
LecA 
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A table detailing the conservation of lecA and production of LecA by the full cohort of 
clinical isolates in conjunction with their QS signal molecule profile can be found in 
Appendix 5. 
3.2.5.1 The detection of LecA in sputum 
In addition to this characterisation of the LecA-status of the clinical isolates, attempts 
were made to detect LecA itself in sputum samples by SDS-PAGE and Western 
blotting. Following repeated experimentation (see section 2.15.2), there was failure to 
detect the protein, possibly because of the presence of only low levels in sputum. 
3.3 Discussion 
The analysis of clinical isolates described in this chapter was achieved by conducting a 
clinical study of CF patients. The establishment and implementation of such a study was 
a rigorous process, necessitating the full approval of the Ethics and R&D departments, 
the assistance of the CF clinical team and clinical microbiology department. The high 
recruitment rate and regular provision of sputum samples by the study participants 
reflects the high motivation and commitment of this relatively young patient group, 
their families and their allied clinical team to participate in and facilitate clinical 
research.  
A cohort of 43 clinical P. aeruginosa isolates was recovered from individual sputum 
samples by the use of selective agar plates and laboratory identification methods. In 
addition, there was access to information on the identification of strains in the clinical 
laboratory from parallel sputum samples provided by each patient. Phenotypic 
differences, principally in mucoidy, were used to further distinguish the putative 
presence of more than one strain from a given sample. It is know however, that 
phenotypic identification of Gram-negative bacteria from CF patients carries a risk of 
misidentification (Wellinghausen et al., 2005) and that differences in morphology may 
reflect the diversification of a single clone (Tummler and Kiewitz, 1999). Such an 
approach, however, was deemed pragmatic in terms of the further laboratory analysis 
planned. Furthermore, the detection of PQS, which to date has only been shown to be 
made by P. aeruginosa, was an independent confirmation of species identification. 
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Twelve (28 %) of the recovered isolates grew as mucoid colonies. This striking 
phenotype is rarely observed outside the CF lung, suggesting that this unique 
environmental niche selects for the occurrence and survival of mucoid mutants. This has 
significance in that the appearance of such mucoid colonies in CF lung disease 
correlates with impairment in lung function and the clinical decline of the patient (Parad 
et al., 1999).  
Other marked differences were noted in pigment production, with the intensity of the 
colours sometimes deepening dramatically as the plated colonies aged. A defining 
characteristic of P. aeurginosa is the production of diffusible fluorescent pigments such 
as pyoverdin, the soluble phenazine pigment pyocanin as well as pyorubin and 
pyomelanin (dark red and black respectively) (Pollack et al., 2000). Indeed, these 
simple observations of the diversity of strains on agar plates reinforced the importance 
of studying clinical isolates. These phenotypic variations reflect the adaptation and 
survival of individual strains within the same hosts, often for a number of years and 
hence differences are likely to occur in other pathogenic mechanisms such as QS 
systems.  
The investigation of the ability of this cohort of clinical isolates to produce four major 
QS signal molecules when grown as broth cultures demonstrated that the majority 
produced C4-HSL (98%), HHQ (100 %) and PQS (95 %). However, 51 % of the 
isolates were deficient in 3-oxo-C12-HSL production. Further investigation of these 22 
isolates revealed that lasR and lasI were detected and expressed in all cases. 
Subsequently, 9 isolates were found to have a sequence error in lasR, which coded for 
the incorporation of a different amino acid (7 isolates), a stop codon (1 isolate) and for a 
shift in the open reading frame (1 isolate). One mutation (substitution of cytosine by 
thymine in codon 222), which was seen in three isolates, was also detected in a 20 year 
old patient as part of the analysis of a cohort of patients with CF conducted by Smith et 
al. (2006), yet their computational prediction suggested that the mutation would be 
tolerated and thus not have an effect on LasR protein function. 
Thus the failure to detect 3-oxo-C12-HSL production by these and the remaining 13 
isolates could be for a number of reasons. These include the sensitivity of the assay 
itself and possible failure to detect low levels of signal production, mutations in other 
regulators such as vfr (Fox et al., 2008) or problems with the translation or stability of 
the response regulator and synthase proteins themselves. 
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Overall, these findings are in keeping with previous studies which have shown that QS 
deficient strains mostly carry mutations in the lasR regulator gene, which impairs the 
response to signal molecules ((Denervaud et al., 2004) (Smith et al., 2006) (Salunkhe et 
al., 2005). There are a number of possible explanations for this. Firstly, QS may not be 
important for growth in these environments and therefore Darwinian selection results in 
QS loss over time. Given that inactivation of lasR reduces P. aeruginosa virulence in 
diverse model hosts (Rumbaugh et al., 1999a), the occurrence of lasR mutants in the CF 
airway could be due to selection against a strategy for acute virulence in favour of the 
opportunity to survive and persist in a chronic state. Additionally, it has been suggested 
that a lasR mutation confers a growth advantage on particular carbon and nitrogen 
sources, which may offer a selective advantage over QS-positive strains (D'Argenio et 
al., 2007).   
In this study, a pair of isolates was recovered in which one was found to make 3-oxo-
C12-HSL (A021-101204A) and the other was deficient (A021-101204B). Indeed, 
another plausible explanation for the prevalence of lasR mutants is that bacteria can 
ÔcheatÕ or ÔfreeloadÕ on QS cooperating populations (West et al., 2006). In 
P. aeruginosa many QS-regulated products are released into the extracellular 
environment and benefit not only the producing cell but also its neighbours. Mutants 
that do not respond to QS signals do not incur the cost of producing these Ôpublic 
goodsÕ but gain the benefit of production by neighbours (Diggle et al., 2007b) (Sandoz 
et al., 2007). Put another way, lasR cheaters have a social fitness advantage over QS-
positive strains. This cooperation and cheating principle has been demonstrated for QS 
in vitro (Sandoz et al., 2007) (Diggle et al., 2007b) and also for the production of other 
public goods, such as siderophores, which in turn influence the virulence of an infection 
(Harrison et al., 2006) (Buckling et al., 2007). Social cheating could reconcile why lasR 
mutants are repeatedly found in clinical isolates from CF patients and yet QS-deficient 
mutants of P. aeruginosa have reduced virulence when grown in monocultures (Wu et 
al., 2001). 
Despite the occurrence of signal deficient isolates, the demonstration that in general, QS 
is conserved amongst these CF airway-derived clinical isolates supports its role as a 
mediator of virulence strategies in vivo. The clear implication of this is that these 
molecules and QS systems themselves represent potential targets for novel and specific 
antipathogenic therapies. For example, antibody interference with AHL-mediated QS 
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systems has been proposed (Kaufmann et al., 2006), along with enzymatic degradation 
of the signal molecule (Dong et al., 2001) and inhibition or blockage of the signalling 
circuit (Hentzer et al., 2003). Such an approach is attractive as it does not exert the same 
strong selective pressure as agents which kill bacteria and would not be expected to 
disturb the communities of beneficial normal flora in the host.!
To characterise further the QS-regulated behaviour of P. aeruginosa and as a prelude to 
the later investigation of biofilm formation, an analysis of the conservation of the highly 
QS-regulated gene lecA and the production of the LecA protein amongst the clinical 
isolates was undertaken. In addition to the laboratory strain, the gene was detected and 
the protein expressed in the majority of isolates, implicating a role for this protein in the 
in vivo pathogenesis of P. aeruginosa in the CF lung. Given its known cytotoxic effects 
on human peripheral lymphocytes (Sharabi, 1979) and respiratory epithelial cells 
(Bajolet-Laudinat et al., 1994) and its role in biofilm formation (Diggle et al., 2006b) 
the detection of this protein could therefore serve as a useful marker of lung damage as 
well as an indicator of the biofilm state. However, attempts to recover the protein by 
Western blot analysis ex-vivo from sputum samples were unsuccessful, possibly due to 
its presence at low levels. 
Despite this and given the evidence presented in this chapter for the production of QS 
signal molecules by clinical isolates, the principle of this approach prompted an 
investigation of the potential role of QS molecules as novel biomarkers of lung 
infection and tissue damage. Furthermore, the production of LecA amongst clinical 
isolates coupled with the report from our laboratory for its role in biofilm development 
(Diggle et al., 2006b) paved the way for ensuing chapters investigating the role of 
lectins in biofilm formation by laboratory and clinical isolates in a flowchamber biofilm 
system. 
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4 Chapter 4:  Investigation of QS signal molecules as 
biomarkers of lung infection and damage 
 
4.1 Introduction 
The demonstration that clinical isolates of P. aeruginosa make QS signalling molecules 
when grown as broth cultures raises the question of whether these compounds can be 
detected in clinical samples derived from the lungs of CF patients. Indeed, evidence that 
QS is functional in vivo dates to 1998 when Storey et al. (1998) demonstrated the 
presence of gene transcripts for the transcriptional regulator protein LasR in CF sputum. 
The first direct detection of AHLs in CF sputum was performed by Middleton et al. 
(2002) using lux-based E. coli AHL biosensors. Both short chain AHLs and a molecule 
which co-migrated with 3-oxo-C12-HSL on thin layer chromatograms were detected. 
Similarly, using the induction of β-galactosidase activity in reporter plasmids, low 
levels of the principal AHLs 3-oxo-C12-HSL and C4-HSL have been detected in 
sputum (Erickson et al., 2002). The use of biosensor strains has been further applied to 
demonstrate the presence of AHLs in other clinical sources of lung material such as 
lung tissue samples from CF patients (Favre-Bonte et al., 2002), material from human 
lung allograft recipients, including subjects with no apparent infection (Ward et al., 
2003), mucopurulent respiratory secretions harvested from portions of lungs from CF 
patients removed at transplant (Chambers et al., 2005) as well as from biofilms forming 
on the cuffs of endotracheal intubation devices (Favre-Bonte et al., 2007).  
In addition to bacterial biosensors, other laboratory approaches have been utilised. For 
example, following TLC separation, UV illumination was used to detect the presence of 
PQS in a range of clinical samples obtained from the CF lung (Collier et al., 2002). The 
use of more sophisticated physical-chemical methods has also been applied to enable 
the separation and unequivocal determination of structures based on their spectroscopic 
properties. Middleton et al. (2002) used LC coupled with high-resolution MS to identify 
C6-HSL and 3-oxo-C12-HSL in pooled sputum samples from CF patients. A recent 
report describes the use of LC-MS-MS to demonstrate the presence of a range of AHLs 
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in the saliva of a small group of healthy subjects and those with gastrointestinal 
disorders (Kumari et al., 2008).  
The detection of P. aeruginosa QS signalling molecules by the analytical approaches 
described provides evidence for the occurrence of QS in vivo. This is a key mechanism 
employed by this organism to regulate virulence and biofilm maturation and enable it to 
adapt and thrive in the particular environmental niche of the CF lung. There is therefore 
the potential to utilise these signals as novel and specific biomarkers of infection, which 
not only enable identification, but also offer specific insight into pathogenic 
mechanisms. 
A biomarker is a characteristic that is objectively measured and evaluated as an 
indicator of normal biological or pathogenic processes or pharmacological responses to 
a therapeutic intervention. There is increasing interest in the use of sputum as a rich, 
non-invasive source of biomarkers of inflammation and infection in CF (Sagel et al., 
2007). To date, a range of host-derived candidate biomarkers have been proposed, such 
as free neutrophil elastase and interleukin 8. Whilst the bacterial densities of 
P. aeruginosa and S. aureus from sputum have also been examined in relation to FEV1 
(Mayer-Hamblett et al., 2007), actual bacterial-derived markers have not yet been 
studied in great detail. The application of such markers alone or in conjunction with 
other candidates is an important and novel approach given the complex relationship 
between airway infection and inflammation in CF. 
This chapter describes the application of LC-MS to detect P. aeruginosa QS signal 
molecules from serial sputum samples from a cohort of CF patients and the 
interpretation of findings in conjunction with patient clinical data. This approach, which 
aimed to estimate associations between the recovery of QS signal molecules and clinical 
status, paves the way for formal testing of the hypothesis that these molecules are 
clinically and biologically relevant, reproducible, sensitive, specific and feasible 
biomarkers of infection and tissue damage by P. aeruginosa in the CF lung. 
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4.2 Results 
4.2.1 Description of study cohort 
As described in section 2.1, a cohort of 62 patients with CF was recruited and at least 
one sputum sample provided by 39 (64 %). From these individuals, a subset of 10 
patients (4 males and 6 females) was chosen for further analysis based on the criteria 
that they had produced at least two sputum samples, each being greater than 1 ml in 
volume. Eight of the patients were diagnosed with CF during their first two years of 
life. Six of the patients were recruited from the adult clinic (study number starting with 
A) with a mean age of 27 years 1 month at the time their first sputum sample was 
collected. Four patients were recruited from the paediatric clinic (study number starting 
with P) with a mean age of 16 years and 8 months. The full genotype of 7 patients was 
known and all had established infection with P. aeruginosa. A median of 6 sputum 
samples was collected from each patient (range 2 to 7). The FEV1 % predicted varied 
from 20 to 90 enabling a classification of disease severity based on Erickson et al. 
(2002). See Table 4-1 for a summary of the baseline characteristics of the study cohort. 
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Table 4-1 Characteristics of study cohort 
Classification of disease severity is based on Erickson et al. (2002) with patients defined as 
suffering from mild pulmonary disease having a forced expiratory volume in 1 s (FEV1) of > 70 
% of expected values. Patients classified as having moderate disease had a FEV1 which fell in 
the range > 40 % and < 70 % of predicted; severe were those patients whose FEV1 was < 40 % 
of expected values. 
 
Study 
number 
Sex Age at 
diagnosis 
Age 
when 
first 
sample 
collected 
Genotype 
1 
Genotype 
2 
Disease 
severity 
Number 
of 
sputum 
samples 
provided 
A001 M 43y 2m 46y 11m Not done Not done Information 
unavailable 
7 
A002 F 3m 28y 2m phe508del phe508del Information 
unavailable 
6 
A004 F 0 19y 2m phe508del Q493X moderate 5 
A014 F 6y 24y Not done Not done severe-
moderate 
7 
A035 M 6m 21y 3m phe508del phe508del severe 6 
A037 M 2y 24y 11m phe508del phe508del severe 6 
P003 F 11m 16y 8m phe508del phe508del moderate 5 
P013 F 6m 18y 4m phe508del Not 
identified 
mild 7 
P015 F 2y 16y 11m phe508del phe508del moderate 2 
P025 M 5m 16y 9m phe508del phe508del moderate 2 
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4.2.2 Synthetic QS molecules detected by LC-MS 
A full spectrum of synthetic AHL and AQ synthetic standards of varying side chain 
length and substitution, at a concentration of 0.5 µM, were examined by LC-MS as 
described in section 2.18.4. This was undertaken in order to determine the relative peak 
area counts (or relative response) that could be detected at this concentration for these 
compounds using this particular method of extraction and analysis by Multiple Reaction 
Monitoring Triggered Traps (MRMTT). This is designed for sensitivity and relative 
quantification, enabling identification of analytes based on expected elution times, 
precursor ion and product ion. Analytes with longer carbon side chains were detected at 
higher peak area counts as were the unsubstituted AQs in comparison to the AHLs 
(Figure 4-1). 
 
 
Figure 4-1 Relative response of synthetic standards. 
LC-MS detection of 0.5 µM synthetic standards of QS molecules using MRMTT. Values 
represent logarithmically transformed peak area counts of a single reading. The key biologically 
significant P. aeruginosa QS signal molecules C4-HSL, 3-oxo-C12-HSL, HHQ and PQS are 
highlighted in red. 
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To enable relative quantification of the key biologically significant molecules C4-HSL, 
3-oxo-C12-HSL, HHQ and PQS, synthetic signal molecule standards at concentrations 
of 0.1 to 0.5 µM were analysed (Figure 4-2). 
 
 
Figure 4-2 Dose-response of QS synthetic standards. 
C4-HSL, 3-oxo-C12-HSL, HHQ and PQS at concentrations ranging from 0.1 to 0.5 µM were 
analysed by LC-MS. Values represent logarithmically transformed peak area counts of a single 
reading.  
 
4.2.3 Sputum QS molecules detected by LC-MS 
The total cohort of 53 sputum samples provided by the study participants were 
individually extracted and analysed by LC-MS as described in section 2.18. A wide 
range of P. aeruginosa-relevant molecules was recovered at varying frequencies and 
relative amounts. C4-HSL, HHQ and PQS were detected in almost all samples yet the 
recovery of 3-oxo-C12-HSL was lower at just over 50 %. The open ring form of this 
compound was detected in 37 (70 %) samples, 10 of which did not contain intact 3-oxo-
C12-HSL. An additional breakdown compound, tetramic acid, was detected in 12 
samples (5 of which did not contain intact 3-oxo-C12-HSL). The failure to detect 3-
oxo-C4-HSL served as a useful negative control as this compound is not known to be 
produced by P. aeruginosa. See Table 4-2. 
 119 
Table 4-2 Range aned frequency of QS signal molecules detected in sputum 
A total of 53 sputum samples from the cohort of 10 patients were individually extracted and 
analysed by LC-MS. A wide range of P. aeruginosa relevant compounds was detected in 
varying frequencies. 
 
Signal molecule 
Number of samples in 
which signal detected 
(total 53) 
% of samples in which 
signal detected 
C4-HSL 52 98 
open ring C4-HSL 19 36 
C6-HSL 44 83 
C8-HSL 19 36 
C10-HSL 3 6 
C12-HSL 25 47 
C14-HSL 16 30 
3-oxo-C4-HSL 0 0 
3-oxo-C6-HSL 6 11 
3-oxo-C8-HSL 4 8 
3-oxo-C10-HSL 11 21 
3-oxo-C12-HSL 28 53 
open ring 3-oxo-C12-HSL 37 70 
3-oxo-C14-HSL 19 36 
tetramic acid 12 23 
3-OH C4-HSL 3 6 
3-OH C6-HSL 4 8 
3-OH C8-HSL 1 2 
3-OH C10-HSL 25 47 
3-OH C12-HSL 28 53 
3-OH C14-HSL 33 62 
C7 AQ (HHQ) 53 100 
C9 AQ 53 100 
C11 AQ 52 98 
n-oxide C7 AQ (HHQNO) 53 100 
n-oxide C9 AQ 51 96 
C7 PQS  52 98 
C9 PQS  53 100 
C11 PQS  46 87 
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Further detailed examination of select molecules known to be important for virulence 
and biofilms was undertaken to achieve an estimation of their relative spread of 
recovery. See Table 4-3. In keeping with the differing relative responses of these 
analytes (refer back to Figure 4-1), it can be seen that the AHLs are mainly recovered at 
the lower to mid ranges (peak area counts up to 10
5
) whilst the AQs are in the mid to 
high end of the spectrum of peak area counts. These values correspond to 
concentrations of approximately 0.1 to 0.5 µM (refer back to Figure 4-2). 
 
Table 4-3 Frequency of detection over a range of peak area counts for select compounds 
Values represent the number of sputum samples from which each compound was detected with 
the percentage in brackets. The range of peak area counts are depicted as 0/+ (counts less than 
10
4
); + (counts of 10
4
-10
5
) and ++ (counts of 10
6
-10
7
) and approximately correspond to 
concentrations of between 0.1 to 0.5 µM. 
 
Peak area count Analyte 
<10
4
 
0/+ 
10
4
-10
5 
+ 
10
6
-10
7 
++ 
C4-HSL 1  (1 %) 44 (83 %) 8 (15 %) 
3-oxo-C12-HSL 40 (75 %) 13 (25 %) 0 
tetramic acid 45 (85 %) 8  (15 %) 0 
C7 AQ 0 6  (11 %) 47 (89 %) 
C9 AQ 0 9  (17 %) 44 (83 %) 
n-oxide C7 AQ 0 22 (42 %) 31 (58 %) 
n-oxide C9 AQ 2  (4 %) 24 (45 %) 27 (51 %) 
PQS 0 22 (42 %) 31 (58 %) 
 
4.2.4 Cross sectional association between FEV1 and sputum QS signal molecules 
In order to determine whether the recovery of sputum QS molecules related to patient 
clinical status, a number of associations were investigated. Figure 4-3 displays 
scatterplots of each of the major P. aeruginosa QS signal molecules versus FEV1 % 
predicted for the first sputum sample collected from each patient. Any values of zero 
(indicating a peak area count below the threshold of detection) for the QS signal 
molecule level were disregarded. 
The null hypothesis (H0) was that the data were not correlated and the alternative 
hypothesis (Ha) was that the data were negatively correlated (ie that a fall in FEV1 was 
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associated with a rise in signal molecule level). The PearsonÕs correlation coefficient (r) 
was determined using Microsoft excel and for a one-tailed test with a cut-off p value of 
0.05, none of the sample correlation coefficients reached the minimum values needed in 
order to be deemed significant. However a trend for a negative association between C4-
HSL and FEV1 was noted. 
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Figure 4-3 Correlation between FEV1 % predicted and each of the major QS signal 
molecules recovered from sputum (A) C4-HSL (B) 3-oxo-C12-HSL (C) HHQ (D) PQS. 
Data plotted represent logarithmically transformed peak area counts from the first sputum 
sample provided by each patient against the corresponding FEV1 % predicted.  
(A) 
(B) 
(C) 
(D) 
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4.2.5 Cross-sectional association between pulmonary exacerbation score and sputum 
QS signal molecules 
Pulmonary exacerbation score is a clinical outcome measure, which serves to reflect 
acute changes in pulmonary status over weeks. Based on a scoring system devised by 
Rosenfeld et al. (2001), which assesses for the presence of clinical features of an 
exacerbation, all patients were assigned a numerical score (see Appendix 3). Figure 4-4 
depicts scatterplots of each major QS signal molecule from the first sputum sample 
provided by each patient against their corresponding pulmonary exacerbation score. 
In this instance, the H0 was the data were not correlated and the Ha was that the data 
were correlated (ie that a rise in pulmonary exacerbation score was associated with a 
rise in signal molecule level). Again, r values represent the PearsonÕs correlation 
coefficient and using a one-tailed test with a cut-off of 0.05, none of the sample 
correlation coefficients reached the minimum values needed in order to be significant. 
Despite this it was interesting to note that the trend of the data suggested a positive 
association between 3-oxo-C12-HSL and pulmonary exacerbation score, with a p value 
(0.075) approaching significance.  
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Figure 4-4 Correlation between pulmonary exacerbation score and each of the major QS 
signal molecules recovered from sputum (A) C4-HSL (B) 3-oxo-C12-HSL (C) HHQ (D) 
PQS. 
Data plotted represent logarithmically transformed peak area counts from the first sputum 
sample provided by each patient against the corresponding pulmonary exacerbation score based 
on Rosenfeld et al. (2001).  
(A) 
(B) 
(C) 
(D) 
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4.2.6 Longitudinal association between QS signal molecule level and pulmonary 
exacerbation 
In order to examine the relationship between patient clinical status and sputum QS 
signal molecule level over time, two-point comparisons of sputum baseline signal levels 
with those at the time of an exacerbation were plotted (Figure 4-5). For this within 
patient comparison, baseline was taken as the first sputum sample collected and an 
exacerbation was defined as the first time that the pulmonary exacerbation score rose 
above 2.6. If the first sample had a score above 2.6, the next sample for which the score 
had dropped (ie lung function had stabilised) was taken as the baseline.  
For certain patients there was a rise in the level of signal molecule at the time of an 
exacerbation. For example, an increase in C4-HSL, HHQ and PQS was seen for patient 
P013. However this trend was not observed for all patients and for all signal molecules. 
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Figure 4-5 The change in sputum QS signal molecule peak area count during a pulmonary 
exacerbation (A) C4-HSL (B) 3-oxo-C12-HSL (C) HHQ (D) PQS. 
Baseline corresponds to the first sputum sample with a pulmonary exacerbation score below 2.6 
and exacerbation is the next sample for which the score has risen above 2.6. 
 
(A) 
(B) 
(C) 
(D) 
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4.2.7 The effect of IV antibiotic treatment on sputum QS molecules 
To examine the effect of IV antibiotic treatment on sputum QS molecule levels, the 
change in levels from a period of pulmonary exacerbation (pulmonary exacerbation 
score >2.6) compared to a sequential sample following a course of IV antibiotic 
treatment was examined. See Figure 4-6. 
For patient P013, in whom a rise in C4-HSL, HHQ and PQS was previously seen in 
association with a pulmonary exacerbation, there was a corresponding fall in the levels 
of these signal molecules following treatment with IV antibiotics. However, as before, 
this trend was not seen consistently for all patients. 
 128 
 
 
 
 
Figure 4-6 The change in sputum QS signal molecule peak area count following an 
exacerbation treated with IV antibiotics (A) C4-HSL (B) 3-oxo-C12-HSL (C) HHQ (D) 
PQS. 
(A) 
(B) 
(C) 
(D) 
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4.2.8 Change in FEV1 versus change in QS signal molecule after IV antibiotics 
The difference in FEV1 between the time of an exacerbation (defined as the first time 
the score was > 2.6) and following a course of IV antibiotics was compared to the 
difference in sputum QS signal molecule peak area counts for the same time-points 
across all patients (Figure 4-7). 
It was hypothesised that an improvement in FEV1 following IV antibiotics would be 
associated with a fall in QS signal molecule level (ie a negative correlation). Using a 
one-tailed test with a cut-off of 0.05, none of the PearsonÕs correlation coefficient r 
values were significant, a likely reflection of the small sample size of this preliminary 
study. Yet in a similar fashion to the data presented in Figure 4-3 and Figure 4-4, C4-
HSL showed a trend to a positive correlation, suggesting a return to a chronic disease 
state. In contrast, 3-oxo-C12-HSL demonstrated a negative correlation, implying that it 
may indicate the resolution of an acute disease state. This data is very intriguing and 
certainly merits further work. 
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Figure 4-7 Change in FEV1 versus change in sputum QS signal molecule peak area count 
(A) C4-HSL (B) 3-oxo-C12-HSL (C) HHQ (D) PQS. 
The difference in FEV1 % predicted from the time of an exacerbation (first score > 2.6) and 
following IV antibiotics was compared to the corresponding change in sputum QS molecule 
logarithmically transformed peak area count. 
(A) 
(B) 
(C) 
(D) 
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4.2.9 The diagnostic potential of sputum QS signal molecules 
All ten patients included in the study were known to have established P. aeruginosa 
lung infection. The routine clinical microbiological culture of corresponding sputum 
samples collected at the same time as the study samples usually recovered one or more 
strains of P. aeruginosa, distinguished by differences in mucoidy and antibiotic 
sensitivity pattern. Of interest were the two samples provided by paediatric patient 
P025. LC-MS analysis of these extracted samples revealed a paucity of QS signal 
molecules and in sample P025-010306, there was failure to recover PQS. Routine 
clinical culture of the corresponding sputum samples detected the presence of S. aureus 
but no strains of P. aeruginosa, suggesting that the recovery of these signal molecules 
could be used to indicate the presence of non-cultured organism. See Figure 4-8. 
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(A) 
 
(B) 
 
Figure 4-8 Detection of QS signal molecules in individual sputum samples provided by 
patients P025 (A) Sample P025-161104 (B) Sample P025-010306. 
(A) Sample P025-161104, provided in November 2004, contains C4-HSL, HHQ and PQS, with 
3-oxo-C12-HSL below the level of detection. (B) In sample P025-010306 (obtained in March 
2006) of the key signal molecules, only HHQ is detected above the threshold level. Routine 
clinical culture of corresponding samples indicated the presence of S. aureus in each sample but 
no P. aeruginosa. 
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4.3 Discussion 
Thus far, data have been presented which demonstrated that a range of P. aeruginosa-
specific QS signal molecules was detected from individually extracted sputum samples 
from CF patients by LC-MS, corresponding to micromolar quantities. The biological 
relevance of these molecules for the pathogenesis of this organism is well documented 
and undisputed. In addition to their major role as regulators of virulence factor 
production, they may mediate bacterial interspecies communication, termed ÔcrosstalkÕ 
(Riedel et al., 2001). In addition, they may function as virulence determinants in their 
own right, with effects on other prokaryotes as well as eukaryotic host tissue itself. In 
order to assess their clinical relevance as sputum biomarkers of infection and tissue 
damage, their relationship with other accepted clinical outcome measures was 
examined. 
When applied to laboratory synthetic standards this method of solvent extraction and 
LC-MS analysis detected a full range of P. aeruginosa-relevant AHLs and AQs at 
concentrations of 0.1 µM and above. Differences in relative response were observed, 
with higher detection of the AQs compared to the AHLs. The analysis of individually 
extracted patient sputum samples indicated that whilst C4-HSL, HHQ and PQS were 
recovered in over 98 % of the cohort of 53 samples, the major signalling molecule 3-
oxo-C12-HSL was only detected in 53 %.  
There are a number of possible reasons for the failure to detect 3-oxo-C12-HSL. As 
discussed in the previous chapter, the analysis of P. aeruginosa clinical isolates 
recovered from the CF lung indicates that a high proportion is deficient in 3-oxo-C12-
HSL production. It is also known that QS signal molecules can be degraded by the 
process of pH-dependent lactonolysis (Yates et al., 2002). The pH of CF sputum is 
reported to range from 5.9 to 7 (Perricone et al., 2000) and some AHL hydrolysis would 
be expected to occur under these conditions. In addition, the action of AHL-degrading 
enzymes such as the paraoxonase (PON) enzymes, which are produced by human 
airway epithelial cells, has been reported (Chun et al., 2004). Indeed, in this analysis, 
the detection of the open ring forms of both C4-HSL (36 % samples) and 3-oxo-C12-
HSL (70 % samples) was evidence for the occurrence of these physiological processes 
in vivo.  
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A further reason for the failure to detect 3-oxo-C12-HSL from sputum could be due to 
its breakdown into tetramic acid. This nonenzymatically formed compound was 
detected in 23 % of samples and together with 3-oxo-C12-HSL itself, has been reported 
to have potent bactericidal activity against Gram-positive strains (Kaufmann et al., 
2005). In the complex environment of the CF lung, this could represent a virulence 
strategy to out-compete other key pathogens such as S. aureus. 
An important reason for the failure to detect 3-oxo-C12-HSL in just over half the 
samples could relate to its role in pathogenesis with the failure to detect low levels 
being the consequence of low production on the part of the organism. Previously, Singh 
et al. (2000) reported that planktonic cells produce more 3-oxo-C12-HSL than C4-HSL 
and that for biofilm organisms, the ratio is reversed. Importantly, they found that 
sputum samples from patients with CF produced higher rates of C4-HSL and took this 
as evidence for the occurrence of P. aeruginosa biofilms in the CF lung. In addition, 
previous reports have indicated that C4-HSL is important during the maturation stage of 
biofilm development (Sauer et al., 2002), for the total amount of biofilm formed (Favre-
Bonte et al., 2003) and for the maintenance of biofilm architecture (Davey et al., 2003). 
The cross-sectional analysis of FEV1 and sputum QS molecules did not yield any 
significant correlations, yet it was interesting to note that the trend of the data suggested 
a negative association between C4-HSL and FEV1. Conversely, whilst no significant 
correlations were observed for the association between pulmonary exacerbation score 
and signal molecule level, a possible positive correlation for 3-oxo-C12-HSL could 
exist. Hence, if biofilms represent a chronic infectious strategy leading to chronic lung 
decline, a high sputum C4-HSL level could represent severe disease progression 
secondary to biofilm maturation and maintenance. In contrast, a high 3-oxo-C12-HSL 
could be due to planktonic organisms leaving the biofilm and causing an acute 
exacerbation in symptoms.  
Whilst there is no conclusive evidence from this study to support these theories, such an 
application of sputum QS signal molecule detection could have major implications for 
planning treatment strategies specifically aimed at bacterial virulence strategies. For 
example, high dose, potent IV antibiotics could be administered at times of high sputum 
3-oxo-C12-HSL in an attempt to target planktonic phase organisms. However such a 
strategy may not be effective at times of high sputum C4-HSL when there may be a 
need for novel anti-biofilm measures instead. 
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As serial sputum samples were collected for each patient, a longitudinal analysis was 
undertaken to investigate the change in sputum signal molecule level with clinical 
events such as the occurrence of a clinical exacerbation or the effect of a treatment 
course of IV antibiotics. Such an approach yields information on the sensitivity and 
specificity of changes in signal molecule levels to changes in clinical status or treatment 
effects. It was apparent that for some patients, a rise in signal molecule from baseline 
did occur at the time of an exacerbation and a fall was observed following treatment. 
For example, for paediatric patient P013, there was a rise in the levels of C4-HSL, HHQ 
and PQS with an exacerbation and a fall in these molecules following a course of IV 
antibiotics. However this pattern was not observed consistently for all patients for 
whom data was available.  
Despite this, it is worth considering the potential clinical use of monitoring sputum QS 
molecules in this manner. Very much like serum CRP and WCC, the change in profile 
in sputum signal molecule levels could be used in conjunction with clinical symptoms 
and signs, as well as other biomarkers, to guide the initiation and termination of 
treatment courses. Such practice could help to rationalise antibiotic use and reduce such 
economic and patient burdens as cost of agent, cost of administration and the incidence 
of side-effects. There would also be the wider health impact of reducing the selective 
pressure for the rise in antibiotic resistance, a particular problem surrounding the 
treatment of P. aeruginosa. 
The very fact that these QS signal molecules are synthesised by the infecting organisms 
themselves raises the question of their utility as a diagnostic test of infection with 
P. aeruginosa. Indeed, for patient P025, S. aureus was recovered from sputum by 
traditional laboratory methods, including Gram-stain and culture. It was very interesting 
to observe that a paucity of P. aeruginosa signal molecules was recovered from 
corresponding samples. In this scenario, was the presence of some, but not a full 
spectrum of, QS signal molecules (eg C4-HSL, HHQ and PQS in sample P025-161104) 
an indicator of the presence of P. aeruginosa that was not detected on routine culture? 
Or in fact, was the failure to detect some key P. aeruginosa QS signal molecules (eg 
lack of C4-HSL, 3-oxo-C12-HSL and PQS in sample P025-010306) due to the fact that 
indeed, this organism was not present in the lungs of this patient. It is very unlikely that 
this latter suggestion is true as all patients enrolled in the study were known to have 
established lung infection with P. aeruginosa.  
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However, the application of this potential diagnostic use of QS molecules may be more 
relevant in patients who are not yet chronically colonised with P. aeruginosa. Indeed, 
Ward et al. (2003) have reported the detection of AHLs in human lung allograft 
recipients even in the absence of apparent infection. Indeed, PQS would be very 
relevant in this context as to date, it has only been shown to be made by P. aeruginosa. 
Hence, the detection of P. aeruginosa-specific QS signal molecules could be used as an 
early sensitive and specific indicator of the presence of the organism before it is 
detected by traditional methods. This would allow the rapid initiation of targeted and 
individualised therapies aimed at eradication, before established infection can occur. 
This study is limited by its small sample size and the retrospective nature of the clinical 
data collection. Despite the lack of conclusive outcomes, this preliminary analysis has 
provided evidence to support the application of sputum P. aeruginosa QS signal 
molecules as novel biomarkers of lung infection in CF, with key insights into organism-
specific pathogenic mechanisms. Clearly a much larger clinical trial with scheduled 
clinical data collection is needed to validate this role. 
This study has provided a rationale for focusing on four key signal molecules: C4-HSL, 
3-oxo-C12-HSL, HHQ and PQS. Using the report of Sagel et al. (2007) as a guide, it is 
clear that more information is needed on their short- and long-term variability in 
conjunction with data on sputum bacterial density and the QS profile of individually 
isolated strains. This needs to be performed in a large number of CF subjects of varying 
ages who are characterised in terms of age, sex, genotype, modifier genes, lung 
function, lung structure and the presence of other microbial pathogens. The association 
between sputum QS signal molecules and other clinical endpoints such as quality of life 
or patient-reported symptoms needs exploring. In addition, given the complex 
relationship between airway infection and inflammation, their role as members of a 
panel of biomarkers of lung injury should be considered.  
The reproducibility of these measures in terms of their variability and repeatability 
needs investigation. This raises the issue of the nature, collection and analysis of 
sputum as a source of biomarkers. A reason for the inconsistency between the detection 
levels of QS signal molecules and patient clinical status could be the variation in 
bacterial load between different sputum samples. This could be addressed by correcting 
the signal molecule level for the number of bacterial colony forming units per volume 
of sputum. Whilst non-invasively and inexpensively obtained, sputum is not produced 
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by all subjects, particularly children and may only reflect pathogenic activity in pockets 
of the lung. Methods of collection, storage and processing may vary between centres. 
Whilst the adoption of standardised approaches may partly address this, the analysis of 
other sources of lung material (eg induced sputum, BAL fluid, even saliva) and clinical 
specimens that may reflect more systemic processes, such as serum and urine, should be 
considered. 
The feasibility of the current approach is an important factor. LC-MS is an expensive 
resource necessitating dedicated expertise. For the purposes of this study, this method 
has provided direct chemical confirmation of the presence of QS signal molecules in 
sputum. However, in terms of the future clinical application of biomarker technology, 
less resource-demanding methods such as the use of sensitive and specific biosensor 
strains in a high-throughput microtitre plate format should be considered. These 
currently exist for a number of molecules including the AHLs (Winson et al., 1998) and 
PQS/HHQ (Fletcher et al., 2007). 
In addition to the many potential uses discussed, there are a number of important and 
exciting future applications of QS signal molecules as biomarkers of P. aeruginosa lung 
infection and tissue damage. A recent report has high-lighted the significance of this 
organism in chronic obstructive pulmonary disease (Murphy et al., 2008), a debilitating 
respiratory condition that affects approximately 5-15 % of adults in industrialised 
countries (Anto et al., 2001). Other applications outside the CF community include 
more acute clinical settings such as ventilator-associated pneumonia, community 
acquired pneumonia and infections in the immunocompromised host. 
 
Finally, the relentless rise of resistance to antibiotics in many species of bacteria, an 
inevitable evolutionary consequence of the huge selective pressure exerted by 
conventional antibiotics, necessitates alternative therapeutic strategies. QS inhibitor 
therapy is a novel and promising route, which aims to disable pathogenic behaviour 
rather than destroy the organism and therefore does not promote the acquisition and 
spread of resistance. Cleary, the detection of QS signal molecules in host tissues will 
allow the screening and evaluation of future therapies in terms of their mechanism of 
action and the response to treatment. They will also have a role in patient stratification 
and could serve as surrogate endpoints in clinical trials of novel therapies. Such future 
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approaches include specifically targeting bacterial biofilms and will be considered in the 
following chapter. 
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5 Chapter 5:  The contribution of lectins to biofilm 
maturation 
 
5.1 Introduction 
This study of the molecular mechanisms governing the pathogenesis of P. aeruginosa in 
the CF lung has focused on QS, with the demonstration that clinical isolates produced 
QS signal molecules and that their detection in sputum indicated a role as biomarkers of 
lung infection and damage. Furthermore, the conservation of the QS-dependent gene 
lecA and consequent production of the virulence determinant LecA amongst these 
clinical isolates, suggested a role for this lectin in the pathogenesis of P. aeruginosa in 
vivo in the CF lung. 
This takes on particular significance when considering that QS has been implicated in 
biofilm formation (Davies et al., 1998), a major virulence strategy employed by 
P. aeruginosa in the CF lung and that exopolysaccharides are considered to be key 
components of the biofilm matrix. Lectins, as a special class of multivalent 
carbohydrate-binding proteins could potentially mediate the binding of bacterial cells to 
each other (cohesion), the anchoring of biofilms to the substratum (adhesion) as well as 
cross-linking components of the inert biofilm scaffold via site-specific binding to 
exopolysaccharides.  
In addition to LecA, P. aeruginosa synthesises a second lectin, LecB (Gilboa-Garber et 
al., 1977). The production of both lectins is regulated by the RhlR/C4-HSL QS system 
(Winzer et al., 2000). LecA is growth phase-dependent and is also subject to regulation 
by other factors, including the stationary phase sigma factor RpoS, the transcriptional 
regulator MvaT and the post-transcriptional regulator RsmA (Diggle et al., 2002) 
(Winzer et al., 2000) (Pessi et al., 2001). The expression of lecA is also positively 
influenced the presence of PQS (Diggle et al., 2003). 
Both lectins are multivalent tetramers showing carbohydrate specificity and affinity. 
LecA (51 kDa) is composed of four subunits of 121 amino acids and binds D-galactose 
plus its derivatives (Gilboa-Garber et al., 1972), whereas LecB (47 kDa) is composed of 
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four subunits of 114 amino acids and binds L-fucose and other monosaccharides 
(Gilboa-Garber et al., 2000). Examination of this capacity for specific glycan 
recognition in biofilm formation has been undertaken in separate studies, which have 
focused on each lectin individually. Diggle et al. reported that a lecA negative mutant 
(PAO1 lecA::lux) formed biofilms with reduced depth and surface coverage compared 
to the parent strain PAO1 and a LecA-overproducing strain PAO-P47 (Diggle et al., 
2006b). Biofilm assays were performed in polystyrene microtitre plate wells and on 
stainless steel coupons under static conditions and laminar flow. In addition, Tielker and 
colleagues (Tielker et al., 2005) showed that a P. aeruginosa lecB mutant was impaired 
in biofilm formation on glass slides under static conditions when compared to the wild-
type strain. 
A focus of recent research into P. aeruginosa biofilm development and pathogenesis 
has been the nature of the biofilm matrix. Whilst known to consist of protein, 
polysaccharide and nucleic acid, a more complete understanding of its composition has 
been advocated since this matrix represents an important interface between the 
organism and host tissues (Ryder et al., 2007). Past investigation of the polysaccharide 
components of this matrix concentrated on the role of alginate, giving rise to the mucoid 
phenotype (Davies and Geesey, 1995). However the demonstration that alginate is not 
essential for P. aeruginosa biofilm development (Nivens et al., 2001) led to the 
identification of two alternative polysaccharide loci, namely pel and psl (Friedman and 
Kolter, 2004b). The psl locus is an operon composed of 15 genes encoding the Psl 
biosynthetic machinery. Carbohydrate and lectin staining analyses indicate that Psl is a 
mannose and galactose-rich polysaccharide, yet its full structure is yet to be elucidated 
(Ma et al., 2007). Using an inducible psl construct it was found that in addition to being 
required for cell-surface and cell-cell interactions, psl is also needed for maintenance of 
the biofilm structure post attachment, suggesting a role as a biofilm scaffold (Ma et al., 
2006). In addition, the demonstration that psl expression is localised at the centre of 
developing microcolonies implies a role in biofilm differentiation (Overhage et al., 
2005). 
The very clear aim of characterising lectin-carbohydrate interactions within 
P. aeruginosa biofilms is to identify novel targets for therapies aimed at tackling this 
problematic disease state, which persists in the CF lung in the face of aggressive 
antimicrobial therapy and a robust immune response. Indeed, lectins by their very 
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nature lend themselves to site-specific inhibition and hence biofilm disruption. Two 
aspects of this include the inhibition of lectins to prevent biofilm formation and the 
inhibition of lectins to disperse pre-formed established biofilms. This was illustrated by 
Diggle et al. (2006) who demonstrated the effect of hydrophobic galactosides against 
LecA. As proof of principle for this novel therapeutic strategy, there is one case report 
in the literature of inhalation therapy consisting of a combination of tobramycin, fucose 
and galactose which was used to successfully treat a P. aeruginosa respiratory infection 
where tobramycin alone had been unsuccessful (von Bismarck et al., 2001). 
The search for suitable lectin-inhibitory ligands has been furthered by organic chemistry 
techniques, reflecting the collaborative and multidisciplinary approach to CF research. 
Glycopeptide dendrimers are polymers with a regular branched structure, which can be 
synthesised with targeted physiochemical or biological properties. A new approach to 
dendrimer property tuning based on the combinatorial variation of dendrimer branch 
length and multivalency has identified ligands which bind to LecB (Johansson, 2007). 
Additional work is underway to identify suitable targets for LecA and together, these 
structures are a promising lead for the development of novel antibiofilm agents against 
P. aeruginosa. 
Hence, this final results chapter utilises the flowchamber biofilm system and other 
biofilm assays to further explore the role of lectins in biofilm formation in laboratory 
strains and clinical isolates. Experiments were undertaken to define the LecA putative 
target ligand and the action of novel anti-LecB dendrimers to prevent and disperse 
biofilms was examined. 
5.2 Results 
5.2.1 Investigation of the role of LecA in biofilm development by laboratory strains in 
the flowchamber biofilm system 
The 2006 report by Diggle et al. proposed a role for LecA in biofilm maturation rather 
than in the initial attachment to the substratum based on simple laboratory biofilm 
assays. To further explore and define this role more fully, a flowchamber biofilm 
system was established, modified and utilised as described in detail in Appendix 4. This 
closed, continuously flowing system is widely regarded as the gold-standard laboratory 
biofilm model and is applicable to direct live, non-destructive high power microscopy. 
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Hence, the ability of the parental wildtype strain PAO1 to form biofilms in the 
flowchamber system was compared to that of a lecA deletion mutant PAO1∆lecA 
(Stacey, 2003). All test strains were fluorescently labelled by transformation with the 
plasmid pUCP18::gfpmut3.1. Incubation of planktonic cells in a microtitre plate assay 
at 37 ¼C demonstrated comparable growth rates and maximal cell densities, indicating 
that any differences in biofilm formation were not due to a general growth defect. See 
Figure 5-1 for growth curves of PAO1 and PAO1∆lecA over 24 h.  
 
 
Figure 5-1 Comparison of growth of fluorescently labelled P. aeruginosa strains PAO1 and 
PAO1ΔlecA. 
Growth of normalised cultures in a 96 well plate over 24 h at 37 ¡C was measured in a 
spectrophotometer. Mean value ± SEM of 20 independent readings plotted. 
 
Strains were then grown at 37 ¡C within separate channels of a flowchamber biofilm 
system in replicate (4 channels per strain). The biofilms, which formed on the glass 
coverslip substrata, were imaged on days 4, 5 and 6 of incubation. The pooled confocal 
data from 3 independent experimental rounds was analysed using the COMSTAT 
programme to yield mean biofilm quantitative parameters. Both the wild type PAO1 
and lecA mutant strains formed surface-attached biofilms, which increased in their mean 
biomass and mean average and maximum thickness over subsequent incubation days. 
By day 4, the wildtype had established biofilms around 12 µm deep with additional 
growth of around 5 µm in thickness each day thereafter. In contrast, the lecA mutant 
formed significantly smaller biomass, thinner biofilms in comparison to the wild type (p 
< 0.05). An exception was the mean maximum biofilm thickness on day 5 incubation in 
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which the difference between the wildtype (35.5 µm) and the lecA mutant (31.3 µm) 
had an associated p value of 0.098. No clear trend of difference in biofilm 
heterogeneity, quantified by the dimensionless roughness coefficient, was detected 
between the two strains. See Table 5-1 and Figure 5-2 for COMSTAT quantitative 
comparative biofilm data for PAO1 and PAO1∆lecA. 
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Table 5-1 COMSTAT Quantitative analysis of 4-, 5- and 6-day old biofilms formed by 
PAO1 and PAO1ΔlecA. 
Each strain was inoculated in 4 separate flow channels and 5 image stacks were collected per 
channel. Mean ± SEM of 3 independent experimental rounds plotted. 
 
Strain Biofilm parameter Day 
PAO1 PAO1∆lecA 
P value 
4 12.42 ± 0.70 9.93 ± 0.49 0.0047 
5 14.31 ± 0.57 9.75 ± 0.57 < 0.0001 
Biomass (µm
3
/µm
2
) 
6 17.81 ± 0.90 11.76 ± 0.55 < 0.0001 
4 12.27 ± 0.78 9.52 ± 0.53 0.0047 
5 15.42 ± 0.63 10.37 ± 0.70 < 0.0001 
Average thickness (µm) 
6 21.13 ± 1.09 13.07 ± 0.80 < 0.0001 
4 32.26 ± 1.28 26.70 ± 1.47 0.0051 
5 35.53 ± 1.24 31.59 ± 1.91 0.098 
Maximum thickness (µm) 
6 45.81 ± 1.61 34.46 ± 2.01 < 0.0001 
4 0.39 ± 0.02 0.38 ± 0.02 0.79 
5 0.31 ± 0.02 0.48 ± 0.04 0.0007 
Roughness coefficient 
6 0.32 ± 0.02 0.37 ± 0.02 0.072 
 
(A)      (B) 
 
(C)      (D) 
 
 
 
 
Figure 5-2 Comparison of PAO1 and PAO1ΔlecA biofilm formation. 
(A) Biomass (B) Maximum thickness (C) Average thickness (D) Roughness coefficient. Mean 
values ± SEM are plotted for each biofilm parameter over successive incubation days. 
PAO1 PAO1∆lecA 
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Representative CLSM generated z-stack data for each strain were further subjected to 
IMARIS image rendering to produce a visual representation of the 3D biofilm structures 
formed. See Figure 5-3 and Figure 5-4. The wildtype PAO1 formed differentiated 
biofilms with evident mound-like microcolonies in this system. In contrast and bearing 
out the COMSTAT generated data, the lecA mutant strain formed flatter, thinner 
biofilms, with less pronounced topographical variation.  
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 Day 4 
PAO1 A 
D C 
B 
 
Figure 5-3 Representative IMARIS rendered images of 4-day old biofilm formed by 
PAO1.  
(A) xy section through biofilm with side panels depicting microcolony profiles through z 
(B) 3D rendered image viewed from above 
(C) Full 3D rendered image 
(D) ÔIsosurfaceÕ image, with space-filling and surface smoothing 
40µm 
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 Day 4 
lecA  A 
D C 
B 
 
Figure 5-4 Representative IMARIS rendered images of 4-day old biofilm formed by 
PAO1ΔlecA. 
(A) xy section through biofilm with side panels depicting microcolony profiles through z 
(B) 3D rendered image viewed from above 
(C) Full 3D rendered image 
(D) ÔIsosurfaceÕ image, with space-filling and surface smoothing 
30µm 
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5.2.2 The effect of IPTG on flowchamber biofilm development by laboratory strains 
Planktonic growth of P. aeruginosa PAO1 is known to be unaffected by the presence of 
isopropyl-β-D-thiogalactoside (IPTG), a hydrophobic galactoside with a strong affinity 
for LecA (Diggle et al., 2006b). This was confirmed by investigating the growth of 
planktonic PAO1 cultures in the presence of 0.2 mM IPTG in a microtitre plate assay 
(Figure 5-5). 
 
 
Figure 5-5 Growth of P. aeruginosa strain PAO1 in the presence and absence of 0.2 mM 
IPTG. 
Growth of normalised cultures ± IPTG at a final concentration of 0.2 mM over 24 h at 37 ¡C 
was performed in a 96 well plate and measured in a spectrophotometer. Mean value ± SEM of 6 
independent readings plotted. 
 
The effect of IPTG on biofilm formation by PAO1 and PAO1ΔlecA was investigated in 
the flowchamber biofilm system. The addition of 0.2 mM IPTG to the culture media 
prior to incubation resulted in the formation of biofilms of similar biomass and 
thickness by the wild type and mutant strains. Indeed, the previously observed 
statistically significant differences between PAO1 and PAO1ΔlecA were abolished in 
the presence of IPTG, with all p values being greater than 0.05. As before, no consistent 
trend for the difference in biofilm heterogeneity was observed. See Table 5-2 and 
Figure 5-6. 
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Table 5-2 COMSTAT quantitative analysis of 4-, 5- and 6-day old biofilms formed by 
PAO1 and PAO1∆lecA in the presence of 0.2 mM IPTG.  
Biofilms were grown in media containing 0.2 mM IPTG from the outset. Each strain was 
inoculated in 4 separate flow channels and 5 image stacks were collected per channel. Mean ± 
SEM of 3 independent experimental rounds plotted. 
 
Strain Biofilm parameter Day 
PAO1 PAO1∆lecA 
P value 
4 13.01 ± 0.76 13.79 ± 0.65 0.44 
5 14.73 ± 0.83 16.27 ± 1.07 0.14 
Biomass (µm
3
/µm
2
) 
6 12.89 ± 0.65 12.33 ± 0.75 0.58 
4 12.92 ± 0.93 13.83 ± 0.75 0.45 
5 14.62 ± 0.97 16.95 ± 1.33 0.16 
Average thickness (µm) 
6 13.37 ± 1.08 13.18 ± 0.92 0.89 
4 25.87 ± 1.37 26.77 ± 1.40 0.65 
5 29.87 ± 1.62 33.39 ± 1.94 0.17 
Maximum thickness (µm) 
6 26.39 ± 1.83 31.09 ± 1.96 0.085 
4 0.37 ± 0.03 0.32 ± 0.01 0.32 
5 0.30 ± 0.02 0.35 ± 0.02 0.098 
Roughness coefficient 
6 0.27 ± 0.01 0.39 ± 0.02 0.0004 
 
(A)      (B) 
 
(C)      (D) 
 
 
 
Figure 5-6 Comparison of PAO1 and PAO1ΔlecA biofilms grown in the presence of 0.2 
mM IPTG. 
(A) Biomass (B) Maximum thickness (C) Average thickness (D) Roughness coefficient. Mean 
values ± SEM are plotted for each biofilm parameter over successive incubation days. 
PAO1 PAO1∆lecA 
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To specifically assess the effect of IPTG on biofilm formation in the wildtype strain, 
PAO1 flowchamber biofilms were grown in separate channels in the presence and 
absence of 0.2 mM IPTG in replicate in two experimental rounds. In accordance with 
the data presented thus far, statistically significant reductions in mean biofilm biomass, 
average and maximum thickness was seen in the presence of IPTG over days 4 and 5 
incubation (p < 0.05). No significant difference was seen for biofilm heterogeneity. See 
Table 5-3 and Figure 5-7.  
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Table 5-3 COMSTAT Quantitative analysis of 4-, 5- and 6-day old biofilms formed by 
PAO1 with and without 0.2 mM IPTG.  
Biofilms were grown in media ± IPTG at a final concentration of 0.2 mM from the outset. The 
test strain was inoculated in 2 separate flow channels per test condition and 5 image stacks were 
collected per channel. Mean ± SEM of 2 independent experimental rounds plotted. 
 
(A)      (B) 
 
(C)      (D) 
  
 
 
Figure 5-7 Comparison of PAO1 biofilms grown in the presence and absence of 0.2 mM 
IPTG. 
(A) Biomass (B) Maximum thickness (C) Average thickness (D) Roughness coefficient. Mean 
values ± SEM are plotted for each biofilm parameter over successive incubation days. 
Strain Biofilm parameter Day 
PAO1 PAO1 + 0.2 mM IPTG 
P value 
4 11.96 ± 0.47 9.77 ± 0.63 0.0087 Biomass (µm3/µm2) 
5 15.45 ± 0.61 10.86 ± 0.95 0.0002 
4 13.36 ± 0.71 10.51 ± 0.99 0.025 Average thickness (µm) 
5 16.32 ± 0.63 11.51 ± 1.20 0.0011 
4 32.49 ± 1.90 21.28 ± 1.53 < 0.0001 Maximum thickness (µm) 
5 35.84 ± 1.59 23.31 ± 1.73 < 0.0001 
4 0.29 ± 0.02 0.30 ± 0.02 0.72 Roughness coefficient 
5 0.30 ± 0.01 0.32 ± 0.04 0.61 
PAO1 + 0.2 mM IPTG PAO1 
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5.2.3 Investigation of biofilm development by clinical isolates differing in their LecA 
status 
Given the demonstration of a role for LecA in biofilm development and the ability of 
the LecA-specific galactoside IPTG to inhibit biofilm formation, three clinical isolates 
with differing LecA status were identified in Chapter 3 and selected for examination of 
their biofilm formation in different laboratory biofilm systems in order to determine 
whether LecA had a role in a clinical context. Table 5-4 details their phenotype and QS 
profiles. Isolates with sensitivity to carbenicillin were chosen to enable transformation 
with the plasmid pUCP18::GFPmut3.1. In addition, isolates possessing a full 
complement of QS signal molecules were chosen so that any differences in biofilm 
formation could be attributed to differences in lectin status rather than signalling. 
 
Table 5-4 Characteristics of clinical isolates selected for examination in the flowchamber 
biofilm system 
 
Clinical isolate Mucoid/ 
Nonmucoid 
Pigment lecA LecA C4 C12 HHQ PQS 
A035-051104A mucoid Pink y y y y y y 
A021-101204A nonmucoid Green y y++ y y y y 
A014-291004 nonmucoid pink n n y y y y 
 
Isolate A035-051104A was recovered together with a lectin-producing nonmucoid 
isolate from sputum, whilst A021-101204A was recovered with a nonmucoid 3-oxo-
C12-HSL-deficient strain. A014-291004 was isolated on its own. 
The examination of the planktonic growth of these clinically derived isolates 
demonstrated variations in growth rate and the maximum cell density reached, with 
isolate A035-051104A showing a slower growth rate and A021-101204A reaching a 
higher maximum cell density compared to the laboratory strain PAO1 (Figure 5-8). 
These features were of important consideration when interpreting the differences in 
biofilm formation between the isolates. 
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Figure 5-8 Comparison of the planktonic growth of clinical isolates with P. aeruginosa 
strain PAO1.  
The growth of normalised cultures over 24 h at 37 ¡C in a 96 well plate was measured in a 
spectrophotometer. Mean value ± SEM of 5 independent readings plotted. 
 
 
The biofilm forming ability of these CF clinical isolates differing in their LecA-status 
was initially investigated in the microtitre well attachment model (see 2.19.2) and the 
steel coupon biofilm (2.19.3) assay. Both assays indicated that all three clinical isolates 
formed biofilms in association with a polystyrene or steel surface. However, the degree 
of biofilm formation was reduced compared to PAO1 and differed between the isolates, 
with A035-051104A (LecA +) demonstrating reduced biofilm formation in comparison 
to A021-101204A (LecA ++) and A014-291004 (LecA -).  
There was no significant effect of IPTG on the ability of these isolates to adhere to 
polystyrene microtitre wells. However, in the steel coupon model, the biofilms formed 
by PAO1 and A021-101204A were highly significantly reduced in the presence of 0.2 
mM IPTG (p <0.0001). The reduction seen for A014-291004 just reached significance 
with an associated p value of 0.042. See Figure 5-9 and Figure 5-10. 
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(A) 
 
(B) 
 
Figure 5-9 Clinical isolate biofilm formation in (A) microtitre well and (B) steel coupon 
biofilm assays. 
(A) Overnight cultures were normalised and grown under static conditions in round bottom 
wells of a 96 well plate for 24 h at 37 ¡C. The wells were washed and their contents stained with 
crystal violet. This was resolubilised and measured in an ELISA plate reader at OD540. Mean 
value ± SEM of 10 independent readings plotted.  
(B) Overnight cultures were normalised and grown in 0.05 % NB ± IPTG at a final 
concentration of 0.2 mM in Petri dishes containing steel coupons. Following incubation at 37 ¡C 
for 40 h with agitation at 60 rpm, the coupons were rinsed and stained with acridine orange. The 
% surface coverage for each strain was measured using the Lucia G/Comet software. Mean 
value ± SEM of 30 independent readings plotted. 
 155 
  PAO1     PAO1 + IPTG   
   
A035-051104A    A035-051104A + IPTG  
   
  A021-101204A   A021-101204A + IPTG  
   
  A014-291004   A014-291004 + IPTG 
   
 
Figure 5-10 Representative images of acridine orange stained biofilms grown in the 
presence and absence of 0.2 mM IPTG.  
Images were captured with the Lucia G/Comet software in conjunction with an inverted 
fluorescent microscope using the x10 objective lens. 
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To investigate biofilm formation in the flowchamber system, these clinical isolates were 
transformed with the plasmid pUCP18::GFPmut3.1 and grown in separate flowchamber 
channels in the presence or absence of 0.2 mM IPTG from the outset. See Figure 5-11 
for day 4 COMSTAT-generated data and Figure 5-12 for IMARIS biofilm 
reconstructions. 
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(A) 
 
(B) 
 
(C) 
 
Figure 5-11 Comparison of day 4 flowchamber biofilm formation by fluorescently labelled 
PAO1 and clinical isolates in the presence and absence of 0.2 mM IPTG (A) Biomass (B) 
Average thickness (C) Maximum thickness. 
The analysis was conducted using the COMSTAT programme. Biofilms were grown in media ± 
IPTG at a final concentration of 0.2 mM from the outset. Each strain was inoculated in 1 
flowchannel per test condition and 9 image stacks were collected per channel. Mean ± SEM of 3 
independent experimental rounds plotted. 
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 PAO1     A035-051104A 
 
 
 A021-101204A   A014-291004 
  
Figure 5-12 Examples of IMARIS rendered images of 4-day old untreated biofilms formed 
by PAO1 and clinical isolates.  
Images depict the ÔisosurfaceÕ reconstruction, with space-filling and surface smoothing. 
 
 
In the flowchamber system, the LecA-producing isolate A035-051104A formed 
comparable biofilms in terms of biomass and thickness to PAO1 and there were some 
reductions in these parameters in the presence of IPTG. The LecA over-producing 
isolate A021-101204A formed biofilms with a greater biomass and thickness from the 
outset in comparison to PAO1 and again, there was an effect of IPTG. The LecA-
deficient isolate A014-291004 was able to form structures whose volume and thickness 
were in keeping with the other strains, yet there was no significant effect of IPTG. 
Overall, it was not possible to give much weight to the effects of IPTG in this series of 
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experiments due to the reduced sampling (only one channel sampled per test condition 
per experimental round compared to 4 on previous occasions). 
The IMARIS reconstructions depicted in Figure 5-12 are of particular interest as they 
suggested that whilst numerically similar, the biofilms formed by the clinical strains 
differed dramatically in their 3D appearance. In contrast to the familiar regular 
undulating microcolonies of PAO1, A035-051104A (LecA +) formed structures with an 
irregular surface morphology. The biofilm of A021-101204A (LecA ++) appeared 
Swiss-cheese like and dense, whilst that of A014-291004 (LecA -) consisted of large 
polyp-like structures. 
5.2.4 Investigation of the role of Psl as a potential LecA target ligand 
The data presented thus far support a role for LecA in P. aeruginosa biofilm 
development by both laboratory strains and clinical isolates, most likely through lectin-
carbohydrate interactions. In order to identify the putative carbohydrate target, the 
ability of LecA to bind bacterial cells was examined in an ELISA plate assay. Purified 
LecA (PA-IL, Sigma) was immobilised on the surface of test wells, which were then 
probed with DIG-NHS-labelled bacterial strains. Alongside the three clinical isolates, a 
psl-negative strain (WFPA800) and its parental wildtype PAO1, kindly provided by the 
Wozniak laboratory, were also investigated to determine whether the Psl carbohydrate 
was a potential LecA biofilm ligand. The subsequent absorbance readings were an 
indication of the relative strength of binding of individual strains to the solid-phase 
LecA target (Figure 5-13). The Psl-producing parent strain showed enhanced binding 
compared the Psl-deficient mutant. Though the difference in binding was non 
significant (p = 0.4), the trend of the data suggested a possible LecA-Psl interaction. Of 
interest, the clinical isolates were also able to bind to LecA with A035-051104A (LecA 
+) behaving like the psl-mutant and A021-101204A (LecA ++) and A014-291004 
(LecA -) demonstrating levels of binding comparable to the Psl-producing PAO1 strain. 
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Figure 5-13 ELISA of bacterial cell binding to LecA. 
Test wells were covalently labelled with LecA and control wells with BSA. Following 
overnight incubation with DIG-NHS-labelled bacterial strains, wells were washed and then 
probed with anti-DIG-NHS antibody. Following the addition of the ABTS enzyme, the resultant 
colour change was measured with an ELISA plate reader at a wavelength of 405 nm. Mean 
values minus background BSA binding ± SEM of 3 independent readings plotted. 
 
 
This putative LecA-Psl interaction was further investigated by examining the effect of 
IPTG, which was hypothesised to disrupt this binding by competitively blocking the 
LecA active sites. An ELISA assay was performed as above with the addition of 
increasing concentrations of IPTG to the test wells. See Figure 5-14. As before, there 
was increased binding of the Psl-producing PAO1 compared to the Psl-deficient mutant 
WFPA800. Furthermore, both strains showed a reduction in binding in the presence of 
both concentrations of IPTG. The sample size was too small for any of these differences 
to reach significance at p = 0.05, hence, these findings were followed up in a steel 
coupon assay (Figure 5-15). PAO1 was able to form biofilms of significantly greater 
surface coverage compared to the Psl-deficient strain (p < 0.0001) and in addition, there 
was a significant reduction in the PAO1 surface coverage in the presence of 0.2 mM 
IPTG (p < 0.0001). Overall, this data implied that Psl was a potential candidate 
carbohydrate target ligand for LecA. 
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Figure 5-14 ELISA of bacterial cell binding to LecA in the presence of IPTG 
Test wells were covalently labelled with LecA and control wells with BSA. Wells were 
incubated with IPTG at a concentration of 0.2 mM or 2 mM overnight. There then followed 
overnight incubation with DIG-NHS-labelled bacterial strains in the appropriate concentration 
of IPTG. Wells were washed and then probed with anti-DIG-NHS antibody. Following the 
addition of the ABTS enzyme, the resultant colour change was measured with an ELISA plate 
reader at a wavelength of 405 nm. Mean values minus background BSA binding ± SEM of 3 
independent readings plotted. 
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(A) 
 
(B)  Wozniak PAO1   Wozniak PAO1 + IPTG  
   
  WFPA800    WFPA800 + IPTG  
   
     
Figure 5-15 The effect of 0.2 mM IPTG on biofilm formation in a stainless steel coupon 
assay by strains varying in their Psl carbohydrate status. 
(A) Steel coupon biofilm % surface coverage (B) Representative acridine orange stained biofilm 
images. Overnight cultures were normalised and incubated in 0.05 % NB ± IPTG at a final 
concentration of 0.2 mM in a Petri dish containing 3 steel coupons at 37 ¡C for 40 h with 
agitation at 60 rpm. The coupons were rinsed and stained with acridine orange. The % surface 
coverage for each strain was measured using the Lucia G/Comet software. Mean value ± SEM 
of 30 independent readings plotted. 
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5.2.5 Visualisation of LecA binding within bacterial biofilms 
Using chemical composition analyses and lectin staining in conjunction with CLSM and 
electron microscopy, Ma et al. provided evidence that the Psl exopolysaccharide is 
galactose and mannose-rich (Ma et al., 2007). LecA is a galactose-specific lectin and 
the data presented above indicated that its putative target may well be the galactose 
components of Psl. Hence, lectin staining was undertaken to determine whether this 
indeed was the case.  
As a test of the general methodology, the FITC-labelled MOA mushroom lectin specific 
for galactose moieties on the end of glycan chains, utilised by the Ma study, was 
obtained and tested for functionality using the Klebsiella pneumoniae M10 strain which 
has a galactose-rich LPS (Tomas et al., 1991). Complete individual cell-associated 
fluorescent staining was clearly seen under the inverted fluorescent microscope with the 
appropriate filter set as expected (Figure 5-16). Examination of binding to the Wozniak 
wildtype and a Psl-inducible strain (WFPA801), grown in the presence of its inducer 
arabinose, was then performed. This demonstrated that the fluorescent signal was 
associated with groups of cells only (Figure 5-17). Further high-powered examination 
using CLSM depicted lectin binding to the material associated with clumps of bacterial 
cells, presumed to be secreted EPS (Figure 5-18). Luyan Ma from the Wozniak group 
confirmed that these images were similar to what they have seen (personal 
communication, January 2008). 
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Figure 5-16 FITC-labelled MOA lectin-stained K. pneumoniae M10 viewed under the 
inverted fluorescent microscope. 
The x100 oil immersion objective and B2 filter set were used. 
 
 
    
Figure 5-17 FITC-labelled MOA lectin-stained Psl-inducible strain WFPA801 viewed 
under the inverted fluorescent microscope. 
(A) Phase microscopy (B) B2 filter for capture of fluorescent signal (C) Merged view. All 
images were obtained using the x100 oil immersion objective. 
 165 
(A)      (B) 
 
Figure 5-18 CLSM imaging of FITC-labelled MOA lectin-stained Psl-inducible strain 
WFPA801. 
(A) Fluorescent signal captured by CLSM (B) Differential interference contrast (DIC) view (C) 
Merged view. Microscopy was performed with a Zeiss Plan-NeoFluar 40x/1.3 oil immersion 
objective. FITC was excited with an Argon laser at 488 nm and emission collected with a 
LP505 filter. 
 
Hence, to determine whether LecA binding could be similarly visualised and related to 
the Psl-carbohydrate status of the test strains, purified LecA was fluorescently labelled 
with a commercially available cyanine dye (Cy5) which fluoresces in the far red end of 
the spectrum (see section 2.20). Successful staining of K. pneumoniae M10 indicated 
that this lectin-fluorophore conjugate was functional (Figure 5-19), although the 
intensity of the fluorescent signal and the extent of the individual bacterial cell binding 
was less than that seen with the FITC-labelled MOA lectin. Indeed, despite repeated 
experimentation, there was failure to capture any Cy5 fluorescent signal as evidence of 
(C) 
 166 
LecA binding to the Psl-producing P. aeruginosa strains. A number of technical factors 
such as choice of fluorophore, optimal ratio of bacterial strain to labelled lectin, length 
of incubation and nature of the wash steps may have contributed to this. Following 
unsuccessful attempts to optimise a number of these factors, this avenue of investigation 
was abandoned. Attention was then turned to the study of the second P. aeruginosa 
lectin LecB and the promising action of anti-lectin compounds on biofilms. 
 
 
 
Figure 5-19 CSLM imaging of LecA-Cy5 staining of K. pneumoniae M10 strain. 
Microscopy was performed with a Zeiss Plan Apochromat 63x/1.4NA oil immersion lens. Cy5 
was excited with a HeNe 633 nm laser and emission collected with a LP650 filter. 
 
5.2.6 The contribution of LecB to biofilm development 
It is known that biofilm development also involves the second P. aeruginosa L-fucose 
specific lectin LecB (Tielker et al., 2005). Indeed, a preliminary analysis indicated 
significant inhibition of biofilm surface coverage of stainless steel coupons with the 
LecB specific monovalent ligand p-nitrophenyl-α-L-fucose (NPF) at 0.5 mM (p = 
0.0014) and an additive effect with 0.2 mM IPTG (Figure 5-20). 
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Figure 5-20 The effect of anti-lectin monosaccharide ligands on P. aeruginosa PAO1 
biofilm formation on steel coupons. 
Overnight cultures were normalised and incubated in 0.05 % NB ± the test compound at the 
appropriate concentration in a Petri dish containing 3 steel coupons at 37 ¡C for 40 h with 
agitation at 60 rpm. The coupons were rinsed and stained with acridine orange. The % surface 
coverage for each strain was measured using the Lucia G/Comet software. Mean value ± SEM 
of 30 independent readings plotted. 
 
Hence, in order to further assess the action of anti-lectin compounds on biofilm 
formation, in addition to the PAO1∆lecA mutant already available, a lecB-negative 
mutant (PAO1∆lecB) was constructed by standard in-frame deletion (see section 2.13) 
and showed normal growth (Figure 5-21). It was observed that NPF inhibited biofilm 
formation in wildtype P. aeruginosa and in PAO1ΔlecA (P = 0.0001 and p = 0.0011 
respectively), but showed no reduction in biofilm formation for PAO1ΔlecB (p = 0.16). 
On the other hand, the galactose ligand IPTG inhibited P. aeruginosa PAO1 wildtype (p 
< 0.0001) and PAO1ΔlecB biofilms (p < 0.0001), but not those of PAO1ΔlecA (p = 
0.20). See Figure 5-22. 
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Figure 5-21 Growth curves for lectin mutant strains. 
Growth of normalised cultures in a 96 well plate over 24 h at 37 ¡C was measured in a 
spectrophotometer. Mean value ± SEM of 10 independent readings plotted. 
 
 
Figure 5-22 The effect of IPTG and NPF on steel coupon biofilm formation by lectin 
mutants. 
Overnight cultures were normalised and incubated in 0.05 % NB ± test compound at the 
appropriate concentration in a Petri dish containing 3 steel coupons at 37 ¡C for 40 h with 
agitation at 60 rpm. The coupons were rinsed and stained with acridine orange. The % surface 
coverage for each strain was measured using the Lucia G/Comet software. Mean value ± SEM 
of 30 independent readings plotted. 
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5.2.6.1 Inhibition of biofilm formation by targeting LecB with C-fucosyl glycopeptide 
dendrimers 
The recent identification of fucose-based anti-LecB dendrimers (Johansson, 2007) in 
conjunction with the reduction in biofilm surface coverage by the lectin-deficient 
strains/lectin-specific ligands prompted the further investigation of these compounds on 
P. aeruginosa biofilm formation. Hence the action of a range of C-fucosyl glycopeptide 
dendrimers was investigated in collaboration with Emma Johansson, University of 
Berne, Switzerland, who had previously performed the dendrimer synthesis. The word 
ÔdendrimerÕ is derived from the Greek ÔδενδρονÕ/dendron, meaning ÔtreeÕ and is the 
term for a repeatedly branched compound. Hence, glycopeptide dendrimers are 
regularly branched structures containing both carbohydrates and peptides. See Figure 
5-23 for a depiction of the general structure of a dendrimer. 
 
 
Figure 5-23 General dendrimer structure. 
Is treelike with a number of branching units. 
 
Dendrimers, with their globular structure, have a number of biomedical applications. 
For example, they can be used to mimic enzymes with an active site in the core or the 
cavities can be loaded with drugs enabling their use as site-specific drug delivery 
systems. A further application is to functionalise the surface in order to create primary 
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recognition elements for target ligands. This was achieved for LecB using α-L-fucoside 
end groups. In this way, a library of dendrimers with variable arm length and 
multivalency was created (Johansson, 2007). See Figure 5-24. 
 
 
Figure 5-24 General structure of C-fucosyl glycopeptide dendrimers synthesised by Emma 
Johansson. 
 
Screening of this library identified five dendrimers (Ò20Ó, Ò6CÓ, Ò9PhÓ, Ò14PhÓ and 
Ò17CÓ) with a high affinity for LecB, which were selected for further study. In the first 
instance, it was established that none of these ligands affected the planktonic growth of 
the PAO1 wildtype, indicating that any subsequent observed effect was not due to 
toxicity (Figure 5-25).  
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Figure 5-25 Effect of fucose dendrimers on the growth of P. aeruginosa PAO1. 
Growth of normalised cultures in a 96 well plate with the addition of the test compound at the 
appropriate concentration over 24 h at 37 ¡C was measured in a spectrophotometer. Mean value 
± SEM of 6 independent readings plotted. 
 
 
The action of these anti-LecB dendrimers was then investigated in the steel coupon 
biofilm assay. Indeed, all the dendrimers showed around a 50 % reduction in biofilm 
surface coverage when added from the outset, with dendrimer 20 showing the most 
pronounced effect, with almost complete biofilm inhibition (p < 0.0001). Furthermore, 
when added to 40 h pre-formed biofilms, all compounds were able to cause dispersal as 
indicated by a reduction in surface coverage and an increase in the subsequent viable 
cell count of released planktonic organisms. The degree of dispersion was similar for all 
compounds and of the same magnitude as that seen with IPTG (approximately 40 % 
reduction in surface coverage) with the exception of dendrimer 20 which showed an 
almost 70 % reduction. See Figure 5-26 and Table 5-5. 
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Figure 5-26 The effect of fucose dendrimers on biofilm formation on steel coupons by 
P. aeruginosa PAO1. 
Overnight cultures were normalised and incubated in 0.05 % NB in a Petri dish containing 3 
steel coupons. Anti-LecB compounds were added to give a final concentration of 0.5 mM for α-
NPF and 0.05 mM for the dendrimers. These were either present from the outset (biofilm 
inhibition assay) or following 40 h incubation (biofilm dispersal assay). The % surface coverage 
following acridine orange staining was measured using the Lucia G/Comet software. Mean 
value ± SEM of 30 independent readings plotted. 
 
 
Table 5-5 Viable counts of planktonic cells released from 40 h biofilms following exposure 
to test compounds. 
 
Compound CFU/plate Viable count (CFU/ml x 10
7
) 
Control 123, 120, 95, 83 1.05 
IPTG 625, 810, 510 5.13 
NPF 1057, 1200, 714 9.90 
Dendrimer 20 905, 1100, 875 9.60 
Dendrimer 6C 974, 1113, 897 9.94 
Dendrimer 9Ph 520, 533, 485 5.13 
Dendrimer 14Ph 830, 325, 625 5.93 
Dendrimer 17C 1350, 886, 1104 11.1 
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The potency of dendrimer 20 to disperse biofilms formed by the laboratory strain PAO1 
was very evident on visual analysis of acridine orange stained steel coupon biofilms 
viewed under the inverted fluorescent microscope and by CLSM, with virtual clearing 
of the coupon surface of attached microcolonies (Figure 5-27). 
 
(A) 
  
untreated   + dendrimer 20 
(B) 
  
untreated   + dendrimer 20 
Figure 5-27 Images of acridine orange stained PAO1 biofilms with and without treatment 
with dendrimer 20 after 40 h growth. 
(A) Fluorescent microscope view using the x10 objective and green filter, captured with 
Lucia/G comet software (B) IMARIS reconstructed CLSM stack captured with a Zeiss Plan-
NeoFluar 40x/1.3 oil immersion objective. Acridine orange was excited with an Argon laser at 
488 nm and emission collected with a LP560 filter. 
 
As a further test of its application, dendrimer 20 was assessed for its ability to inhibit 
biofilms formed by the clinical isolates A035-051104A, A021-101204A and A014-
291004 investigated previously. Highly significant reductions in biofilm surface 
coverage were seen for all three isolates and PAO1 (p < 0.0001) suggesting a generality 
of the inhibition effect. See Figure 5-28. 
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Figure 5-28 The action of dendrimer 20 on steel coupon biofilm formation by clinical 
isolates. 
Overnight cultures were normalised and incubated in 0.05 % NB ± test compound at the 
appropriate concentration in a Petri dish containing 3 steel coupons at 37 ¡C for 40 h with 
agitation at 60 rpm. The coupons were rinsed and stained with acridine orange. The % surface 
coverage for each strain was measured using the Lucia G/Comet software. Mean value ± SEM 
of 30 independent readings plotted. 
 
 
5.2.6.2 Cytotoxicity study of dendrimer 20 
The pronounced ability of dendrimer 20 to inhibit biofilm formation by laboratory and 
clinical isolates of P. aeruginosa and in addition, its dispersal effect on preformed 
PAO1 biofilms, raised the question of its potential therapeutic application. This would 
only be a possibility if this compound was not harmful to human cells. Hence 
investigation of dendrimer 20 in a LDH cytotoxicity assay against Human 293T kidney-
embryonic cells was performed and indicated that this compound showed no significant 
increase in LDH production over the untreated cells over a range of concentrations 
including 0.05 mM (all p values greater than 0.05). See Figure 5-29. This suggests that 
this dendrimer is not cytotoxic to eukaryotic cells and could potentially be tested in 
animal models of infection and eventually in humans. 
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Figure 5-29 LDH release from human 293T kidney-embryonic cells in the presence of 
dendrimer 20. 
Cells were cultured in a 96 well plate and incubated overnight in media containing the 
appropriate concentration of dendrimer 20. The cell-free supernatant was collected and 
transferred into the corresponding wells of an optically clear 96-well flat bottom microplate and 
to these, aliquots of freshly prepared LDH detection Reaction mixture were added. Following 
incubation for 30 min at room temperature the absorbance of the samples was measured at 492 
nm using an ELISA plate reader. Mean values of 3 independent readings ± SEM plotted. 
 
5.3 Discussion 
There has been a recent shift in thinking amongst the biofilm community from the view 
that the EPS is an amorphous physical carbohydrate scaffold, to the realisation that it is 
Òa chemically complex mechanically and structurally adaptive material that has multiple 
biological functionsÓ (Palmer and Stoodley, 2007). Yet relatively little is known about 
the regulation, composition and function of this material, which is the hallmark that 
distinguishes biofilm populations from planktonic cultures.  
The report by Diggle et al. (2006) highlighted that other adhesins besides alginate may 
have a larger influence on biofilm structure than was previously supposed. The 
flowchamber biofilm quantitative and qualitative data comparing the wildtype and lecA-
negative mutant presented here firmly support the role proposed by Diggle et al. 
(2006b) for LecA in P. aeruginosa biofilm development. Specifically, the data 
demonstrate that whilst the lecA-negative mutant can form surface attached biofilms, 
these were significantly smaller and thinner than those of the wildtype strain. The 
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IMARIS views implied that these spatial differences reflected a lack of surface 
differentiation into microcolonies, implying a role for LecA in biofilm maturation. 
However, a difference in how much the biofilm thickness varied (biofilm 
heterogeneity), as measured by the roughness coefficient, was expected but not seen. 
This may be because this particular parameter is not a suitable measure for the variation 
of surface topology. This also emphasises that whilst the IMARIS biofilm views are 
visually striking and appealing, they only reflect individual points of the data set. The 
drier COMSTAT data gives a robust, non-subjective overall description of the 
structures formed and should generally be more heavily weighted. 
IPTG is a hydrophobic galactoside with a high specific affinity for LecA (Garber et al., 
1992). The demonstration of its ability to abolish these differences between wildtype 
and LecA-deficient biofilms by significantly reducing the biomass and thickness of the 
biofilms formed by the wildtype strain suggested inhibition of LecA-biofilm 
interactions by specific blockage of its active sites. Whilst it is recognised that LecA is 
only one of a number of components likely to be important for biofilm development, the 
fact that lecA is the most highly upregulated gene under anaerobic conditions (Marvin 
Whiteley, personal communication) points to a specific role in the CF lung, where there 
is increasing evidence for the occurrence of an anaerobic microenvironment (Worlitzsch 
et al., 2002). 
Thinking within the context of the CF lung prompted the important investigation of the 
behaviour of CF clinical isolates differing in their LecA production. Several interesting 
points for discussion were raised by this work using three different in vitro biofilm 
assays. The microtitre plate assay is a simple attachment assay and this demonstrated 
that all three strains, including the LecA-deficient A014-291004, were able to attach to 
some degree to a polystyrene surface, though less efficiently than the wildtype. This 
behaviour of A014-291004 and the observation that the inclusion of IPTG in microtitre 
wells had no effect on the mean absorbance measures for the lectin-producing strains 
suggested that LecA is not important for attachment to such a surface. Furthermore, it 
has been reported that LecA is not involved in adhesion to human tracheobronchial 
mucin (Sonawane et al., 2006). 
The steel coupon assay is a somewhat more sophisticated system in which 
measurements of the fluorescence of acridine orange-stained bacterial cells above a 
certain threshold are made. These reflect the degree of surface coverage of biofilm 
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microcolonies as can be clearly seen by the microscope images of the untreated WT 
PAO1. A limitation is that measurements are made in a horizontal plane, yielding no 
information on biofilm depth. Despite this, this assay provided further information on 
the behaviour of the clinical strains. A035-051104A showed little microcolony 
formation, whilst A021-101204A and A014-291004 formed clumps of cells, which 
though different morphologically to the WT, likely represented differentiated 
microcolonies. Importantly, the significant inhibition of this microcolony formation in 
the presence of 0.2 mM IPTG in both the WT and LecA-overproducing strain A021-
101204A, further suggested a role for LecA in biofilm maturation that was not restricted 
to PAO1.  
The poor biofilm formation by isolate A035-051104A in these two assays could be a 
reflection of its reduced planktonic growth compared to the wildtype and other isolates. 
It was thus very interesting to observe that within the flowcell biofilm system, this 
isolate formed biofilms with volume and thickness parameters comparable to PAO1, 
suggesting that the prevailing environmental conditions within this flowing system 
favoured biofilm formation by this strain. Isolate A035-051104A was known to make 
LecA and indeed, biofilm inhibition was demonstrated in the presence of IPTG in this 
system. Interestingly, the LecA-overproducing strain A021-101204A and LecA-
deficient strain A014-291004 formed more substantial biofilms compared to PAO1, 
again suggesting that these isolates were somehow better adapted to forming biofilms in 
this environment. IPTG inhibition was seen in A021-101204A but not for A014-
291004. Whilst the effects of IPTG are in keeping with the known LecA-status of these 
isolates, some caution is needed in the interpretation of these data as no significant 
effect of IPTG was seen on the WT strain. This was most likely due to the reduced 
sampling, with only one channel per strain per test condition, undertaken in this series 
of experiments.  
The IMARIS reconstructions of the flowcell data were particularly interesting, 
demonstrating strikingly different biofilm morphologies amongst the isolates and from 
the wildtype laboratory strain. Despite the earlier caution, these observations highlight 
how informative IMARIS reconstructed biofilm images can be when interpreted in 
conjunction with the COMSTAT data. From the perspective of understanding 
P. aeruginosa biofilm formation and its implications for pathogenesis in the CF lung, 
they are in keeping with other reports that CF isolates have a highly variable biofilm 
 178 
architecture ((Lee et al., 2005) (Kirov et al., 2007), reflecting the great bacterial 
diversity that occurs within the airways of these patients. These structural differences 
are certain to represent different adaptive strategies resulting from the effects of the 
hostÕs genotype (affecting airway physiology and immune response), exposure to 
antibiotics, cohabiting flora and bacterial interspecies interactions and the length of 
bacterial colonisation. 
Attempts were made to characterise the LecA target ligand by focusing on the recently 
reported mannose and galactose-rich Psl carbohydrate. The enhanced binding of the Psl-
producing Wozniak PAO1 strain to LecA in an ELISA assay and the inhibition of its 
steel coupon biofilm formation by IPTG were very suggestive of a LecA-Psl 
interaction. The ability of the clinical isolates to attach to LecA in comparison to the 
laboratory strains differing in their Psl-status suggested that A035-051104A may be Psl 
deficient whilst A021-101204A and A014-291004 may be Psl rich. This emphasises 
that multiple factors are involved in the complex process of biofilm development, 
particularly in clinical isolates, which have adapted to a unique host environment over a 
number of years. Thus, the observed differences in the biofilms formed between the 
clinical isolates cannot simply be attributed to differences in a single component such as 
their LecA status and will be affected by a range of other factors such as the nature of 
their EPS. 
An assimilation of this data enables the proposition of a hypothesis for the role of LecA 
in biofilm maturation: in mediating cellÐcell and cellÐEPS adhesion as well as 
interactions between inert EPS components themselves (see Figure 5.30). To achieve 
this, it is known that whilst most of its activity is stored intracellulary, small but 
significant fractions of LecA are present on the cytoplasmic membrane, on the outer 
membrane and in the periplasmic space (Glick and Garber, 1983). Hence efforts were 
made to capture images of fluorescently-labelled LecA binding to P. aeruginosa cells. 
The inability to achieve this demonstrates the great difficulty in undertaking biofilm 
carbohydrate chemical analyses, due to the diversity of sugar monomers, linkages and 
unique structures present in the carbohydrate fraction of the EPS matrix material 
(Flemming et al., 2007). Indeed, replication of the work by Ma et al. (Ma et al., 2007) 
with FITC-labelled MOA lectin was performed with difficulty, likely reflecting that 
individual-user handling of strains and interpretation of live cell microscopy is variable 
and subjective. 
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Figure 5-30 Possible role for LecA in biofilm maturation: cross-linking bacterial cells with 
each other and the polysaccharide matrix. 
 
Whilst there is the need to characterise the nature of biofilm structural interactions, the 
overall aim of this work was to identify novel therapeutic targets for biofilm disruption. 
The direction of the study took an exciting turn with the collaborative investigation of 
the effect of novel anti-LecB synthetic furanoside dendrimers (Johansson, 2007). 
Previously, Diggle et al. (2006) reported no effect of 0.013 mM NPF on biofilm 
formation. This value, together with the value of 0.2 mM IPTG, were chosen as these 
concentrations are known to inhibit two haemagglutination units of LecB (Garber, 
1987) and LecA (Garber et al., 1992) respectively. This study showed that a much 
higher concentration of NPF (0.5 mM) had an inhibitory effect on steel coupon biofilm 
formation and a possible additive effect with 0.2 mM IPTG.  
The furanoside dendrimers are many times more potent than NPF and dramatic biofilm 
inhibitory effects were seen at 0.05 mM concentrations in both the laboratory wildtype 
and the CF clinical isolates. Importantly, at these test concentrations, there was no 
inhibitory effect on the planktonic growth of the wildtype. Furthermore, evidence that 
these biofilm inhibitory effects were mediated by LecB was provided by investigating 
biofilm inhibition in deletion strains lacking either LecA or LecB. NPF inhibited 
 
P. aeruginosa forms 
biofilms in the CF lung 
Polysaccharide glycocalyx is 
the biofilm scaffold 
LecA is a tetramer with a high 
specific affinity for 
hydrophobic galactosides 
 180 
biofilm formation in the wildtype and lecA-mutant, with no significant effect on the 
lecB-mutant.  
Dendrimer 20 showed the most potent biofilm inhibitory effect when added to the 
incubating media from the outset of growth. Of major significance was its enhanced 
ability, in comparison to NPF and the other dendrimers, to disperse 40 h preformed 
P. aeruginosa PAO1 biofilms. The associated increase in planktonic viable count was 
evidence that the mechanism of this action was release of organisms from the biofilm 
rather than cell death. Furthermore, this dendrimer showed no significant cytotoxic 
effect against human cells in culture. Taken together, this non-cytotoxic compound, 
which has the ability to disperse biofilms, has a potentially important clinical 
application in the treatment of established biofilms, without exerting a selective 
pressure through a bactericidal action for the emergence of resistance. 
These findings will be discussed in the light of the work presented in the previous 
chapters, together with the indications and implications for future work, in the ensuing 
final chapter. 
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6 Chapter 6:  Conclusions and future work 
 
CF is a common incurable inherited disease. P. aeruginosa infects and thrives in the CF 
lung and is the major cause of morbidity and mortality in this patient group. The 
realisation that within the airways, P. aeruginosa adopts sophisticated patterns of 
behaviour, offers new insights into its disease causing behaviour. Whilst set in the 
general context of P. aeruginosa pathogenesis in the CF lung, this study set out to 
specifically explore a) the links between QS signal molecule production and disease 
status in CF patients and b) the role of lectins in biofilm formation. 
Crucial to this undertaking was the decision to base the analysis on clinical isolates 
recovered from sputum samples provided by adult and paediatric patients with CF. The 
lengthy and tightly regulated process of setting up this clinical study was a worthwhile 
endeavour for the clinical strain collection established represents a valuable resource, 
which was utilised for this study and which is already being accessed to investigate 
other hypotheses relating to the behaviour of P. aeruginosa in a clinical context.  
The biosensor data presented in Chapter 3 demonstrated that these clinical isolates 
retained the ability to produce a number of different QS signal molecules in vitro, 
implying a role for QS during in vivo pathogenesis. The occurrence of signal-deficient 
isolates, particularly for 3-oxo-C12-HSL, suggested specific adaptive behaviour within 
the CF airways. 
Given that QS molecules and QS systems are important components of the in vivo 
pathogenesis of P. aeruginosa, Chapter 4 assessed the ability to recover these molecules 
from individual sputum samples by LC-MS. The unique feature of this investigation 
was that it was performed in conjunction with a review of the patient medical records 
and the collection of patient clinical information. The analysis revealed that a wide 
range of QS molecules was detected, including several signalling molecules considered 
important for virulence gene regulation such as 3-oxo-C12-HSL, C4-HSL and PQS. 
Furthermore, the data suggested some associations between sputum QS signal molecule 
level and CF disease status, response to IV antibiotics and the presence of non-cultured 
P. aeruginosa. In particular, it was suggested that a high sputum C4-HSL level could 
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reflect severe disease progression secondary to chronic biofilm formation and a high 3-
oxo-C12-HSL could be due to planktonic organisms leaving the biofilm and causing an 
acute exacerbation. A fall in signal molecule level after IV antibiotics would be a useful 
marker of response to treatment and the detection of bacterial signal in the absence of 
the cultured organism could represent a sensitive early indicator of infection, enabling 
targeted eradication therapy. 
These findings, though limited by the small sample size, clearly indicate the potential 
for a larger targeted clinical study with prospective collection of clinical data in order to 
validate the role of QS molecules as biomarkers of lung infection and damage in CF. 
Future applications might include evaluation of novel antipseudomonal therapies based 
on QS inhibitors and in other infections caused by P. aeruginosa, such as COPD. 
The formation of bacterial biofilm communities is of major importance in the 
pathogenesis of P. aeruginosa in the CF lung environment. To enable the study of 
biofilm formation in vitro, a flowchamber biofilm system and allied technology was 
established and optimised as described in Appendix 4. This very practical undertaking 
uncovered both the advantages and disadvantages of such a system. It was incredibly 
exciting to be able to visualise live, fully hydrated biofilms in real-time, with the 
generation of descriptive quantitative and qualitative data. This was tempered by the 
realisation that to obtain robust and meaningful measures, simple comparisons with 
non-subjective sampling and sufficient repeats was essential and this necessitated a 
lengthy analysis period.  
This established flowcell system is a very important analytical tool, which can be 
further utilised to provide baseline data for examining theoretical questions. It is, 
however, recognised that there is a need to study biofilm behaviour in a manner that 
reflects the natural environment. For example, the development of a static tissue culture 
model system for the study of interactions between P. aeruginosa and CF-affected 
human airway epithelial cells was described by Greg Anderson of Dartmouth College at 
the 2007 ASM conference on biofilms (Palmer and Stoodley, 2007). Indeed, the 
potential to incorporate human respiratory epithelium as the biofilm substratum into the 
flowchamber design is to be actively pursued with Respiratory Medicine colleagues. 
Previous findings of a role for LecA in biofilm formation by our laboratory (Diggle et 
al., 2006b) and the demonstration of the conservation and expression of lecA amongst 
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the clinical isolates examined in Chapter 3 were the basis for the investigation of the 
contribution of lectins to biofilm formation described in Chapter 6. It was confirmed 
that LecA contributes to biofilm maturation in both laboratory strains and clinical 
isolates and hydrophobic galactosides were shown to be able to inhibit biofilm 
development. The biofilm target ligand for LecA was putatively identified as the Psl 
exopolysaccharide. Mutants defective in either lecA or lecB were shown to produce 
defective biofilms, which could be inhibited and/or dispersed by galactosides or 
furanosides respectively, including novel synthetic furanoside dendrimers. The latter 
proved inhibitory to both laboratory and clinical P. aeruginosa isolates and constitute a 
potential novel therapeutic. 
The demonstration of this role for lectins in biofilm formation is set in the context of 
other reports in the literature that these lectins have multiple functions. In addition to 
those previously discussed, there is the finding that both LecA and LecB immobilise the 
ciliary beating of ex-vivo human nasal mucous membranes by competing for the same 
binding site(s). This immobilisation of the mucociliary elevator prevents the expulsion 
of the invading bacteria from the lungs and could be inhibited by lectin-specific sugars 
(Mewe et al., 2005). Furthermore, it has been reported that LecA binds AHLs (Boteva 
et al., 2005). The authors hypothesise that this could regulate the free and accessible 
pool of lactones and prevent destruction of these molecules by maintaining a fraction of 
them in a protein-bound state. This clearly has important implications within the 
complex microenvironment of a biofilm and may well offer an explanation for the 
observation that some of their ascribed functions are secondary effects on other systems 
rather than direct effects of the lectins themselves (Sonawane et al., 2006). 
The implications of the striking and powerful action of anti-LecB dendrimers on biofilm 
formation are being explored using several lines of investigation. Collaborative work is 
underway to synthesise and assess dendrimers targeting LecA to determine whether a 
combination approach targeting both lectins has a more significant impact on the ability 
to inhibit or disperse P. aeruginosa biofilms. The tissue-culture based assay, which 
indicated that these compounds are unlikely to be toxic to human cells, enables plans to 
assess their activity in animal models to be developed. Given that these agents both 
inhibit and disperse biofilms, potential applications include their use to prevent biofilm 
formation as a prophylactic therapy and their use as a treatment in the case of 
established biofilm diseases. The finding that biofilm dispersal occurred upon 
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dendrimer application suggests that any future use will be in combination with other, 
perhaps traditional, approaches to tackle the potential exacerbation of symptoms caused 
by the release of viable planktonic bacterial cells. 
The widespread occurrence and significant impact of biofilms offers opportunities to 
exploit the actions of anti-lectin agents in many diverse settings. Beyond CF, 
P. aeruginosa is an important respiratory pathogen in pneumonia and COPD. Elsewhere 
in the human host, it has the potential to infect chronic wounds such as burns and 
diabetic foot ulcers. Beyond the clinical setting, P. aeruginosa biofilm formation leads 
to contamination of industrial and commercial waste pipes. The economic implications 
of these effects are sizeable in terms of costs to patients, their carers, health care 
providers, industrial and commercial sectors and the state. The clear need for effective 
anti-biofilm measures needs to go hand in hand with increased recognition and 
incorporation of biofilm concepts into the routine practices of these settings. For 
example, in the future, clinical microbiology may embrace biofilm diagnostic 
technology, which not only involves novel in vitro assays, but also includes in vivo 
imaging techniques. 
The aim of this thesis was to investigate the molecular mechanisms governing the 
pathogenesis of P. aeruginosa in the CF lung. From the outset, it was recognised that 
P. aeruginosa does not exist as individual bacterial cells in isolation. The approaches 
used in this study have recognised the extensive individual diversification that occurs 
within the CF lung and the subsequent impact of the complex interactions, 
communication and community living of these sophisticated and social microorganisms. 
This, coupled with their short generation time and genetic agility, enables rapid and 
successful adaptation to a niche, explaining their success as pathogens. Added 
complexity occurs in the CF lung with the presence of other bacterial, viral and fungal 
competitors, further influencing the dynamics and behaviour of population subsets. 
Clearly understanding, unravelling, modelling and tackling this complex behaviour is 
challenging. There is the need to not only consider how pathogenesis occurs in a 
mechanistic sense, but also consider why such behaviours arise. Hence, the overall 
conclusion of this body of work is that the important in vitro characterisation of discrete 
pathogenic processes needs to be combined with a consideration of their clinical 
context, in this instance, the complex ecosystem of the CF lung. This translates as a 
major shift from the failing single-antibiotic for a single-pathogen traditional approach 
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to tackling bacterial infection. A more detailed understanding of the ecology of the CF 
lung together with the identification of alternative therapeutic targets will allow a 
combination of novel approaches to diagnosis and treatment, with different agents 
tackling different aspects of the disease process at different stages of its development. It 
is hoped that this will enable the design of future effective and sustainable strategies to 
manage chronic lung infections caused by P. aeruginosa in CF. 
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Appendix 1 
STUDY PROTOCOL 
Lectin-mediated biofilm maturation, quorum sensing and Pseudomonas aeruginosa infections in Cystic 
Fibrosis 
SUMMARY 
Chronic respiratory infections with Pseudomonas aeruginosa are primarily responsible for much 
morbidity and mortality in cystic fibrosis (CF) patients. In this Gram-negative pathogen, many 
virulence determinants including the cytotoxic lectin PA-1L (which also promotes adherence to 
respiratory epithelial cells) are regulated via cell-to-cell communication (quorum sensing; QS).  
P. aeruginosa forms biofilms in the lungs of CF patients and biofilm formation is also QS-dependent. 
Preliminary work in The Institute of Infections and Immunity has uncovered a role for PA-1L (the 
product of the lecA gene) in the maturation of P. aeruginosa biofilms.  The primary aim of this project 
is to elucidate the molecular basis for the contribution of PA-IL to biofilm development and the 
persistence of P. aeruginosa in the CF lung by investigating (a) the conservation of the lecA gene in 
mucoid and non mucoid P. aeruginosa CF isolates, (b) the expression of lecA in vitro and in vivo in CF 
sputum, (c) the spatial localization of PA-1L within P. aeruginosa biofilms and (d) the mechanism by 
which PA-1L is secreted. Since the identity of the target macromolecule(s) within the biofilm 
architecture is not known, experiments will be undertaken to determine which exopolymer(s) are cross-
linked by this multivalent galactophilic lectin. PA-1L is regulated via N-acylhomoserine lactone 
(AHL)-dependent QS, and this laboratory has shown that AHLs can be sensitively detected in CF 
sputum using bioluminescence (lux)-based biosensors.  The potential of P. aeruginosa AHLs for 
predicting the effectiveness of IV antibiotic therapy in pulmonary exacerbations caused by P. aeruginosa 
will therefore be explored. A cohort of CF subjects of differing P. aeruginosa  sputum status will be 
studied to determine whether an increase in AHL sputum levels is a useful marker of clinical 
deterioration. Sputum samples will also be assayed for PA-1L since lectin production is likely to be an 
indicator of biofilm development and given its cytoxicity, may also prove to be a useful diagnostic 
indicator of airway damage.  
 
LAY SUMMARY 
The bacterium Pseudomonas aeruginosa causes chronic chest infections in patients with Cystic 
Fibrosis. It has many strategies for causing disease which are coordinated by a form of bacterial 
communication involving small diffusible signal molecules, termed quorum sensing. One such 
strategy is the formation of slime layers called biofilms. Another is the formation of a protein PA-
1L which is toxic to respiratory cells. Interestingly, preliminary work has shown that PA-1L plays 
an important role in the maturation of biofilms. The project aims to investigate this by determining 
whether the PA-1L gene is present in P. aeruginosa strains isolated from the sputum of Cystic 
Fibrosis patients, whether the protein is made, how is it transported out of the bacterial cells, where 
the protein binds in the biofilm, what is binds to, whether this binding be disrupted and if the 
protein levels in infected sputum and the quorum sensing signal molecules which regulate it are 
useful markers of disease severity. 
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DETAILS OF RESEARCH PROJECT 
 (a) Aims of the project 
Chronic infections particularly with Pseudomonas aeruginosa (PA) are primarily responsible for the 
decline in lung function and ultimate mortality in cystic fibrosis (CF) patients [1]. Preliminary work in 
this laboratory has uncovered a role for the lectin, PA-1L in the maturation of PA biofilms.  The primary 
aim of this project is to elucidate the molecular basis for the contribution of the PA-IL lectin to biofilm 
development and the persistence of PA in the lungs of individuals with CF. Both lectin expression and 
biofilm maturation in PA are dependent on quorum sensing (QS), a cell-to-cell communication 
mechanism involving the production and sensing of diffusible signal molecules The potential of PA QS 
signal molecules which regulate PA-1L expression as diagnostic markers for predicting the effectiveness of 
IV antibiotic therapy in controlling pulmonary exacerbations caused by PA will be explored.  
(b) Work leading up to the project 
In their natural environments, bacteria do not generally exist as isolated, planktonic cells, but grow in 
organised communities termed biofilms. The attachment process and the formation of an organised 
bacterial biofilm community are key steps in the chronic establishment of bacterial pathogens on host 
tissues [2-4].  Electron microscope studies indicate that PA forms biofilms in the lungs of CF patients 
[1,4,5] and as a consequence, can develop unique characteristics which protect the micro-organism from 
host defences, shear forces and antimicrobials [6]. Within the biofilm, bacterial microcolonies are 
embedded within an exopolysaccharide matrix separated by aqueous channels through which nutrients, 
waste products, oxygen and quorum sensing signalling molecules can be transported [3,6]. In CF, one of 
the most striking and clinically important features of PA infections is the conversion of the bacterium to a 
mucoid phenotype which probably initiates the chronic infection stage of the disease [1]. Mucoidy results 
from the production of an alginate muco-exopolysaccharide which makes an important contribution to the 
evasion of the host immune response [1]. Although the precise contribution of alginate to biofilm 
architecture is not clear, both mucoid and non-mucoid PA readily form surface associated biofilms.  
In PA, the attachment phenotype is driven by extracellular appendages including flagella and type IV pili 
[6]. During the subsequent stages of biofilm development, other factors are required for biofilm 
maturation, shape determination and the physical resistance of the biofilm structure.  These include 
exopolysaccharides and the chaperone usher fimbrial pathway genes [6,7]. In addition, recent work in this 
laboratory has uncovered an unexpected function for the so-called ÒinternalÓ lectin PA-1L, the product of 
the lecA gene [8]. PA-1L is a 13 kDa protein which exhibits specificity for hydrophobic galactosides, is 
cytotoxic for mammalian cells and promotes the attachment of PA to respiratory epithelial cells [9,10]. In 
contrast to the parent PA strain, a  lecA mutant was unable to form mature biofilms and mutants defective 
in MvaT,  a negative regulator of lecA, overproduce PA-1L and form significantly thicker biofilms which 
cover a correspondingly greater surface area [11;unpublished data]. These observations suggested that 
biofilm formation in  PA might be prevented and pre-formed biofilms dispersed by the exogenous 
provision of a non-metabolizable, hydrophobic galactoside.  Preliminary experiments suggest that this is 
indeed the case; inclusion of  p-nitrophenyl- α-D-galactoside (NPG) abolishes biofilm formation on 
stainless steel and disperses pre-formed PA biofilms [unpublished data]. These experiments also 
indicate that PA-1L is likely to play a major role in stabilizing the biofilm matrix by either promoting 
bacterial cell-cell interactions, bacterial-host cell interactions and/or by stabilizing the biofilm glycocalyx 
 209 
through lectin-exopolysaccharide/lipopolysaccharide or lectin-fimbrial interactions. Furthermore, the 
presence of PA-1L in the cell-free, extracted biofilm matrix confirmed that the lectin must be secreted, 
even though the lecA gene carries no signal sequence. 
Expression of the lecA gene is directly dependent on QS, a cell-to-cell communication mechanism 
involving the production and sensing of diffusible signal molecules [8]. In PA, virulence determinants, 
secondary metabolites and biofilm maturation are regulated via N-acylhomoserine lactone (AHL)-
dependent QS systems [12]. Work in this and other laboratories has revealed that PA possesses two AHL-
dependent QS circuits termed the las and rhl systems, comprising of the LuxR/I homologues, LasR/I  and 
RhlR/I. LasI directs the synthesis of primarily N-(3-oxododecanoyl)homoserine lactone (3-oxo-C12-
HSL) and together with the transcriptional regulator LasR regulates the production of e.g. elastase, 
alkaline protease and exotoxin A [12]. In addition, the las system controls  genes involved in the 
regulation of the Type II general protein secretion pathway [13] and plays a role in regulating  the 
maturation of PA biofilms [14]. RhlI directs the synthesis of N-butanoylhomoserine lactone (C4-HSL) 
which activates RhlR such that RhlR/C4-HSL induces the production of rhamnolipid, elastase, LasA 
protease, cyanide, pyocyanin and siderophores as well as the lectins PA-1L and PA-IIL [8,15]. The las 
and the rhl systems are organised in a hierarchical manner such that the las system exerts transcriptional 
control over rhlR and over rhlI [16].  
These data strongly implicate a role for both QS and the PA-1L lectin in the aetiology of PA infections in 
CF patients. However, they were generated using a non-CF, non-mucoid laboratory strain of PA and their 
direct relevance to CF has not been established. This project will therefore combine basic and clinical 
studies to investigate the conservation and expression of the lecA gene in both mucoid and non-mucoid 
CF clinical isolates and to determine whether the lectin can be detected in infected CF sputum. This work 
will be complemented by studies of the secretion of PA-1L and its spatial location within biofilms 
generated in vitro.   
In addition, the potential of the QS signal molecules and PA-1L as diagnostic markers for predicting the 
effectiveness of IV antibiotic therapy in controlling pulmonary exacerbations caused by PA, will be 
investigated.   
 
(c) Experimental design and methods  
Conservation and expression of lecA in CF isolates of PA. 
In addition to the laboratory PA strain PAO1, lecA is known to be present in several environmental 
isolates. To determine whether the lecA gene is conserved in non-mucoid and mucoid PA strains isolated 
from CF sputum will be subjected to PCR and Southern blot analysis using oligonucleotide primers and 
probes previously synthesized in the laboratory. The expression of lecA in vitro will be examined by 
Northern blot analysis (using as a probe, the cloned lecA gene labelled with  [α-
33
P]ATP) and by Western 
blot analysis using antibodies previously raised against the PA-1L protein [8]. To determine whether the 
lecA gene is expressed in vivo in the CF lung, infected sputum will be collected, treated with Sputolysin 
(Calbiochem) and subjected to (a) SDS-PAGE and Western blotting for PA-1L protein detection or (b) 
real time-RT-PCR (ABI PRISM 7700) after extraction of total RNA to quantify sensitively lecA 
transcript levels. Once these assays are fully established, they will be used to follow the course of lecA 
expression in CF patient sputa during pulmonary exacerbations (section 4).  To obtain further evidence for 
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lectin expression in the CF lung, both serum and sputum samples from CF patients colonized with PA will be 
subjected to Western blot analysis and ELISA for the presence of antibodies to PA-1L. 
 
2. Spatial localization and secretion of PA-1L  within PA biofilms.  
Preliminary work in this laboratory has shown that biofilms of the non-mucoid PA strain PAO1 can be 
disrupted by hydrophobic galactosides.  To determine whether this finding is of relevance in the CF 
context, biofilms will be formed by non-mucoid and mucoid strains from CF patients and treated with or 
without NPG. As controls for these experiments, the lecA mutation will be introduced into the CF strains 
using a suicide plasmid as described by Winzer et al [8] to construct  isogenic mutants. Biofilms will be 
generated statically on glass slides and also using Stovall flow cells (Stovall Life Sciences Inc.; [17] 
which are designed for the direct and non-destructive, on-line microscopic examination of bacterial 
biofilm development and maturation. Biofilms will be imaged using fluorescence or confocal laser 
scanning microscopy (CLSM) of acridine orange or green-fluorescent protein (GFP)-tagged bacteria 
respectively to obtain quantitative information on surface coverage and biofilm depth [18]. To gain 
insights into the spatial localization of the PA-1L lectin in association with the bacterial cells and within 
the biofilm, lecA translational fusions to the GFP will be constructed. Since it is not possible to predict 
which fusion protein will be most efficiently produced and secreted, both N and C-terminal PA-1L 
fusions will be engineered. The fusion protein will be introduced on a pUCP-based plasmid vector  into 
PA by electroporation. Bacterial cells will be fractionated (cyotoplasm, periplasm, outer and inner 
membranes, extracellular supernatant (planktonic cells) or matrix (biofilm cells) compartments) and the 
distribution of the fusion examined by Western blotting using antibodies to both PA-1L and GFP to 
ensure that the lectin-fusion protein is expressed as an intact stable fusion which is exported efficiently. 
Biofilm development and disruption by hydrophobic galactosides will be followed using the flow cell 
system and imaged using CLSM. Biofilms will be formed using both parent and isogenic mvaT PA 
mutants (which over-express the PA-1L and form very thick biofilms; [11; unpublished data] 
transformed with a plasmid carrying the gfp-lecA gene an either intact or disrupted chromosomal copy of 
lecA.  
Cell-free culture supernatants of PA contain PA-1L even though the lecA gene carries no signal sequence 
[8]. PA possesses Type I, Type II (two systems - xcp and hxc) and Type III secretion systems [19;19a]. 
Strains with mutations in each secretion system have been constructed by Dr Alain Filloux (CNRS, 
Marseille, France) and have been made available to us. Using the cell fractionation techniques described 
above, Western blot analysis will be used to determine the fraction of PA-1L in each compartment. The 
accumulation of the protein within the cytoplasm or periplasm for a given secretion mutant will identify 
the secretion system required.  Since, the inability to secrete the PA-1L should correlate with the inability 
to produce mature biofilms, the nature of the biofilm formed by the relevant secretion mutant will be 
investigated.  
 
Identification of the PA-1L biofilm target  ligand  
Since PAO1 biofilms can be disrupted by hydrophobic galactosides and as the corresponding lecA 
mutants form poor biofilms, this suggests that the PA-1L lectin stabilizes biofilms presumably, given its 
multivalent nature, by cross-linking a bacterially produced polysaccharide (e.g.LPS) or a glycoprotein 
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(e.g. pilin).  Apart from the LPS core oligosaccharide which contains D-galactosamine, there are no 
obvious galactoside-containing macromolecules although rhamnose, a major component of PA LPS [20] 
is weakly capable of inhibiting the binding of galactose to PA-1L [21]. To determine whether PA-1L is 
capable of interacting with PA LPS O-antigen or core, Western ligand blot analysis will be performed 
using both glycine and tricine SDS-PAGE [22] to separate the purified LPS O-antigen and core 
components which will be probed with biotin-labelled PA-1L.  A similar approach will be used to 
determine whether PA-1L interacts with any proteins/glycoproteins present in the biofilm extracellular 
matrix (prepared as described by Wingender et al [23] or on the bacterial cell surface. These findings will 
be confirmed using beads coated with PA-1L in agglutination assays with the purified macromolecular 
target. If PA-1L interacts with any PA proteins, mass spectrometry will be used to identify the protein; 
the corresponding gene identified from the genome database and a mutant constructed to evaluate its 
contribution to biofilm development.  
 
4. Diagnostic potential of the PA-1L lectin and the QS signal molecules 
Current treatment regimens for controlling PA infections in CF require aggressive chemotherapy 
involving prophylactic, nebulised antibiotics and 2 week courses of intravenous antibiotics during 
infective exacerbations [1]. A sensitive marker of airway infection and inflammation would provide a 
useful tool to guide the initiation and cessation of antibiotic therapy. Previous studies from this group and 
others have shown that neutrophil elastase/alpha 1 anti-trypsin complex (NE/AAT), lactoferrin and C 
reactive protein provide an index of the inflammatory process in CF patients and show a reduction 
following effective anti-pseudomonal treatment in patients colonised with PA [24]. Since PA-1L is 
regulated via QS and this laboratory has previously shown that AHLs can be detected sensitively in CF 
sputum using lux-based AHL biosensors [25], a cohort of CF subjects with differing PA sputum status 
will be studied to determine whether an increase in sputum AHL levels is a useful marker of clinical 
deterioration. 
In the PA colonised CF subjects, we will determine whether the levels of AHLs:  i) rise at the time 
of an exacerbation and ii) fall with antibiotic treatment in line with the clinical response. A group of 
CF subjects without PA will serve as a negative control group.  However in this group we would expect a 
proportion of subjects to acquire the organism over the course of the study. By assaying sputum AHL 
levels in such subjects, we will be able to determine whether AHLs are present in sputum when PA is 
acquired which would imply that biofilm formation is an early event or whether AHLs are detectable only 
when the airways become chronically colonised.  The sputum samples obtained will also be assayed for 
PA-1L  (section 1) since lectin production is also likely to be an indicator of biofilm formation and also 
given its cytotoxic properties on respiratory airway cells may also be a useful diagnostic indicator of 
airway damage.  For these clinical investigations, 20 subjects with CF colonised with PA, 20 subjects 
who have never had PA isolated and 20 with intermittently positive pseudomonas cultures will be 
studied. The diagnosis of CF has been established previously in all of these subjects by genetic testing 
and/or sweat test. The presence of Burkholderia cepacia will be an exclusion criteria. There will be no cut 
off level for FEV1. To be included in the study subjects must be sputum producers and both adults and 
children will be studied. 
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For this clinical study, subjects will be followed longitudinally over 2 years. Subjects will be studied two 
monthly at clinic visits. Whenever they have an exacerbation they will be studied at the beginning and 
end of a 2 week course of i.v. antibiotics, one month later then two until their next exacerbation. 
Measurement of white cell count, C reactive protein, sputum measurement of AHL and spirometry (FEV1 
and FVC) will be made at each visit. Subjects will be treated with a standard antibiotic regime depending 
on sensitivity testing. This is likely to include an intravenous aminoglycoside (tobramycin/gentamicin) in 
addition to either Ceftazidime, Meropenem or Aztreonam. Non parametric statistics (Wilcoxon) will be 
used to determine whether AHL levels are higher during an exacerbation than between exacerbations and 
whether the levels fall with antibiotic therapy. P<0.05 will be regarded as significant. 
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Appendix 2 
 
 
ADULT  PATIENT  INFORMATION  SHEET  
 
LECTIN-MEDIATED BIOFILM MATURATION, QUORUM SENSING AND 
PSEUDOMONAS  AERUGINOSA  INFECTIONS  IN  CYSTIC  FIBROSIS 
 
 
A  STUDY  OF  THE  FORMATION  OF  BACTERIAL  COLONIES  IN  
THE LUNGS  OF  PATIENTS  WITH  CYSTIC  FIBROSIS 
 
PROF A KNOX,  DR A SMYTH,  DR S CRUSZ 
 
You are being invited to take part in a research study. Before you decide 
whether you would like to take part it is important that you understand why the 
research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information (contact 
details are at the end of this leaflet). Take time to decide whether or not you 
wish to take part. 
 
Thank you for reading this. 
 
What is the purpose of the study?  
 
Pseudomonas aeruginosa is a type of bacteria. It can cause chest infections in 
many people with Cystic Fibrosis.  One way it does this is to form colonies 
called biofilms in the lungs.  Biofilms are made up of bacterial cells and a 
support structure or matrix.  A certain protein made by the bacteria called a 
lectin is thought to play an important role in this matrix.  The aim of this study is 
to understand this role.  To do this we hope to study bacteria from sputum 
samples collected over a period of two years. 
 
Why have I been chosen? 
 
You have been chosen as you have Cystic Fibrosis and produce sputum.  We 
are studying both people who are known to have Pseudomonas infection and 
those who are not.  We hope to study about sixty patients. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form.  If you decide to take part you are still free to withdraw at any time 
and without giving a reason.  A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive. 
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What will happen to me if I take part? 
 
When you attend the outpatient clinic, we would like to collect a sputum sample.  
This would be an extra sample in addition to the one that you normally produce.  
We would also like permission to look at your hospital case notes and test 
results.  We hope to collect a sputum sample each time you attend clinic over a 
period of two years. We can then study the bacteria in the sputum at times 
when you are well and during periods when you may be ill. 
 
What are the possible disadvantages of taking part? 
 
There are no specific disadvantages. 
 
What are the possible advantages of taking part? 
 
This study hopes to understand more about how the bacteria Pseudomonas 
aeruginosa causes lung infections in people with Cystic Fibrosis.  This may 
identify new areas for treatments to be developed.  The study will be of no 
direct benefit to you. 
 
What happens if something goes wrong? 
 
It is unlikely that anything will go wrong as a result of you being in this study.  If 
you are unhappy about anything related to the study, you can mention it to your 
Cystic Fibrosis doctor or contact me.  You are also entitled to contact the 
complaints department at your hospital. 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research 
will be kept strictly confidential.  Any information about you, which leaves the 
hospital, will have your name and address removed so that you cannot be 
recognised from it. Your CF doctor will know that you are taking part in the 
study and we will let your GP know if you would like us to. 
 
What will happen to the results of the research study? 
 
We hope to carry out the study over the next two years.  We will then publish 
the findings in a medical research journal.  We will send every patient who had 
participated a summary of the results. 
 
Who is organising and funding the research? 
 
The Cystic Fibrosis team at Nottingham City Hospital is carrying out this study. 
The Wellcome Trust funds it. 
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Contact for further information 
 
Dr Shanika Crusz 
Wellcome Trust Medical Microbiology Training Fellow 
Institute of Infection, Immunity and Inflammation 
Centre for Biomolecular Sciences 
University of Nottingham 
University Park 
Nottingham 
NG7 2RD 
 
Tel 0115 951 5089 
 
Thank you for taking the time to read this information. 
 
If you wish to take part in this study please keep a copy of this information sheet 
and a signed copy of the consent form. 
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PATIENT CONSENT FORM 
 
 
Title of project  Lectin-mediated biofilm maturation, quorum sensing and 
Pseudomonas aeruginosa  infections in Cystic Fibrosis 
 
Site   Cystic Fibrosis OutpatientsÕ clinics 
 
Investigators  Prof A Knox,  Dr A Smyth,  Dr S Crusz 
 
The patient should complete the whole of this sheet himself/herself. 
 
Please cross out as necessary 
         
¥ Have you read & understood the patient information sheet YES/NO 
 
¥ Have you had opportunity to ask questions & discuss the study YES/NO 
           
¥ Have all the questions been answered satisfactorily  YES/NO 
  
¥ Have you received enough information about the study  YES/NO 
     
¥ Who have you spoken to  Dr/ ÉÉÉÉÉÉÉÉÉÉ.. 
  
¥ Do you understand that you are free to withdraw from the study 
  
¥ at any time       YES/NO 
         
¥ without having to give a reason    YES/NO 
       
¥ without affecting your future medical care   YES/NO 
    
¥ Do you agree to take part in the study    YES/NO 
    
¥ Do you agree to your GP being informed    YES/NO 
  
Signature (Patient)       Date  
     
Name (Block capitals)     
 
  
 
I have explained the study to the above patient and he/she has indicated his/her 
willingness to take part. 
 
Signature (Doctor)       Date 
         
Name (In block capitals) 
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Dear Dr 
 
 
Your patient,   
 
 
has given me permission to write to inform you that they have agreed to take 
part in the study ÒLectin-mediated biofilm maturation, quorum sensing and 
Pseudomonas aeruginosa infections in Cystic FibrosisÓ. 
 
This is a study of bacterial communication (quorum sensing) and the formation 
of bacterial colonies (biofilms) in the lungs of patients with Cystic Fibrosis.  It is 
funded by The Wellcome Trust and will be conducted by members of the Cystic 
Fibrosis team, including Prof Alan Knox, Dr Alan Smyth and myself. 
 
We plan to study bacteria from sputum samples collected over a two-year 
period at Cystic Fibrosis outpatient clinics at Nottingham City Hospital.  The aim 
is to understand more about the pathogenesis of Pseudomonas aeruginosa in 
the Cystic Fibrosis lung and identify novel treatment targets. 
 
The project has been approved by the Director of Research and Development 
at Nottingham City Hospital and the Nottingham Research Ethics Committee. 
 
Any information collected about your patient will be kept strictly confidential 
and they have the right to withdraw at any time.  At the end of the study, all 
participants and their GPs will be sent a summary of the findings. 
 
Please do not hesitate to contact me if you would like any further information. 
 
Yours sincerely 
 
 
 
 
 
Dr Shanika Crusz 
Wellcome Trust Medical Microbiology Training Fellow 
Institute of Infection, Immunity and Inflammation 
Centre for Biomolecular Sciences 
University of Nottingham 
University Park 
Nottingham 
NG7 2RD 
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Appendix 3 
 
Biofilm Study Data Collection Proforma 
 
Patient study no. 
Patient sample no. 
 
Current date: 
FEV1  L FEV1 predicted  L FEV1   %predicted  
FVC  L FVC predicted  L FVC   %predicted 
 
Last routine value date: 
FEV1  L FEV1 predicted  L FEV1   %predicted  
FVC  L FVC predicted  L FVC   %predicted  
 
Current Pulse oximetry: 
 
Last available  WCC   CRP   with date: 
 
Antibiotics  Dates: 
   Type: 
   Duration: 
   Route: 
 
Clinical features of a pulmonary exacerbation (Rosenfeld et al., 2001)  
 
Clinical feature 
 
A 
1 if 
present 
0 if 
absent 
B 
Coefficient 
AxB 
decreased exercise tolerance 
 
 1.8  
increased cough 
 
 1.5  
increased sputum / cough congestion 
 
 1.5  
absence from school or work 
 
 1.6  
increased adventitial sounds on lung 
examination 
 
 1.2  
decreased appetite 
 
 1.1  
Total (score of >2.6 = pulmonary 
exacerbation) 
 
   
 
Decline in FEV1 of >10% in last month  Y/N 
 
 
 
Microbiology: affix microbiology result overleaf (with identifiers removed) 
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Appendix 4 
Establishing a flowchamber biofilm system 
Introduction to the flowchamber biofilm system 
The study of the physiological behaviour of bacteria in the laboratory has traditionally 
been performed on batch-cultures of planktonic cells in suspension. The recognition that 
most bacterial activity in nature occurs in sessile microbial biofilm communities has 
prompted the development of technology to enable their study in vitro. 
Imaging techniques, ranging from simple light microscopy to high resolution electron 
microscopy, provide visual evidence for the formation of aggregates of bacterial cells, 
often in association with a surface. This can be applied to a range of ex-vivo samples 
such as sputum and abscess material from the CF lung (Hoiby et al., 2001). The in vitro 
study of these sessile bacterial life forms can be modelled in a number of simple assays 
of static growth on inert surfaces such as polystyrene microtitre wells (Stepanovic et al., 
2000) or stainless steel coupons (Dhir and Dodd, 1995). These approaches, which yield 
information on bacterial attachment, can be extended to biotic surfaces such as the 
eukaryotic nematode Caenorhabditis elegans. Further animal models of biofilm bacteria 
can be established in rats and mice by the intratracheal inoculation of bacteria in agar or 
alginate beads, thus allowing the examination of histopathological changes, the immune 
response and efficacy of antibiotic therapy (Hoiby et al., 2001). 
In nature, biofilms are complex structures consisting of a high density of mixed 
bacterial populations embedded in a self-produced polymeric matrix, often on 
submerged surfaces or as flocs in the water column of aquatic environments (Costerton 
et al., 1999). Within these microbial Ôslime citiesÕ, internal heterogeneities and 
structure/function relationships develop which are important to biological activity. It is 
also known that individual cells and entire communities respond to the prevailing 
chemical, physical and biological environment. For example, hydrodynamics is known 
to influence biofilm morphology. Under conditions of low-shear laminar flow, a 
P. aeruginosa PAO1 biofilm was observed to consist of a monolayer of cells with 
mound-shaped circular microcolonies. However, under high-shear turbulent flow 
conditions, the biofilm formed filamentous structures (Stoodley et al., 1999). The fluid 
dynamics within a flowing system assists the dispersal of cells, the arrival of bacteria at 
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the substratum as well as the concentration of nutrients, signal molecules, waste 
products and antibiotics.  
Whilst a number of laboratory devices such as the rototorque bioreactor and Robbins 
device have been developed, the flowchamber biofilm system is widely favoured due to 
its relatively simple design and its applicability to direct on-line microscopic 
examination of the biofilms. This system utilises a number of important molecular and 
imaging tools. Biofilms are grown in a defined nutrient and temperature stable 
environment with a fixed rate laminar flow. Live, fluorescently-tagged bacterial 
biofilms can be periodically and non-destructively examined with confocal laser 
scanning microscopy (CLSM). Here, digital images are acquired by photomultiplier 
tube detection of fluorescence excited by a laser light source. This technology 
overcomes the problem faced by traditional light microscopy of a loss of resolution as 
the thickness of the specimen increases due to the contribution from unfocused parts of 
the viewing field. Instead, by collecting fluorescent light from only the thinnest focal 
plane afforded by the objective lens and by scanning several planes interspersed by 
short distances, it is possible to reconstruct virtual three-dimensional (3D) images of the 
biofilm structures tens of microns thick.  
This high quality reconstruction of biofilm images can be achieved by the powerful 
Unix-based software package IMARIS (Bitplane, Switzerland). In addition, this digital 
data can be analysed using the COMSTAT image processing software (Heydorn et al., 
2000b) to yield a number of biofilm parameters. Together, this qualitative and 
quantitative approach has greatly assisted in the application of laboratory biofilm study 
to natural, clinical and industrial settings.  
Within this Appendix, the processes undertaken to establish a local flowchamber 
biofilm system and allied technology are described in detail.  
Construction of flowchamber 
Biofilms were cultivated in flowchambers kindly provided by Dr Thomas Bjarnsholt of 
the Center of Biomedical Microbiology (CBM), Danish Technical University (DTU), 
Copenhagen. A flowchamber was composed of three parallel channels machine-cut in 
perspex (poly[methyl methacrylate]), covered with a no. 1 24 x 50 mm glass coverslip 
(SLS Ltd.) which served as the biofilm substratum. Each channel had a dimension 
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(length x width x height) of 40 x 4 x 4 mm and was wiped down with 70 % (v/v) 
industrial methylated spirit (IMS) prior to use. To assemble the flowchamber, a thin 
continuous layer of clear silicone (3M, U.S.A.) was applied sausage-like between the 
channels with a 2 ml syringe with a cut 200 µl pipette inserted as a nozzle. The glass 
cover slip was placed on top of the silicone and carefully pushed down until the silicone 
covered the whole area of perspex between the channels, without actually entering the 
channels themselves. The silicone was allowed to dry overnight before use. Silicone 
tubing (Versilic, France) with dimensions 1 mm inner diameter (ID), 3 mm outer 
diameter (OD), was connected to each end of the flow channel. See Figure A-1. 
 
 
Figure A-1 A 3-channel flowchamber. 
A glass cover slip was attached with silicone glue to a perspex base containing three machine-
drilled flow channels with dimensions 40 x 4 x 4 mm. Silcone tubing (ID 1 mm and OD 3 mm) 
was connected to the inlet and outlet of each channel. 
 
Assembly of flow system 
To assemble the flow system, the protocol developed by the CBM, DTU (Haagensen et 
al., 2006) was followed. Except for the tubes passing through the pump and those 
attached to the flow channels, the flow system was assembled using 2 mm ID and 4 mm 
OD silicone tubing. For the pump, the much stronger Marprene tubing, ID 0.88 mm 
(Watson Marlow Ltd., Cornwall, England), was used. The media bottle (Nalgene 
 223 
Company, U.S.A.), bubble traps and flowchambers were connected with silicone tubing 
and plastic connectors as shown in Figure A-2. Midistart 2000 0.20 µl pore venting 
filters (Sartorius, Germany) were fitted to the media and effluent containers. The 
connectors between the silicone and inlet Marprene tubing were covered with several 
layers of parafilm to prevent drag once the pump was operational. 
The bubble traps were 5 ml syringes mounted on a perspex base (DTU) with inlet and 
outlet within the bubble trap. The inlet holes were situated higher than the outlet holes 
to allow bubbles to rise and hence not enter the onward flowing media. The syringes 
were closed at the top with stoppers and the bubble traps were placed in petri dish lids 
to collect spills. 
The effluent media was collected in a 10 L vessel which contained 200 ml Trigene 
surface disinfectant (Medichem International, UK) to give a final working strength of 
1:50. 
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(A) 
 
 
(B) 
 
Figure A-2 Original biofilm flowchamber experimental setup. 
(A) Schematic representation of the closed, continuous flow system which was constructed by 
connecting the inlet media vessel, flowchambers and effluent vessel by a series of tubes fitted 
with connectors. Media was circulated by means of an 8-channel peristaltic pump. Bubble traps 
were incorporated in to the design upstream of the flow chambers (diagram not to scale). (B) 
Photograph of the fully assembled system. 
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Modifications to the design of the flowchamber biofilm system 
When running the original flowchamber system at 37 ¡C, persistent problems of air 
bubble formation within the tubing and flowchambers were encountered. In order to 
dislodge bubbles, the flowchambers were gently tapped at their base, however this 
mechanical force was likely to disrupt the developing biofilms and necessitated constant 
vigilance.  
To overcome this problem, advice was sought from the Renal Dialysis Technicians, Mr 
John West and Mr Paul Harbuz, Nottingham City Hospital Campus Renal Unit. 
Together with this and further experimentation, a number of modifications were made 
to the system design. Firstly, inlet media vessels were rendered airtight with silicone 
sealant and fitted with an internal noncollapsable tube connected to a venting air filter. 
These vessels were then inverted and suspended above the level of the flowchambers on 
clamp-stands, allowing the flow of media by gravity, thus reducing the work of the 
peristaltic pump. This also reduced the negative pressure created within the tubing by 
the pulling action of the pump, which itself had encouraged air bubbles to come out of 
solution.  
Prior to running the system, the media outlet port was clamped off and using a 50 ml 
syringe, air within the inlet vessel above the media was drawn off via the air filter in 
order to create a negative pressure within the vessel. This allowed any dissolved gases 
within the media to be drawn out of solution. The system was then allowed to 
equilibrate prior to running.    
It was observed that the 8 channel peristaltic pump itself introduced bubbles into the 
system, which were able to enter and lodge within the flow channels despite the 
presence of bubbletraps. Hence, the pump was moved downstream of the flowcells and 
the bubbletraps were removed from the design. This modification had the added 
advantage of allowing the pump to gently pull non-attached free-floating biofilm 
material distally out of the channel so that it would not interfere with the microscopy. 
See Figure A-3 for a depiction of the unique technological modifications made to the 
design of the flowchamber system. 
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Figure A-3 Modified flowchamber experimental set-up. 
The media inlet bottle was inverted and suspended above the height of the flowchamber. Air 
could be drawn out of the vessel via the air filter connected to a rigid tube in order to create a 
negative pressure within the chamber, forcing dissolved gases to rise out of solution. The 
peristaltic pump was positioned downstream of the flowchamber and the bubbletraps were 
removed from the design (diagram not to scale). 
 
Sterilisation and saturation of flow system 
Sterilisation of the flow system was performed by pumping 1 L 0.5 % (v/v) sodium 
hypochlorite bleach through the system over 3 hours at a pump setting of 0.450 ml/min. 
The flow system was then washed to remove the hypochlorite by filling and emptying 
the system two to three times with 1.5 L sterile dH2O. The flow system was then filled 
with media pre warmed to 37 ¡C and the pump was set to 48.3 µl/min which gave a 
flowrate of 3.3 ml/hr/channel when the system was calibrated. The system was allowed 
to run overnight at 37 ¡C to saturate the silicone tubing before inoculation. 
Inoculation of flow channels 
Before inoculation of the flow channels, the flow was stopped and the tubing between 
the flow channel and bubble trap clamped off. The effluent container was placed at a 
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level higher then the flowchambers to prevent air being drawn in to the system when the 
tubing was breached. The tubing at the flow channel inlet was sterilised with 96 % (v/v) 
EtOH. A 1 ml insulin syringe (Sterilin) was filled with prepared culture and air bubbles 
expelled from the syringe. The syringe needle was inserted in to the tubing as near as 
possible to the flow channel inlet and the cells carefully injected in to the channel. After 
inoculation, the tubing was sterilised with 96 % (v/v) EtOH and the injection hole 
sealed by applying a thin layer of silicone. To allow the cells to establish on the glass 
coverslip substratum, the flowchamber was inverted with the glass surface facing 
downwards and incubated at 37 ¡C for 1 h. Following this, the tubing was unclamped, 
the media flow resumed and the chambers were suspended vertically to ensure that any 
air bubbles that did enter rose to the distal end of the channel and passed out of it. 
Incubation of biofilm flowchamber system 
Flowchambers were incubated at 37 ¡C for up to 6 days. Any backgrowth that formed in 
the flow channel inlet tubing was cut out on a daily basis to prevent the influence of 
upstream biomass on the flow chamber biofilms. This was performed by clamping off 
the tubing downstream of the flowchamber and sterilising the tubing upstream with 96 
% (v/v) EtOH. This upstream tubing was then cut with a sterile scalpel immediately 
above the backgrowth and the tubing containing the backgrowth removed. The 
upstream tubing was then reconnected aseptically to the flowchamber ensuring that no 
bubbles were introduced into the channel. The clamps were removed and the flow 
resumed. 
Live / dead staining with propidium iodide 
As for inoculation of the flow channels, the flow was stopped and the tubing between 
the flowchamber and bubble trap clamped off. A bolus of 250 µl 0.2 mM propidium 
iodide (PI) solution in DMSO was injected into the channel via the downward facing 
surface of the inlet tubing and the injection site was quickly sealed with silicone. The 
flowchamber was covered in tin foil to avoid degradation of PI by light and the cells 
were allowed to incubate for 10 min before two channel CLSM was undertaken. 
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CLSM image collection 
¥ Specimen transportation 
The flow system was periodically transported on a two-tier trolley to the microscope 
facility in order to undertake live confocal microscopic examination of the biofilms on 
days 4, 5 and 6 incubation. This was generally for a 3 h period, during which 
unavoidable temperature fluctuations were encountered. This was addressed by 
covering the inlet media vessel with a plastic insulating jacket to reduce cooling. The 
flow chambers were examined on a heated microscope stage maintained at 37 ¡C. The 
pattern of microscopic examination and hence temperature shift was kept constant for 
all experimental rounds as far as was practically possible.  
¥ Microscope settings 
Biofilm images were captured with a Zeiss LSM 510 UV META Kombi confocal 
system on an inverted Zeiss Axiovert 100M microscope (Carl Zeiss, Germany). 
Scanning was performed with the Argon ion and HeNe 1 laser units to enable excitation 
of GFP and PI respectively. The Plan-Neofluar 40x/1.3 oil phase 3 working objective 
lens was chosen to enable good biofilm depth penetration in addition to visualising 
reasonable size areas of the field of interest.  
The fluorescent filters and tracking were configured to enable the detection of one or 
more fluorescent proteins. For GFP detection, single-track imaging was performed 
using the Argon 488 nm laser to excite the specimen and the long pass (LP) 505 
emission filter to capture the signal. For simultaneous detection of GFP and PI, multi-
track imaging with sequential excitation and capture was performed to reduce bleed 
through of signal. The 488 nm laser coupled with the 505-530 band pass (BP) filter and 
the 543 nm laser coupled with the LP560 filter were used for GFP and PI detection 
respectively. 
The scanning parameters were set to capture a frame size of 512 x 512 pixels, with a 
scan speed of 9 in one direction only. To improve the signal to noise ratio, mean line 
averaging was performed 4 times. The data depth was set as 8 bit and the pinhole size 
adjusted to equal 1 airy unit. 
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¥ Specimen placement 
An existing microscope stage with a central 2 x 2.5 cm viewing aperture was utilised 
which could hold an individual flowchamber. As the microscope was an inverted 
system, the flowchamber was mounted onto the stage with the coverslip facing 
downwards. Scanning was undertaken with the pump running at 48.3 µl/min. 
Any excess silicone present on the upper surface of the flowchamber prevented it lying 
flat when inverted and positioned on the microscope stage. This consequently led to 
distorted and tilted images. Equally, any silicone applied to seal the inlet tubing would 
also prevent the flowchamber lying flat, hence all inoculations to the channels were 
performed via the dorsal aspect of the tubing. In addition, imaging of certain peripheral 
areas of the flowchamber led to tilting by the conical microscope objective, restricted by 
the fixed viewing aperture of the microscope stage. Furthermore, at these peripheral 
areas, oil could seep under the stage and its surface tension led to movement of the 
chamber as well as difficulties with fine focusing. The use of lead weights to secure the 
flowchamber was necessary to overcome this mobility and in addition, exerted a 
downward pressure to level the chamber.   
When turned coverslip-side down, any non-adherent free-floating biomass within the 
flowchamber channels settled on top of the biofilms growing on the glass substratum 
(Figure A-4). This material reduced the quality of the images obtained by causing 
movement artefact and gave a false impression of the size of the biofilm, necessitating 
the collection of larger stacks over longer time periods (Figure A-5). This was 
overcome by gently tapping each channel to dislodge loosely- or non-attached debris 
and then standing vertically inlet-end up for 15 min prior to imaging to allow this matter 
to settle and be drawn out of the distal end of the channel (Figure A-6). In addition, 
subsequent COMSTAT image analysis was performed with the default option of 
connected volume filtration, which removes biomass that is not in some way connected 
to the substratum. 
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 Figure A-4 Non-attached cellular debris settles on top of the glass substratum-attached 
biofilms when flowchambers are positioned on an inverted microscope system. 
 
 
 
Figure A-5 Side-profile (z view) CLSM image of 3-day old PAO1 biofilm forming on glass 
coverslip. 
Free-floating unattached biomass settles on top of the glass substratum-attached biofilms, giving 
a false representation of the size and morphology of the structures formed. Micron bar = 40 µm. 
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Figure A-6 Inversion of the flowchamber prior to imaging. 
Allows unattached debris to be drawn out of the channels by gravity and the action of the 
downstream pump. 
 
¥ Image collection 
With the microscope in visual mode, the bacterial cells were located with phase contrast 
microscopy at the centre of the channel 5 mm in from the inlet. The microscope was 
then placed in LSM mode and the first image acquired with the detector sensitivity 
automatically pre-adjusted. Using continuous fast scanning, the fine focus was adjusted 
to find the area of maximum brightness (and hence thickness). At this position, the 
detector gain and amplifier offset were adjusted in order to reduce over (red pixels) and 
undersaturation (blue pixels) of the image.  
A z-series was collected by selecting the first image at the level of the coverslip at the 
point when the cells first appeared. The focus was then moved to the top of the biofilm 
and the last image of the z series was set. The interval between slices was adjusted to 
between 1-2 µm and typically 10 to 40 slices were collected per stack. Four further z-
stacks through the biofilm from within an area of 1 mm
2
 in each flow channel were 
 232 
captured randomly by moving the fine position dial a set number of turns in x and y. 
Each image depicted an area of 230.3 µm x 230.3 µm. See Figure A-7. In total, the 5 
captured stacks represented an area of 2.651 x 10
5 
µm
2
 at the centre of the flowchannel. 
 
 
Figure A-7 Series of xy slices collected through z from 4 day PAO1 biofilm. 
Slices were separated by an interval of 1.6 µm and each slice represented 230.3 µm x 230.3 µm. 
A tilted coverslip lead to non-flat initial images. 
 
COMSTAT image analysis 
Biofilm structure was quantified from the confocal stacks using the image analysis 
software package COMSTAT (Heydorn et al., 2000b). The program was written as a 
script in MATLAB 5.1 (The MathsWorks Inc., Natick, Massachusetts), equipped with 
the Image Processing Toolbox and was originally designed to analyse images from the 
Leica TCS4D confocal microscope. Hence to enable COMSTAT analysis of the Zeiss 
LSM 510 data, the Ô.lsmÕ images were converted to Ô.tifÕ files using the batch export 
facility. A user written MATLAB function ÔtiffreadÕ (Dr Franois Ndlec, Cell 
Biology and Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, 
Germany) was used to extract the necessary information from the Ô.tifÕ files to produce 
an Ô.infoÕ file. This contained details of the number of slices in each stack and their 
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pixel size in x, y and z. A MATLAB script was subsequently written in-house to 
automate generation of Ô.infoÕ files for image stacks. 
Prior to running COMSTAT, the CONVERT000 program was used to name the image 
stacks in the appropriate format. The CHECKALL program ensured that all the image 
stacks were intact. Threshold values were determined with the aid of the LOOK and 
LOOKTIF programs. Thresholding an image stack resulted in a 3D matrix with a value 
of ONE in positions where the pixel values in the original image were above or equal to 
the threshold value and ZERO where the pixel values were below the threshold value. 
The value ONE represented biomass, while ZERO represented background. To 
determine the threshold, a random selection of images was chosen. These were assigned 
different thresholds and the most representative threshold value was determined 
subjectively by simultaneously scrutinising the LSM acquired images. This value was 
then applied to all images undertaken within that session. 
The COMSTAT program was capable of generating up to 11 different statistical 
parameters for the purpose of quantifying biofilm 3D structure (see Table A-1). For the 
present study, three parameters were employed to quantify the differences between 
biofilms formed by different strains or under different experimental conditions. These 
parameters were biomass (option 1), average biofilm thickness (option 3) and maximum 
biofilm thickness (option 11). See Table A-2 for a description of these select image 
analysis features (Heydorn et al., 2000b).  
In addition, the option to correct for a non-flat first image was selected as the 
calculations performed by COMSTAT depended on the first image of the stack showing 
exactly the layer of biomass at the substratum. As described earlier, by default, 
connected volume filtration was performed on all images to remove biomass that was 
not connected to the substratum. This was deemed to be reasonable for when working 
with a continuous-flow system, biomass that was not connected to the substratum would 
be expected to be washed away. However, when analysing biofilms additionally stained 
with PI, this default was overridden in order to determine the relative biomass of the 
live and dead cells. 
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Table A-1 COMSTAT image analysis tools. 
 
COMSTAT 
option 
Description of image analysis tool 
1 Biomass 
2 Area occupied by bacteria in each layer (also executes 3) 
3 Thickness distribution & average thickness 
4 Identification and area distribution of microcolonies at the 
substratum 
5 Volumes of microcolonies identified at the substratum (also executes 
4) 
6 Fractal dimension (Minkowski sausage) of each microcolony 
identified at the substratum (also executes 4) 
7 Fractal dimension (slope of the cross correlation function) in the x 
and y direction of each image in the stack 
8 Dimensionless roughness coefficient (also executes 3) 
9 Distribution of diffusion distances and maximum diffusion distance 
10 Surface area and surface to volume ratio (also executes 1) 
11 Maximum thickness of the biofilm 
 
Table A-2 Description of the COMSTAT image analysis features used in this study. 
 
COMSTAT 
feature 
Unit of 
meassurement 
Description 
Biomass µm
3
/µm
2
 The biomass was calculated by normalising the 
volume of the biofilm by the surface area of the field 
of view, which gives the biomass parameter as 
biofilm volume per unit surface area. The biomass 
parameter represents the volume of the biofilm cells 
present in a given confocal image. stack. 
Average 
thickness 
µm The average thickness was the average biofilm 
height taken over the entire field of view. Hence 
average biofilm thickness was a measure of the 
spatial size of the biofilm. 
Maximum 
thickness 
µm The maximum biofilm thickness was the maximum 
distance from the substratum that the biofilm colony 
reaches. 
Roughness 
coefficient 
none Biofilm roughness provided a measure of how much 
the thickness of the biofilm varied and was an 
indicator of biofilm heterogeneity. 
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Statistical analysis 
Mean and standard error of the mean (SEM) values were based on the average of each 
parameter calculated by COMSTAT from 5 confocal image stacks per channel per 
experiment. To illustrate this, see Table A-3 and Figure A-8 for COMSTAT generated 
data on mean biomass, average thickness and maximum thickness for P. aeruginosa 
PAO1 biofilms grown in four channels from a single experimental round. 
 
Table A-3 Biomass, average thickness and maximum thickness of 4-, 5- and 6-day old 
biofilms formed by P. aeruginosa PAO1 pUCP18::GFPmut3.1.  
Values are means ± SEM of data from 20 image stacks (5 image stacks from 4 channels). 
 
Biofilm parameter Day P. aeruginosa PAO1 
4 12.10 ± 0.57 
5 15.74 ± 0.94 
Biomass (µm
3
/µm
2
) 
6 19.67 ± 1.19 
4 12.27 ± 0.50 
5 17.44 ± 0.98 
Average thickness (µm) 
6 22.40 ± 1.21 
4 28.34 ± 0.93 
5 36.25 ± 1.86 
Maximum thickness (µm) 
6 44.72 ± 2.56 
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(A) 
 
(B) 
 
(C) 
 
Figure A-8 (A) Biomass, (B) average thickness and (C) maximum thickness of 4-, 5- and 6-
day old biofilms formed by P. aeruginosa PAO1. 
Values are means ± SEM of data from 20 image stacks (5 image stacks from 4 channels). 
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When investigating the difference between test conditions or test strains, usually three 
independent experimental rounds were performed with analysis of the pooled data. 
Using SPSS for windows, interexperimental variation and interchannel variation were 
assigned as random effects and were incorporated into an analysis of variance 
(ANOVA) using a general linear model (GLM). This indicated that whilst both channel 
and experiment were having an effect, this could be disregarded. Subsequently, 
therefore, the analysis applied the studentÕs t test to determine whether the difference 
between the means of two data sets was significant at P Ü 0.05 
(http://www.physics.csbsju.edu/stats/t-test.html). 
IMARIS image processing and rendering 
Simulated 3D images were obtained using the IMARIS package (BITplane, 
Switzerland). Raw z-stack data sets were imported as confocal Ô.lsmÕ files and opened 
within the software. Image processing functions were applied to enable 3D 
reconstruction with the option to render the surface morphology solid. This enabled a 
visual representation of the biofilms captured which were saved using the ÔsnapshotÕ 
function as Ô.tifÕ files. See Figure A-9 for examples of P. aeruginosa PAO1 
pUCP::GFPmut3.1 four-day old biofilms. 
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Figure A-9 IMARIS reconstruction of 4-day old PAO1 biofilm image stack. 
(A) xy section through biofilm with side panels depicting microcolony profiles through z. 
(B) 3D rendered image viewed from above. 
(C) Full 3D rendered image 
(D) ÔIsosurfaceÕ image with space-filling and surface smoothing 
50µm 
30µm 
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Live / dead staining 
With the flowchamber system established and optimised and the technology in place to 
undertake the image analysis, it was possible to increase the sophistication of the 
methodology to capture two separate fluorophores. Thus far, live cells expressing a 
plasmid-based GFP (pUCP::GFPmut3.1) were captured. This 26.9 kDa fluorescent 
protein was originally isolated from the jelly fish Aequorea victoria and has a major 
excitation peak at a wavelength of 395 nm and an emission peak at 509 nm, which is in 
the lower green portion of the visible spectrum. Extensive engineering of the original 
protein has led to many mutants with different spectral characteristics, which have a 
wide range of applications.  
Propidium iodide is a fluorescent molecule and intercalating agent, which binds both 
DNA and RNA. PI is membrane impermeant and is therefore generally excluded from 
viable cells. This, together with its broad emission spectrum peaking in the orange at 
620 nm, allows it to be used to identify dead cells in a population and as a counterstain 
in multicolour fluorescent techniques.  
The potential to use GFP in conjunction with PI staining to distinguish live and dead 
biomass was investigated in the flowchamber system. Five-day old P. aeruginosa 
PAO1 pUCP::GFPmut3.1-labelled biofilms were treated with the aminoglycoside 
antibiotic tobramycin, which is frequently used in the treatment of CF lung disease. 
Confocal imaging, with the simultaneous use of the Argon ion and HeNe 1 laser units, 
was undertaken on day 6 following incubation with locally applied propidium iodide. 
COMSTAT calculation of biomass was performed on the separate green (live) and red 
(dead) signals (Figure A-10). The IMARIS reconstructions of these dual labelled 
images gave a striking view of the action of this antibiotic on the biofilm (Figure A-11). 
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Figure A-10 Effect of tobramycin on day 6 PAO1 biofilm biomass viability. 
The analysis was conducted using the COMSTAT programme to quantify biofilm biomass. Day 
5 biofilms growing in 2 separate channels were incubated with 340 µg/ml tobramycin for 20 h. 
Multi-track CLSM was undertaken on day 6 following PI staining, with 5 image stacks 
collected per channel. Mean ± SEM of 2 independent experimental rounds (10 image stacks per 
experiment) plotted. 
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Figure A-11 IMARIS reconstruction of two-channel CSLM imaging of 6-day old PAO1 
biofilm following 20 h exposure to 340 µg/ml tobramycin.  
Bacterial viability was assessed using PI staining: live cells appear green; dead cells are red. 
(A) XY section through biofilm with side panels depicting microcolony profiles through Z 
(B) 3D rendered image viewed from above 
(C) Full 3D rendered image 
(D) ÔIsosurfaceÕ image, with space-filling and surface smoothing 
30µm 
 242 
General comments on the establishment and operation of a flowchamber biofilm 
system 
The construction and operation of a flowchamber biofilm system posed a number of 
technical and practical considerations such as access to dedicated equipment (peristaltic 
pump, media vessels, flowchambers etc.) and appropriate autoclave, incubation and 
imaging facilities. The general design was modified to overcome the issue of bubble 
formation in the system and the method of image capture adapted to the particular 
specification of the confocal microscope. Furthermore, the analysis of the digital data 
captured required the application of the specialist software packages COMSTAT and 
IMARIS.  
Whilst a popular model system, the flowchamber biofilm method does have some 
disadvantages. Contamination of the large volumes of liquid media can occur unless 
adequate autoclaving is performed. Chemical sterilisation with hypochlorite bleach 
requires careful attention to aseptic technique as do subsequent manipulations to the 
tubing in order to inoculate strains and remove backgrowth. Any enclosed system is 
subject to wall effects with aberrations in flow in the corners of the chamber (Palmer, 
1999). Finally, in cases of high biomass within the flowchamber, it is possible that a 
gradient of nutrients and waste products could be established over its length. 
These latter issues expose one of the fundamental challenges to any study of biofilm 
formation in that it is to a certain extent a stochastic process (Heydorn et al., 2000a). To 
address this and in order to achieve robust biofilm descriptive data, guidance from 
Heydorn et al. (2000) was followed in an effort to ensure that all allied conditions were 
kept constant so that any variations observed could be attributed to differences in the 
test condition.  
Specifically, in order to minimise variation between successive experimental rounds, 
the main factors that influence biofilm formation were kept constant. Hence, flow rate 
was fixed at 3.3 ml/hr/channel, biofilms were routinely grown at 37 ¡C and any 
temperature shifts were reproduced. The nutrient composition of the media was not 
varied and cultures with the same history were used for all experiments. In addition, the 
same operator performed all experimental rounds and specifically fixed the microscope 
and COMSTAT thresholds (which is a subjective process). 
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To minimise variation between channels containing the same strain, machine-made flow 
channels were used so that biofilm structure variation caused by small differences in 
channel shape and size could be minimised. Attention was paid to large macrocolonies 
growing at the inlet of the channel which could exhaust the carbon source, leaving the 
downstream growth as essentially a single layer of cells. Additionally, backgrowth 
forming in the upstream tubing was removed daily for the same reasons. 
Within each channel, spatial heterogeneity in biofilm structure was observed. For 
example, the biofilm near the inlet was typically thicker than the biofilm near the outlet 
and the biofilms in the regions near the sides of the channel often displayed differences 
in structure to those forming in the centre. Hence, the issue of representative sampling 
was considered. The nature of the microscope stage itself limited the area of the flow 
channel that could be imaged as previously discussed. The decision to capture images 
from 5 random positions from an area 1 mm
2 
at the centre of the channel 5 mm from the 
inlet balanced practical considerations with the satisfaction that an adequate area had 
been investigated in order to obtain representative data (Korber, 1993). 
The impact of these practices was assessed statistically using both sophisticated 
(ANOVA using a GLM within SPSS for windows) and simple (studentÕs t test via a 
web-based link) approaches. The effect of doing the more sophisticated analysis 
incorporating experimental round and different channel would be to explain some of the 
variation as variation between experimental round and channel and leave some as 
random error. By performing the simple t-test, the assumption was made that all the 
variation was random error and this was in fact the more conservative approach. Simply 
stated, if a significant difference was observed with a t-test then the difference would 
also be significant in the GLM. The added complexity of performing the GLM would 
be useful in the situation when the t-test was not significant and further work could be 
performed to find evidence for a difference with the GLM. 
Full implementation of this locally developed system enabled the successful growth, 
imaging and analysis of biofilms of P. aeruginosa PAO1 labelled with the fluorescent 
tag pUCP18::GFPmut3.1. By day 4, established biofilms around 12 µm deep had 
formed with a characteristic surface topology made up of microcolonies. Additional 
growth of around 5 µm in thickness was observed each day thereafter. This data 
represented the benchmark for the behaviour of the wildtype PAO1 strain in this 
particular system. In addition, the ability to undertake more sophisticated analyses was 
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confirmed using live / dead staining following exposure of the biofilm to tobramycin. 
These successes firmly established this locally-implemented flowchamber system as a 
robust model with many potential applications. 
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Appendix 5 
 
The QS signal molecule profile and lecA status of the cohort of clinical isolates  
 
LecA produced 
Strain 
Mucoid/ 
nonmucoid Pigment lecA LecA C4 C12 HHQ PQS 
A001-200804 nm none y y y y y y 
A002-051104 m none y y y y y y 
A003-280504 nm green y y y y low y y 
A004-130804 m pink y y y y y y 
A005-100904 nm green y y y y low y y 
A007-110604 nm green y y y y y y 
A009-110604 nm green y y y y low y y 
A012-180604A nm green y y y n y y 
A012-180604B m none y y low n n y y 
A017-081004 m green y y y n y y 
A019-040205 nm green y y y n y y 
A021-101204A nm green y y y y y y 
A021-101204B nm green y y y n y y 
A023-200804 nm green y y  y y y y 
A024-270804 nm green y y y n y y 
A026-130804 nm green y y y n y y 
A029-110305 nm green y y y n y y 
A032-200804 nm green y y y n y y 
A033-200804 nm green y y y y y y 
A035-051104A m pink y y y y y y 
A035-051104B nm green y y y y y y 
A037-230205A m pink y y y y y y 
A037-230205B nm green y y  y y y y 
P003-170804 nm green y y  y low n y n 
P004-010205 nm green y y  y y low y y 
P006-170804 nm green y y y low n y n 
P007-280904 nm green y y y n y y 
P009-280904 nm green y y y n y y 
P010-211204 m green y y y n y y 
P013-101204A m none y y y n y y 
P013-101204B nm green y y y n y y 
P015-170804A m none y y  y n y y 
P015-170804B nm green y y  y n y y 
P016-280904 nm none y y y n y y 
P018-161104 nm green y y y n y y 
P024-070904 m green y y y y y y 
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no LecA 
Strain 
Mucoid/ 
nonmucoid Pigment lecA LecA C4 C12 HHQ PQS 
A014-291004 nm pink n n y y y y 
A018-151004 nm green n n y y y y 
A025-221004 m pink n n y y y y 
A031-030904 nm green n n y n y y 
P010-191004 nm green n n y y y y 
P020-191004 m none n n y y y y 
P021-211204 nm green y n y n y y 
 
 
 
 
